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Antibody correlates of protection for Ebola virus infection: Effects of 
mutations within the viral glycoprotein on immune escape. 
Kimberley Steeds 
Abstract 
Ebola virus (EBOV) is an enveloped, single-stranded RNA virus that can cause Ebola virus 
disease (EVD), a highly lethal illness with up to 90% mortality.  It is thought that EVD 
survivors are protected against subsequent infection with EBOV and that neutralising 
antibodies to the viral surface glycoprotein (GP) are potential correlates of protection.  
Serological studies are vital to assess neutralising antibodies targeted to GP; however 
handling of EBOV is limited to containment level 4 laboratories.  Pseudotyped viruses can 
be used as alternatives to live infectious viruses that require high levels of bio-containment 
in serological and receptor binding and assays. 
Neutralisation capacity can differ among pseudotyped virus platforms.  The ability of EBOV 
GP pseudotyped lentivirus and vesicular stomatitis virus (VSV) systems to measure the 
neutralising ability of EVD convalescent plasma were compared.  The results demonstrate 
that the sensitivity, specificity and correlation with live EBOV neutralisation are greater for 
the VSV-based pseudotyped virus system. 
The extensive human-to-human transmission of EBOV observed during the 2013-2016 EVD 
epidemic in West Africa resulted in an accumulation of mutations within the EBOV genome.  
The current study undertook to assess how these might impact upon immune escape.  
Specifically, the influence of mutations within the EBOV GP on escape from neutralising 
antibodies derived from EVD convalescent individuals was assessed. 
Site-directed mutagenesis was performed to introduce specific mutations that occurred 
during the 2013-2016 EVD outbreak into EBOV GP expression plasmids, which were 
subsequently used to generate a panel of mutant EBOV GP pseudotyped viruses.  The effect 
of these mutations on neutralisation by polyclonal and monoclonal antibody (mAb) samples 
was assessed.  Overall, the results suggest that multiple naturally occurring amino acid 
changes in EBOV GP do not have a significant impact on polyclonal neutralising antibodies 
derived from EVD convalescent volunteers or EBOV GP vaccinated individuals.  However 
these mutations can result in reduced neutralisation by certain EBOV GP-specific mAbs.  
Specifically, a G74R mutation located in the receptor binding domain (RBD) of EBOV GP is 
associated with partial escape from neutralisation by a human anti-EBOV GP mAb, KZ52. 
Sequencing studies and pseudotyped viruses represent an opportunity to study the possible 
impact of naturally occurring EBOV GP mutations on immune escape, which in turn has the 
potential to provide a better understanding of EVD vaccine efficacy and correlates of 
protection against EBOV. 
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Chapter 1 Introduction 
1.1 History of Ebola virus (EBOV) 
1.1.1 Filovirus discovery 
The family Filoviridae, classified within the order Mononegavirales which includes viruses 
with non-segmented, linear, single-stranded, negative-sense RNA genomes (Pringle et al., 
1991), contains three genera; Marburgvirus, Ebolavirus and Cuevavirus (Kuhn et al., 2010).  
The genus Marburgvirus consists of one species, Marburg marburgvirus, which includes 
two viruses: Marburg virus (MARV) and Ravn virus (RAVV).  The genus Ebolavirus is 
composed of six known species: Sudan ebolavirus (Sudan virus, SUDV), Zaire ebolavirus 
(Ebola virus, EBOV), Reston ebolavirus (Reston virus, RESTV), Taï Forest ebolavirus (Taï 
Forest virus, TAFV), Bundibugyo ebolavirus (Bundibugyo virus, BDBV) and Bombali 
ebolavirus (Bombali virus, BOMV), and the genus Cuevavirus contains one species, Lloviu 
cuevavirus (Lloviu virus, LLOV). 
The first recorded outbreak of filovirus disease occurred in 1967, simultaneously in 
Marburg and Frankfurt, Germany, and Belgrade, former Yugoslavia (now Serbia), when 
laboratory workers developed severe haemorrhagic fever following contact with blood and 
tissues of African green monkeys (Cercopithecus aethiops) that had been imported from 
Uganda (Kissling et al., 1968; Martini, 1973).  A total of 31 people were infected, seven of 
which died.  This new virus was named Marburg virus, after the city with the most cases 
(Brauburger et al., 2012). 
In 1976, two simultaneous outbreaks of viral haemorrhagic fever occurred in Nzara, 
southern Sudan (now the Republic of South Sudan) (Report of a WHO/International Study 
Team, 1978) and Yambuku, northern Zaire (now the Democratic Republic of the Congo, 
DRC) (Report of an International Commission, 1978), with case fatality rates of 53% and 
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88%, respectively.  Viruses were isolated from patients of both outbreaks, and were shown 
to be morphologically similar but serologically distinct from MARV (Bowen et al., 1977; 
Johnson et al., 1977; Pattyn et al., 1977).  This virus was named Ebola virus, after a nearby 
small river in north-western DRC, to ensure that the Yambuku community was not 
stigmatised (Etymologia: Ebola, 2015; Breman et al., 2016).  These two outbreaks were 
later determined to be caused by two distinct species of Ebola virus, SUDV and EBOV (Cox 
et al., 1983; Richman et al., 1983).  Since its discovery in 1976, EBOV has caused sporadic 
outbreaks, mainly across Central Africa (Table 1.1), and was responsible for the 2013-2016 
Ebola virus disease (EVD) epidemic in West Africa (Baize et al., 2014), which resulted in 
more than 28,600 cases and over 11,300 deaths.  RESTV was identified in 1989 at a 
quarantine facility in Reston, Virginia (VA), United States of America (USA), in cynomolgus 
macaques (Macaca fascicularis) that had been imported from the Philippines (Jahrling et 
al., 1990).  RESTV causes lethal illness in some non-human primates (NHPs), but is non-
pathogenic in humans and seroconversion has been observed in some individuals (Barrette 
et al., 2009; CDC, 1990; Miranda et al., 1999).  In 1994, the forth ebolavirus species was 
discovered, when TAFV was isolated from an ethnologist who was infected while 
performing a necropsy on a dead chimpanzee found in the Taï Forest National Park, Ivory 
Coast (Le Guenno et al., 1995).  The patient survived, and thus far, this is the only observed 
human infection of TAFV (Formenty et al., 1999).  BDBV was discovered in 2007 in Uganda 
when it caused a large outbreak with a case fatality rate of 25% (Towner et al., 2008).  A list 
of human EVD outbreaks is shown in Table 1.1. 
Recently, the complete genome of a new ebolavirus, BOMV was detected in samples 
collected from free-tailed bats in Sierra Leone between March and September 2016 
(Goldstein et al., 2018).  This virus showed 55-59% nucleotide identity to other ebolaviruses 
and phylogenetic analyses showed that BOMV is sufficiently distinct to represent the 
prototype strain of a new species within the Ebolavirus genus. 
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Table 1.1 Outbreaks of human Ebola virus disease (EVD).  In chronological order.  
Grouped according to Ebolavirus species.  Data obtained from WHO (World Health 
Organization, 2018, 2019) and CDC (Centers for Disease Control and Prevention, 
2017b). 
Year Country 
Reported number 
of human cases 
Reported number (%) 
of deaths among cases 
Ebola virus 
1976 Zaire (DRC) 318 280 (88%) 
1977 Zaire 1 1 (100%) 
1994 Gabon 52 31 (60%) 
1995 DRC (formally Zaire) 315 254 (81%) 
1996 Gabon 31 21 (68%) 
1996 Gabon 60 45 (75%) 
1996 South Africa (ex-Gabon) 1 1 (100%) 
2001-2002 Gabon 65 53 (82%) 
2001-2002 Republic of the Congo 59 44 (75%) 
2003 Republic of the Congo 143 128 (90%) 
2003 Republic of the Congo 35 29 (83%) 
2005 Republic of the Congo 12 10 (83%) 
2007 DRC 264 187 (71%) 
2008 DRC 32 14 (44%) 
2014-2016 Multiple countries 28,646 11,323 (40%) 
2014 DRC 66 49 (74%) 
2017 DRC 8 4 (50%) 
2018 DRC 54 33 (61%) 
2018-present DRC 991  614 (62%)-ongoing 
Sudan virus 
1976 Sudan (South Sudan) 284 151 (53%) 
1979 Sudan (South Sudan) 34 22 (65%) 
2000 Uganda 425 224 (53%) 
2004 Sudan (South Sudan) 17 7 (41%) 
2011 Uganda 1 1 (100%) 
2012 Uganda 24 17 (71%) 
2012 Uganda 7 4 (57%) 
Reston virus  
1990 USA 4 (asymptomatic) 0 (0%) 
1989-1990 Philippines 3 (asymptomatic) 0 (0%) 
2008 Philippines 6 (asymptomatic) 0 (0%) 
Taï Forest virus 
1994 Cote d’Ivoire (Ivory Coast) 1 0 (0%) 
Bundibugyo virus   
2007 Uganda 149 37 (25%) 
2012 DRC 57 29 (51%) 
Abbreviations: DRC, Democratic Republic of the Congo; USA, United States of America. 
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In 2011, a novel ebolavirus-like filovirus, LLOV, was detected in insectivorous bats 
(Miniopterus schreibersii) in Cueva del Lloviu, Spain (Negredo et al., 2011), and has since 
been reported to be present within the same bat species in Hungary (Kemenesi et al., 
2018).  LLOV is the first filovirus detected in Europe that was not imported from an endemic 
area in Africa. 
1.1.2 Ecology and transmission 
Human EBOV infection is thought to occur through zoonotic events, either from a natural 
animal reservoir or from an incidental animal host, such as chimpanzees, gorillas or forest 
duikers (antelope) (Groseth et al., 2007) (Figure 1.1).  The natural reservoir for EBOV 
remains unknown; however several species of bat have been implicated (Leroy et al., 2009; 
Pourrut et al., 2007).  EBOV RNA and EBOV-specific antibodies have been detected in 
naturally infected wild bats, although live virus isolation has not been achieved (Leroy et al., 
2005; Pourrut et al., 2009).  Experimental infection of African bats has shown that these 
animals are capable of supporting EBOV replication and high viremia without showing 
clinical signs of disease (Swanepoel et al., 1996).  NHPs are not thought to be a reservoir 
host for EBOV, as they are susceptible to EBOV infection and are regarded as end hosts, 
however they may amplify the virus in nature, and some instances of human infection have 
been preceded by disease and mortality in wild NHP populations (Lahm et al., 2007; Leroy 
et al., 2004; Rouquet et al., 2005).  It has been hypothesised that the increase in frequency 
of EVD outbreaks in Africa (Table 1.1) is a result of increased contact between wildlife and 
humans (Jones et al., 2008).  Human encroachment into previously uninhabited areas, due 
to hunting (Leroy et al., 2009) and deforestation (Rulli et al., 2017) for example, can bring 
them into contact with EBOV infected animals.  Furthermore, climate change and seasonal 
patterns (Ng and Cowling, 2014; Pinzon et al., 2004; Schmidt et al., 2017) can cause certain 
animals to modify their geographical and ecological distribution and bring them into closer 
proximity to human communities.  Humans can become infected with EBOV by contact with 
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bodily fluids or droppings from an infected animal, or by handling contaminated fruit or 
bushmeat (Leroy et al., 2009). 
 
 
 
 
 
 
 
Figure 1.1: Ebola virus disease (EVD) ecology and transmission.  EVD is a zoonosis.  
Bats have been implicated as a reservoir host for Ebola virus (EBOV).  Animals, such 
as apes, monkeys and duikers, or humans can become infected with EBOV through 
contact with the reservoir host or another infected animal.  Human-to-human 
transmission of EBOV can occur through the contact of bodily fluids from infected 
individuals or bodies of those who have died from EVD.  Figure adapted from CDC 
(Centers for Disease Control and Prevention, 2017a). 
 
The suspected index case of the 2013-2016 EBOV outbreak in West Africa was believed to 
be a two year old boy from Meliandou, a small village near Gueckedou in the Republic of 
Guinea, who died on 6 December 2013, and likely contracted the disease after exposure to 
an infected bat (Mari Saez et al., 2015).  However EBOV, as the causative agent of the 
epidemic, was not detected and reported until March 2014 (Baize et al., 2014). 
Following the initial transmission event from animal to human, the most likely human-to-
human spread of EBOV is by direct or close contact of an individual with contaminated 
bodily fluids or fomites from an infected and symptomatic, or deceased patient of EVD 
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(Bausch et al., 2007; Dietz et al., 2015; Lawrence et al., 2017) (Figure 1.1).  In humans, EBOV 
has been found, either directly or via detection of viral RNA, in a range of bodily fluids 
including blood, urine, stool, saliva, sweat and tears, as well as breast milk and semen 
(Bausch et al., 2007; Rodriguez et al., 1999).  Carers at home, family members and 
healthcare workers are at particular risk of infection (Dowell et al., 1999; Roels et al., 1999).  
Nosocomial transmission observed during the first recorded EVD outbreak was associated 
with contaminated needles (Report of an International Commission, 1978).  Bodies of 
individuals that have died from EVD are a source of infectious virus at high levels (de La 
Vega et al., 2015; Diallo et al., 2016; Lanini et al., 2015), and therefore funerals and burial 
practices can pose a risk for continued EBOV transmission (Brainard et al., 2016; Tiffany et 
al., 2017).  Sexual transmission of EBOV also presents a risk, even when patients are no 
longer symptomatic (Mate et al., 2015).  Infectious EBOV can be detected in semen of 
survivors up to 16 months after convalescence (Deen et al., 2017; Diallo et al., 2016; 
Sissoko et al., 2017a; Sow et al., 2016; Uyeki et al., 2016), and sexual transmission was 
linked to the initiation of new transmission chains during the 2013-1016 EBOV outbreak 
(Arias et al., 2016; Blackley et al., 2016).  EBOV can persist in immune privileged sites such 
as the testes, central nervous system (CNS) and eyes, and persistent EBOV infection can 
lead to outbreak flare-ups or re-ignition, as well as relapses or complications in some 
affected individuals (Jacobs et al., 2016; Lee and Nishiura, 2017; Varkey et al., 2015). 
Previous outbreaks of EBOV have been limited in size and geographical spread, typically 
involving a small number of people in remote forested areas.  The extensive human-to-
human transmission documented during the 2013-2016 EBOV epidemic in West Africa was 
thought to be due to societal factors such as poverty, urban density, population migration 
patterns, and poor public healthcare infrastructure (Chan, 2014; Spengler et al., 2016; WHO 
Ebola Response Team, 2014).  The first infections of the 2013-2016 EBOV outbreak 
occurred within a remote rural area of Guinea where no outbreaks of EBOV had previously 
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been identified.  The lack of capacity in Guinea to detect EBOV and delay in identification 
allowed the virus to spread to bordering Liberia and Sierra Leone.  These three countries 
had no past experience in recognising and managing EBOV outbreaks, were extremely 
resource-poor, and were recovering from the effects of years of civil instability, which 
included the collapse of government institutions and struggling basic healthcare 
infrastructures (Bausch and Schwarz, 2014).  Inability to diagnose EVD, slow recognition of 
suspected cases, and absence of appropriate surveillance early in the outbreak severely 
hampered interruption of EBOV spread.  Furthermore, high population mobility within each 
country and porous borders into neighbouring countries exacerbated widespread 
dissemination and transmission of EBOV. 
1.1.3 Origin and evolutionary rate 
The 2013-2016 EVD epidemic in West Africa was caused by a novel EBOV variant Makona, 
named after a river at the border of Guinea and Sierra Leone (Kuhn et al., 2014).  Molecular 
clock dating analyses of the sequenced EBOV Makona lineages suggest that the common 
ancestor be placed at the beginning of 2014 (Carroll et al., 2015; Dudas and Rambaut, 2014; 
Gire et al., 2014), which is in agreement with epidemiological investigations which placed 
the first case around late December 2013.  These studies also suggest that EBOV Makona 
diverged from the other EBOV variants around 2004, and that all EBOV variants share a 
common ancestor around 1975 (Dudas and Rambaut, 2014; Gire et al., 2014; Walsh et al., 
2005). 
Various genomic sequencing studies performed in Guinea (Carroll et al., 2015; Quick et al., 
2016; Simon-Loriere et al., 2015), Sierra Leone (Arias et al., 2016; Park et al., 2015; Tong et 
al., 2015) and Liberia (Hoenen et al., 2016; Kugelman et al., 2015c; Ladner et al., 2015) 
during the epidemic identified local viral lineages and transmission patterns within each 
country, and provided key insights into EBOV evolution and molecular epidemiology (Dudas 
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et al., 2017; Holmes et al., 2016).  It was initially reported that mean evolutionary rate 
[defined here as the observed rate at which new variants arise and spread in the viral 
population (Holmes et al., 2016)] of EBOV early in the epidemic was approximately twice as 
high as that from previous EBOV outbreaks (Gire et al., 2014).   However later studies 
reported lower rate estimates, which were more consistent with rates observed in previous 
EBOV outbreaks (Biek et al., 2006; Carroll et al., 2013; Walsh et al., 2005).  Evolutionary 
rates in RNA viruses can be dependent on the timescale over which they are measured.  
Higher rates can often be observed over short timescales, such as within disease outbreaks, 
because mildly deleterious mutations may not have yet been removed by purifying 
selection (Duchene et al., 2014).  This may explain why some estimates of evolutionary rate 
measured early in the 2013-2016 EVD epidemic appeared high.  A list of evolutionary rates 
of EBOV reported during the 2013-2016 EVD epidemic in West Africa are shown in Table 
1.2. 
 
Table 1.2 Evolutionary rates of Ebola virus (EBOV) reported during the 2013-2016 
Ebola virus disease (EVD) epidemic in West Africa. 
Study 
Evolutionary rate 
(substitutions per site per year) 
(Gire et al., 2014) 1.9 x 10-3 
(Hoenen et al., 2015) 1.3 x 10-3 
(Park et al., 2015) 1.1 x 10-3 
(Kugelman et al., 2015c) 0.9 x 10-3 
(Simon-Loriere et al., 2015) 0.9 x 10-3 
(Carroll et al., 2015) 1.3 x 10-3 
(Tong et al., 2015) 1.2 x 10-3 
(Quick et al., 2016) 1.2 x 10-3 
(Hoenen et al., 2016) 1.4 x 10-3 
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1.1.4 Clinical manifestations 
Generally, the abrupt onset of EVD follows an incubation period of two to 21 days, 
averaging four to 10 days, and is characterised by fever, chills, headache, malaise, fatigue 
and myalgia (muscle pain) (Bwaka et al., 1999; Feldmann and Geisbert, 2011).  The initial 
signs and symptoms of EBOV infection are non-specific and can resemble other more 
common diseases that are endemic to the area, such as Lassa fever, yellow fever and 
malaria (Boisen et al., 2015).  Therefore initial cases in an epidemic can often be 
misdiagnosed, leading to spread among family members and healthcare workers (Mahanty 
and Bray, 2004).  Once identified, an EBOV outbreak can usually be controlled by effective 
patient isolation and barrier nursing practices.  The subsequent signs and symptoms of EVD 
indicate multisystem involvement and include systemic, gastrointestinal (anorexia, nausea, 
vomiting, abdominal pain, diarrhoea), respiratory (cough), vascular, and neurologic 
(confusion) manifestations (Feldmann et al., 2013).  Haemorrhagic signs develop during the 
peak of illness, and a characteristic macropapular rash associated with varying degrees of 
erythema may develop by day five to seven of illness (Bwaka et al., 1999; Feldmann and 
Geisbert, 2011).  In fatal cases, clinical signs develop early during infection and death 
typically occurs six to 16 days after onset as a result of hypovolemic shock and multiple 
organ failure (Ksiazek et al., 1999a).  Non-fatal cases have fever for several days and 
improve typically around day six to 11 (Feldmann et al., 2013).   
Asymptomatic EBOV infection has been reported in close contacts of symptomatic EVD 
patients during follow up studies (Leroy et al., 2001; Leroy et al., 2000); however the 
frequency and impact of asymptomatic infection is unclear (Dean et al., 2016; Glynn et al., 
2017; Mbala et al., 2017).  A case of possible EBOV transmission from an asymptomatic 
mother via breastfeeding to her nine month old child, who had died from EVD with an 
unknown epidemiological link, has been reported (Sissoko et al., 2017b). 
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1.1.5 Disease pathogenesis 
There is limited information regarding the pathogenesis of EVD in humans, and the majority 
of data has been obtained from animal studies.  NHPs (cynomolgus and rhesus macaques) 
are considered the ‘gold standard’ animal model for EBOV (Bennett et al., 2017; Geisbert et 
al., 2015).  They can be lethally infected with non-adapted human isolates of EBOV and the 
resulting pathology closely resembles that described in humans (Baseler et al., 2017; Bente 
et al., 2009).  EBOV can enter the host through mucosal surfaces or breaks or abrasions in 
the skin.  EBOV initially replicates in monocytes, macrophages and dendritic cells (DCs) at 
the site of infection (Geisbert et al., 2003a; Geisbert et al., 2003c), and is disseminated via 
these cells to regional lymph nodes through the lymphatics, and to the liver and spleen 
through the blood (Schnittler and Feldmann, 1998).  EBOV infected monocytes, 
macrophages and DCs then migrate out of the spleen and lymph nodes to other cells and 
organs, such as the adrenal glands, thereby further disseminating the infection (Bray and 
Geisbert, 2005; Martines et al., 2015).  EBOV can cause extensive necrosis of hepatocytes 
leading to a decrease in the production of clotting factors and dysregulation of the 
coagulation cascade (Baseler et al., 2017; Martines et al., 2015), whereas infection and 
necrosis of adrenocortical cells may negatively affect blood pressure homeostasis, leading 
to haemorrhage (Geisbert et al., 2003c). 
EBOV infection triggers the production of several inflammatory mediators, including 
interleukin 6 (IL-6), IL-8, monocyte chemoattractant protein 1 (MCP-1), macrophage 
inflammatory proteins (MIPs), tumour necrosis factor alpha (TNFα), tissue factor (TF) and 
nitric oxide (NO) by macrophages and other cell types (Baize et al., 1999; Baize et al., 2002; 
Ebihara et al., 2011; Geisbert et al., 2003b; Hensley et al., 2002; Villinger et al., 1999).  This 
causes a significant inflammatory response and lymphoid cell apoptosis (Geisbert et al., 
2000; Wauquier et al., 2010), which leads to lymphopenia and suppression of an effective 
adaptive immune response, as well as vascular leakage and coagulation abnormalities.  
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Secreted chemokines can recruit more monocytes and macrophages to sites of infection, 
which act as new targets for viral infection.  Inflammatory mediators released from virus 
infected cells can induce Fas and TNF related apoptosis inducing ligand (TRAIL) pathways 
(Baize et al., 1999; Bradfute et al., 2010; Gupta et al., 2007; Hensley et al., 2002), which can 
contribute to lymphocyte apoptosis and lack of an effective adaptive immune response. 
EBOV and released inflammatory mediators can activate endothelial cells and induce 
endothelial cytotoxicity and permeability, leading to vascular leakage (Hensley et al., 2002) 
and haemorrhagic manifestations.  Pro-inflammatory cytokines can also upregulate 
expression of TF, resulting in over activation of the extrinsic pathway of coagulation and the 
development of disseminated intravascular coagulation (DIC) (Geisbert et al., 2003b), a 
condition in which blood clots form throughout small blood vessels.  These clots can reduce 
or block blood flow through the blood vessels, leading to organ damage.  Additionally, 
increased blood concentrations of NO can also induce bystander lymphocyte apoptosis, 
tissue damage and loss of vascular integrity, which may contribute to hypotension and 
virus-induced shock (Feldmann and Geisbert, 2011; Sanchez et al., 2004). 
Inhibition of the type I interferon (IFN) response (Gupta et al., 2001; Harcourt et al., 1998, 
1999), one of the major antiviral host defences, is another important aspect in the 
pathogenesis of EBOV (Kash et al., 2006). 
Whereas macrophages are activated by EBOV infection (Stroher et al., 2001), DC 
maturation and function are impaired.  EBOV infected DCs fail to secrete pro-inflammatory 
cytokines and do not upregulate expression of co-stimulatory molecules, leading to 
impairment in antigen presentation to T cells and induction of an adaptive immune 
response (Bosio et al., 2003; Mahanty et al., 2003).  EBOV infected DCs may also promote T 
cell apoptosis via induction of Fas and TRAIL pathways (Bradfute et al., 2010). 
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EBOV infection is associated with severe lymphopenia; however lymphocytes themselves 
are not infected by EBOV (Geisbert et al., 2000; Iampietro et al., 2017).  EBOV has been 
shown to bind to and activate CD4+ T cells.  Interaction of EBOV GP with toll-like receptor 4 
(TLR4) on T cells triggers T cell death (Iampietro et al., 2017), whereas interaction of viral 
membrane-associated phosphatidylserine (PtdSer) with T cell immunoglobulin (Ig) and 
mucin domain 1 (TIM-1 [also known as Hepatitis A virus cellular receptor 1 (HAVCR1)] on T 
cells induces cytokine production (Younan et al., 2017).  Additionally, interaction of EBOV 
GP with TLR4 on monocytes stimulates differentiation, which results in an increased 
susceptibility to EBOV infection (Iampietro et al., 2017). 
Therefore, EBOV is able to disrupt both the host innate and acquired immune responses, 
leading to uncontrolled viral replication and dissemination, and a strong and potentially 
deleterious inflammatory reaction that can lead to severe coagulopathy, multiple organ 
failure and shock (Figure 1.2). 
Higher levels of viremia are often associated with fatal EVD cases compared to survivors, 
and are a strong indicator of disease outcome (de La Vega et al., 2015; Faye et al., 2015; 
Ksiazek et al., 1999a; Lanini et al., 2015; Schieffelin et al., 2014). 
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Figure 1.2: Model of Ebola virus (EBOV) pathogenesis.  EBOV initially replicates in 
dendritic cells (DCs), monocytes and macrophages and is disseminated via these cells 
to various cells and organs, such as the liver.  DC function is impaired leading to 
decreased antigen presentation and suppression of adaptive immunity.  
Macrophages are activated and produce inflammatory mediators, which can cause 
lymphocyte apoptosis, vascular leakage, coagulation abnormalities and tissue 
damage.  EBOV also inhibits elements of the innate immune response enabling 
further viral replication and dissemination.  Overall these events result in high 
viremia, shock and multiple organ failure.  Figure adapted from (Mohamadzadeh et 
al., 2007) and (Leroy et al., 2011).  
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1.2 Virology 
1.2.1 Genome structure and organisation 
EBOV has a non-segmented, linear, negative-sense, single-stranded RNA genome of 
approximately 19 kb in length that encodes seven sequentially arranged open reading 
frames (ORFs), in the order: 3’ (leader), nucleoprotein (NP), virion protein 35 (VP35) 
(polymerase cofactor), VP40 (major matrix protein), glycoprotein (GP), VP30 (minor 
nucleoprotein), VP24 (minor matrix protein), RNA-dependent RNA polymerase (L) and 5’ 
(trailer) (Figure 1.3A).  Each ORF is flanked by highly conserved transcription start (3’ end) 
and stop (5’ end) signals, which either overlap (VP35-VP40, GP-VP30 and VP24-L) or are 
separated by intergenic regions (IRs) (Sanchez et al., 1993).  There are extragenic sequences 
at the 3’ (leader) and 5’ (trailer) ends of the genome (Sanchez et al., 1993), which contain 
promoters for replication and transcription (Volchkov et al., 1999; Weik et al., 2005). 
 
A   
 
B 
 
 
 
Figure 1.3: A) Organisation of Ebola virus (EBOV) genome and B) Schematic 
representation of EBOV particle.  [Abbreviations: IR, intergenic region; GP, 
glycoprotein; NP, nucleoprotein; VP, virion protein; L, large protein (RNA-dependent 
RNA polymerase)].  Figure adapted from (Mahanty and Bray, 2004). 
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1.2.2 Virion structure and viral proteins 
The Filoviridae family name is derived from filum, which is Latin for thread, because of the 
viruses’ characteristic filamentous morphology (Kiley et al., 1982).  EBOV virions are 
filamentous in shape, but can also appear branched, or in U-shaped, 6-shaped, or circular 
conformations (Geisbert and Jahrling, 1995).  Virions are approximately 800-1100 
nanometres (nm) long and have a uniform diameter of 80 nm (Figure 1.3B).  The single 
stranded RNA genome is encapsulated in a ribonucleoprotein (RNP) complex (the 
nucleocapsid) consisting of the NP, VP30, VP35 and L (Elliott et al., 1985), which is 
approximately 50 nm in diameter and runs the length of the particle.  The nucleocapsid is 
surrounded by a matrix layer consisting of VP40 and VP24, which is further surrounded by a 
lipid bilayer (envelope) derived from the host cell plasma membrane.  The viral envelope is 
studded with membrane-anchored, homotrimeric GP spikes that project approximately 10 
nm from the surface (Feldmann et al., 2013). 
VP30 is a transcription activator (Muhlberger et al., 1999), and has also been implicated in 
supressing antiviral immunity through its antagonistic effect on the host cellular RNA 
interference (RNAi) pathway (Fabozzi et al., 2011).  VP35 is an essential cofactor in the viral 
polymerase complex that affects replication and transcription (Muhlberger et al., 1999) and 
in addition, has an antagonist effect on the type I IFN pathway by binding virus generated 
double-stranded RNA (dsRNA) and by interfering with pathway kinases (Basler et al., 2003; 
Basler et al., 2000; Cardenas et al., 2006; Hartman et al., 2008).  The major matrix protein 
VP40 is critical to the viral assembly and budding processes, as it initiates and drives 
envelopment of the nucleocapsid by the host plasma membrane (Noda et al., 2002), and 
also contributes to regulation of genome replication and transcription (Hoenen et al., 
2010).  VP24 has a minor matrix protein function (Han et al., 2003) and, like VP35, has also 
been reported to antagonise the type I IFN signalling pathway (Halfmann et al., 2011; Reid 
et al., 2006).  The surface GP is responsible for host cell attachment, fusion and entry 
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(Martinez et al., 2013; Takada et al., 1997; Wool-Lewis and Bates, 1998) and is also thought 
to play a role in pathogenesis and immune evasion (Cook and Lee, 2013; Ning et al., 2017). 
1.2.3 EBOV GPs 
EBOV produces several forms of GP due to transcriptional editing and post-translational 
modifications (Cook and Lee, 2013; Feldmann et al., 2001; Ning et al., 2017). 
Surface GP 
The EBOV GP ORF contains an editing site of seven consecutive template uridine 
nucleotides (Sanchez et al., 1996; Volchkov et al., 1995).  During transcription, slippage or 
stuttering of the viral polymerase at this site results in the introduction of an additional 
adenine nucleotide in approximately 25% of messenger RNA (mRNA) transcripts (Mehedi et 
al., 2011).  This insertion causes a frame-shift of the coding mRNA, leading to production of 
full length structural GP.  The GP mRNA transcript is initially translated as a single precursor 
polypeptide, GP0, that is cleaved by furin in the Golgi into two subunits (Volchkov et al., 
1998): a surface subunit, GP1, and a membrane spanning subunit, GP2, which remain linked 
by a single disulphide bond (Jeffers et al., 2002).  This heterodimer associates non-
covalently with two other GP1,2 heterodimers into a 450 kDa trimer to form the GP spike 
that projects from the virion surface (Lee et al., 2008; Sanchez et al., 1998).  EBOV GP1,2 is 
heavily glycosylated with both N- and O-linked glycans (Feldmann et al., 1994). 
The GP1 subunit is responsible for mediating cellular attachment and contains the receptor 
binding domain (RBD).  The GP2 subunit is responsible for fusion of the viral and host cell 
membranes and contains a hydrophobic internal fusion loop (IFL), two heptad repeats (HR1 
and HR2) and a transmembrane domain (Gallaher, 1996).  GP1 can be divided into three 
subdomains; base, head and glycan cap (Lee et al., 2008).  The base forms a semi-circular 
surface that clamps the IFL and HR1 region of GP2 in its pre-fusion conformation.  The head 
is located between the base and glycan cap, and contains residues required for receptor 
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binding (Brindley et al., 2007; Kuhn et al., 2006).  The glycan cap is composed of a 
continuous polypeptide chain that contains six N-linked glycosylation sites and forms a 
dome over the GP1 head (Lee et al., 2008; Lennemann et al., 2014).  The GP1 subunit also 
contains a highly glycosylated domain at the C-terminus, termed the mucin-like domain 
(MLD), which contains eight N-linked glycan sites and possibly up to 80 O-linked glycan sites 
(Jeffers et al., 2002; Lennemann et al., 2014). 
The GP forms a three-lobed chalice-like structure, with the bowl of the chalice formed by 
the three GP1 subunits and the base formed by the three GP2 subunits (Figure 1.4A), which 
anchor the trimer to the viral membrane.  The IFL and HR1 region of the GP2 subunit wrap 
around the outside of the GP1 trimer, and are thought to stabilise the structure (Lee et al., 
2008).  The RBD is recessed in the bowl of the chalice and sits on top of the base domain 
with residues critical for binding facing up.  The glycan cap is positioned on top and blocks 
access to the RBD.  The MLD extends up and away from the viral membrane and globular 
GP1 domains. 
In addition to host cell attachment and fusion, EBOV surface GP1,2 has an important role in 
the pathogenesis of EVD.  Expression of GP1,2 in vitro causes rounding and detachment of 
cultured adherent cells, and induces detachment of endothelial cells in blood vessel 
explants leading to increased vascular permeability (Chan et al., 2000a; Francica et al., 
2009; Simmons et al., 2002; Takada et al., 2000; Yang et al., 2000), which may contribute to 
the clinical manifestations of EVD, such as haemorrhage, shock and multiple organ failure. 
A putative immunosuppressive domain (ISD) of EBOV GP1,2 may also contribute to viral 
suppression of cell-mediated immunity, by inducing T cell dysfunction and apoptosis 
(Volchkov et al., 1992; Yaddanapudi et al., 2006). 
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Figure 1.4: A) Schematic representation of Ebola virus (EBOV) surface glycoprotein 
(GP1,2) trimer and B) linear organisation of GP sequence.  (Abbreviations: N, amino 
terminus; SP, signal peptide; b, base; RBS, receptor binding site; h, head; FL, fusion 
loop; HR, heptad repeat; TM, transmembrane; C, carboxy terminus.  SS indicates 
disulphide bonds).  Figure adapted from (Miller and Chandran, 2012). 
 
It has also been suggested that the MLD of GP1,2 is involved in activation of the 
inflammatory response (Martinez et al., 2007; Okumura et al., 2010).  GP1,2 on virus like 
particles (VLPs) can activate DCs and macrophages and stimulate activation of nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-kB), and elicit the production of 
inflammatory cytokines via the TLR4 signalling pathway (Wahl-Jensen et al., 2005; Ye et al., 
2006).  Interaction of EBOV GP with TLR4 on monocytes stimulates differentiation, whereas 
interaction of EBOV GP with TLR4 on T cells triggers cell death, demonstrating that GP1,2 is 
able to directly subvert the host’s immune response by increasing the susceptibility of 
monocytes to EBOV infection and triggering lymphopenia (Iampietro et al., 2017).  Liver and 
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lymph node sinusoidal endothelial cell C-type lectin (LSECtin; also known as CLEC4G) has 
also been shown to play an important role in GP1,2-mediated inflammatory responses in 
human DCs, and acts as a pattern recognition receptor (PRR) for EBOV GP1,2.  Ebola GP1,2 
can trigger TNFα and IL-6 release by DCs through interaction with LSECtin, which initiates 
signalling via association with a 12-kDa DNAX-activating protein (DAP12) and induces 
spleen tyrosine kinase (Syk) activation (Zhao et al., 2016).  These effects are involved in the 
excessive and dysregulated inflammatory reactions elicited by EBOV infection and therefore 
contribute to EBOV pathogenicity. 
EBOV GP1,2 also functions in immune evasion.  A number of neutralising antibodies have 
been generated against the MLD; however the MLD is not necessary for EBOV entry (Wilson 
et al., 2000).  The MLD masks antigenic epitopes of the core structure of GP1,2, thereby 
blocking recognition by neutralising antibodies (Lennemann et al., 2014).  Furthermore, the 
MLD act as a ‘glycan umbrella’ and sterically shields epitopes and functions of host cellular 
surface proteins important in response to viral pathogens, such as major histocompatibility 
complex (MHC) class I molecules (Francica et al., 2010; Reynard et al., 2009). 
It has been suggested that RNA editing of the GP gene may be an important mechanism 
utilised by EBOV to regulate GP1,2 expression in order to optimise virus production and 
infectivity, while also evading the host immune response (Mohan et al., 2015; Volchkova et 
al., 2015). 
Shed GP 
Proteolytic cleavage of surface GP1,2 at the membrane proximal external region by TNFα 
converting enzyme (TACE) results in release of a soluble trimeric form of GP, termed shed 
GP, from the surface of infected cells (Dolnik et al., 2004).  As shed GP is structurally similar 
to surface GP1,2, it may function as a decoy antigen by binding to and sequestering 
neutralising antibodies directed against surface GP1,2, thereby contributing to viral immune 
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evasion (Dolnik et al., 2004).  Additionally, shed GP has been shown to activate 
macrophages leading to secretion of inflammatory cytokines, and increases the 
permeability of human umbilical vein endothelial cell (HUVEC) monolayers (Escudero-Perez 
et al., 2014).  Therefore, shed GP may have an effect in immune dysregulation and damage 
of endothelial barriers. 
Secreted GP (sGP) 
The primary product of the EBOV GP ORF is a non-structural protein termed secreted 
glycoprotein (sGP) (Sanchez et al., 1996; Volchkov et al., 1995).  Post-translational 
proteolytic cleavage of pre-sGP by furin results in the mature sGP and a 40 amino acid, 
heavily O-glycosylated, non-structural, secreted carboxy (C) terminal fragment termed delta 
() peptide (Volchkova et al., 1999).  Monomers of sGP are joined in a parallel orientation 
by two disulphide bonds to form a 110 kDa, mainly N-glycosylated homodimer that is 
secreted from infected cells (Barrientos et al., 2004; Falzarano et al., 2006; Sanchez et al., 
1998).  As a result of transcriptional editing, GP1,2 and sGP have the same amino (N) 
terminal 295 amino acids, but have distinct C terminal regions (Volchkov et al., 1995).  
Therefore, similarly to shed GP, sGP may function as a decoy antigen by adsorbing 
antibodies raised against GP1,2 (Ito et al., 2001; Wilson et al., 2000).  Alternatively, sGP may 
mediate ‘antigentic subversion’ and actively re-direct the host immune response towards 
non-neutralising epitopes it shares with surface GP1,2 (Mohan et al., 2012). 
Recent studies have shown that the EBOV  peptide is a viroporin; a small, hydrophobic, 
virus-encoded protein that is able to permeabilise cellular and viral membranes, and may 
play a role in the pathogenesis of EVD (He et al., 2017; Pokhrel et al., 2019).  It has been 
suggested that the EBOV  peptide may affect the gastrointestinal tract by damaging cells 
after its release from infected cells, and that this activity may contribute to the severe 
gastrointestinal illness of EVD patients (Guha et al., 2018; He et al., 2017). 
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Small secreted GP (ssGP) 
Deletion of one, or addition of two adenines at the editing site by the viral polymerase 
during transcription leads to the expression of another non-structural glycoprotein, termed 
small secreted glycoprotein (ssGP) (Mehedi et al., 2011).  ssGP is secreted as a 110 kDa, N-
glycosylated homodimer that is held together by a single disulphide bond.  ssGP shares the 
same N terminal 295 amino acids as and sGP and GP, but again, differs at the C terminus, 
however its role in viral infection remains unclear (Mehedi et al., 2011). 
1.2.4 EBOV life cycle 
The first stage of any virus life cycle is attachment to the host cell surface (Figure 1.5).  
Proteins on the viral envelope interact with specific receptors on the host cell surface to 
mediate viral entry.  Calcium-dependent (C-type) lectins (CLECs), such as dendritic cell-
specific intercellular adhesion molecule (ICAM)-3-grabbing non-integrin (DC-SIGN; also 
known as cluster of differentiation (CD) 209), liver and lymph node-specific ICAM-3-
grabbing non-integrin (L-SIGN; also known as CLEC4M), LSECtin and human macrophage 
galactose- and N-acetylgalactosamine-specific C-type lectin (hMGL), are capable of 
interacting with N- and O-linked glycans on EBOV GP to facilitate virus entry into a number 
of different cell types (Alvarez et al., 2002; Lennemann et al., 2014; Powlesland et al., 2008; 
Simmons et al., 2003; Takada et al., 2004).  Members of the Tyro3, Axl, Mer (TAM) family of 
receptor tyrosine kinases have also been suggested to be involved in EBOV entry (Brindley 
et al., 2011; Hunt et al., 2011; Shimojima et al., 2007; Shimojima et al., 2006).  TIM-1 and 
TIM-4 have been demonstrated to enhance EBOV entry into cells (Kondratowicz et al., 
2011; Moller-Tank et al., 2013; Rhein et al., 2016; Yuan et al., 2015).  TAM, TIM-1 and TIM-4 
are thought to interact with PtdSer on the surface of the viral envelope.  The host cell 
surface molecules described above are proposed to act as attachment factors, rather than 
specific entry receptors, to concentrate virions at the cell surface and promote subsequent 
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receptor attachment (Marzi et al., 2007; Matsuno et al., 2010).  The ability of EBOV to 
utilise multiple attachment factors may contribute to its broad tissue tropism. 
Following attachment to the host cell surface, EBOV virions are internalised into endosomes 
by macropinocytosis and trafficked to late endocytic compartments (Aleksandrowicz et al., 
2011; Mingo et al., 2015; Nanbo et al., 2010; Saeed et al., 2010).  Once inside the late 
endosome, the GP must be primed, and then triggered to induce fusion of the viral and 
host membranes, leading to release of the nucleocapsid into the cytoplasm (Harrison, 2008; 
White et al., 2008).  Priming of GP is mediated by the low pH dependent cysteine proteases 
cathepsin B (CatB) and cathepsin L (CatL) (Brindley et al., 2007; Chandran et al., 2005; 
Schornberg et al., 2006), which remove the MLD and glycan cap from GP1 to produce a 17 
to 19 kDa protein (Dube et al., 2009; Hood et al., 2010).  Proteolytic cleavage of GP exposes 
the RBD, enabling it to interact with Niemann-Pick C1 (NPC1) (Carette et al., 2011; Cote et 
al., 2011; Miller et al., 2012), a cholesterol transporter present in late endosomal 
membranes.  Following binding, NPC1 participates in triggering of the fusion activity of 
primed GP; however the signal required for fusion triggering remains unknown (Kuroda et 
al., 2015). 
In response to the fusion trigger, conformational changes, and possibly further proteolytic 
processing of primed GP (Brecher et al., 2012; Mingo et al., 2015; Wong et al., 2010) expose 
the hydrophobic fusion loop in GP2 (Gregory et al., 2011), resulting in insertion of 
hydrophobic residues at the tip of the fusion loop into the endosomal membrane (Gregory 
et al., 2014).  Following insertion, unwinding of the GP2 trimer causes refolding of the 
helical regions into an antiparallel, hairpin-like six-helix bundle between the HR 1 and 2 
regions, pulling the viral and host membranes into proximity for fusion (Weissenhorn et al., 
1998), allowing subsequent release of the nucleocapsid into the cytoplasm. 
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Once inside the host cell cytoplasm, the negative-sense RNA genome undergoes 
transcription and replication.  Transcription is initiated by binding of the polymerase 
complex to a single binding site located within the leader region of the negative-sense RNA 
genome, which is then transcribed into 5’-capped, 3’-polyadenylated monocistronic mRNAs 
as the polymerase complex recognises conserved start and stop sequences on the template 
(Muhlberger, 2007).  The mRNAs are then translated into proteins.  As the concentration of 
viral proteins increases, there is a switch from transcription to replication.  The negative-
sense genomic RNA template is copied into full length positive-sense copies of the viral RNA 
which, in turn, serve as templates for synthesis of full length negative-sense RNA genomes.  
Following replication, the newly synthesised genomes are assembled into new 
nucleocapsids.  mRNAs encoding GP are translocated to the endoplasmic reticulum (ER) 
where GP is synthesised and processed.  GP is further modified in the Golgi and transported 
to the plasma membrane in secretory vesicles (Hartlieb and Weissenhorn, 2006).  The 
nucleocapsids assemble with the membrane associated proteins (VP24, VP40 and GP) at 
the plasma membrane, and the resultant virions bud from the cell surface (Noda et al., 
2006).  A summary of the EBOV life cycle is shown in Figure 1.5. 
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Figure 1.5: Ebola virus (EBOV) life cycle.  The virion attaches to the host cell surface 
and is internalised into an early endosome by macropinocytosis.  Upon acidification 
of the late endosome, the cellular proteases cathepsin B and cathepsin L cleave 
glycoprotein (GP), which allows it to interact with the host protein Niemann-Pick C1 
(NPC1).  GP then mediates fusion of the viral and the endosomal membranes, 
releasing the viral ribonucleocapsid into the cytoplasm, where the negative-strand 
RNA genome undergoes transcription and replication. Production of 5’-capped, 
3’-polyadenylated mRNAs from individual viral genes, and translation of viral proteins 
occurs.  Genome replication follows in which the genomic RNA template is copied 
into a full-length positive-sense copy, which serves as a template for the synthesis of 
additional negative-sense genomes.  New nucleocapsids assemble with membrane 
associated proteins at the plasma membrane and resultant virions bud from the cell 
surface.  (Abbreviations: NP, nucleoprotein; VP, virion protein; L, large protein (RNA-
dependent RNA polymerase); sGP, secreted GP).  Figure adapted from (Messaoudi et 
al., 2015).  
25 
 
1.3 Immune response to EBOV 
1.3.1 Innate immune response 
The innate immune system is the host’s first line of defence against infection.  It consists of 
a network of non-specific cells and proteins that function to limit pathogen spread, and 
leads to initiation of the host adaptive immune response (Chaplin, 2010; Moser and Leo, 
2010).  Leukocytes (white blood cells) of the innate immune system include natural killer 
(NK) cells, mast cells, eosinophils, basophils and phagocytes, including macrophages, 
neutrophils and DCs.  Proteins involved in the innate immune response include components 
of the complement system as well as cytokines and chemokines, which are cell signalling 
molecules that function to recruit more immune cells to the site of infection, induce 
inflammation, and assist in development of an effective adaptive immune response. 
Comparison of cytokine and chemokine responses between human survivors and non-
survivors of EVD can offer insights into innate immune responses that may contribute to 
survival from EBOV infection.  In a study of blood samples obtained during five EVD 
outbreaks that occurred between 1996 and 2003 in Gabon and the Republic of the Congo, 
fatal outcome was associated with abnormal innate immune responses characterised by a 
‘cytokine storm’, with hypersecretion of numerous pro-inflammatory cytokines, 
chemokines and growth factors (Wauquier et al., 2010).  Significant upregulation of pro-
inflammatory cytokines and chemokines was also observed in fatal EVD cases during the 
2013-2016 EBOV outbreak in West Africa (McElroy et al., 2014; Ruibal et al., 2016).  
Survivors from two EVD outbreaks in Gabon demonstrated a transient release of IL-1, IL-6, 
TNF, MIP-1 and MIP-1 in plasma early in disease (Baize et al., 2002).  Additionally, 
asymptomatic EBOV infections were also characterised by transiently high levels of IL-1, 
IL-6, TNF, MCP-1, MIP-1 and MIP-1 in plasma approximately one week following the 
first potential exposure to infectious material (Leroy et al., 2000).  These studies suggest 
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that survival from EBOV infection is associated with early, transient, and well-regulated 
inflammatory responses, which may help to control EBOV replication and induce an 
effective adaptive immune response. 
1.3.2 Adaptive immune response 
The adaptive immune response is responsible for eliminating pathogens from infected 
hosts, as well as preventing pathogen replication and spread, and can generate 
immunological memory (Bonilla and Oettgen, 2010).  It consists of antibodies 
[immunoglobulins (Igs)], which are produced by B cells (lymphocytes that mature in the 
bone marrow), and T cells [lymphocytes that mature in the thymus and express a T cell 
receptor (TCR)]. 
There are two main classes of T cell, defined by the co-receptor they express; CD4 or CD8.  
Upon activation, CD8+ T cells differentiate into cytotoxic T lymphocytes (CTLs), which kill 
infected cells or tumour cells by inducing apoptosis.  Whereas CD4+ T cells, upon activation, 
differentiate into T helper (Th) cells, which release cytokines that can stimulate further T 
cell function, macrophage activation or B cell antibody production.  Th cells can be further 
subdivided into Th1, Th2, Th17 and regulatory T (Treg) cells, based on their cytokine 
secretion profiles and functions (Bonilla and Oettgen, 2010; Moser and Leo, 2010).  Th1 
cells are associated with control of intracellular pathogens and produce cytokines such as 
IL-12 and interferon gamma (IFN), whereas Th2 cells are important for protection against 
extracellular pathogens and helminths by producing cytokines such as IL-4, IL-5 and IL-13.  
Th17 cells are characterised by the production of IL-17 and are important for defence 
against extracellular pathogens, and have also been linked to autoimmunity (Bettelli et al., 
2008).  Treg cells have a role in regulating and suppressing other immune cells by producing 
cytokines that have a suppressive function, such as IL-10 (Vignali et al., 2008).  CTLs can also 
secrete cytokines, primarily IFN and TNFα. 
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Upon binding antigen via their membrane bound cell surface receptor, B cells are activated 
and differentiate into antibody-secreting plasma cells or memory B cells (Moser and Leo, 
2010).  Antibodies are ‘Y’ shaped glycoproteins that consist of two identical heavy (H) 
polypeptide chains and two identical light (L) polypeptide chains, which are linked by 
disulphide bonds (Figure 1.5).  The N terminal variable (V) domains of the heavy (VH) and 
light (VL) chains together make up the variable region of the antibody, and form the antigen 
binding sites, while the constant (C) domains of the heavy (CH1, CH2 and CH3) and light (CL) 
chains make up the constant region (Schroeder and Cavacini, 2010).  Different parts of the 
antibody molecule are responsible for various functions.  The Fab (Fragment antigen 
binding) fragments, which correspond to the two identical arms of the antibody molecule 
and contain the complete light chains paired with the VH and CH1 domains of the heavy 
chains, bind to antigen.  The Fc (Fragment crystallisable) fragment, which corresponds to 
the paired CH2 and CH3 domains, interacts with effector molecules and cells via Fc receptors 
(FcRs), thereby mediating various immune functions.  There are five major classes of Ig 
(IgM, IgD, IgG, IgA and IgE) defined by the structure of their heavy chain (µ, δ, , α and ε, 
respectively), which determines the effector function of the antibody molecule. 
Immunity mediated by antibodies is known as humoral immunity.  Antibodies can function 
by binding to and coating the surface of pathogens, thereby targeting them for destruction 
by phagocytes via Fc-FcR interactions.  Fc-FcR interactions can also result in the death of 
pathogens, or pathogen infected cells via degranulation of effector cells, thereby inducing 
lysis or apoptosis of the target cells.  This process is known as antibody-dependent cellular 
cytotoxicity (ADCC).  Finally, antibodies can activate the complement cascade, resulting in 
destruction of the pathogen or infected cell by either direct lysis or phagocytosis.  
Antibody-antigen complexes can trigger the classical complement pathway by binding to 
the C1q subcomponent of C1 via the antibody Fc region.  Following activation, as series of 
proteins are recruited to generate C3 convertase, C4b2a, which cleaves C3 into two 
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fragments; the large fragment, C3b, which remains attached to the surface of the microbial 
pathogen, and acts as an opsonin to enhance phagocytosis; and the small fragment, C3a 
(anaphylatoxin), which is released and mediates inflammation.  Activated C3 can trigger the 
lytic pathway, which ultimately results in formation of a membrane attack complex (MAC) 
and target cell lysis.  This process is known as complement-dependent cytotoxicity (CDC) In 
addition to influencing immune pathways, antibodies can also bind directly to toxins and 
viruses, thereby neutralising them by preventing interaction with host cells. 
 
 
 
 
 
 
 
Figure 1.5: Schematic representation of immunoglobulin G (IgG) structure.  Ig 
molecules are composed of two heavy (H) and two light (L) chains, linked by 
disulphide (S-S) bonds.  Both chains have variable (VH and VL) and constant regions 
(CH and CL).  (Abbreviations: N, amino terminus; C, carboxy terminus; Fab, Fragment 
antigen binding; Fc, Fragment crystallisable).  Figure adapted from www.abcam.com. 
 
There is evidence that an early and well-regulated specific adaptive immune response is 
required for survival from EBOV infection in humans (Prescott et al., 2017; Wong et al., 
2014). 
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Humoral immune response 
Comparison of immune responses between survivors and non-survivors during two EVD 
outbreaks in Gabon found that the early appearance of virus-specific IgM and IgG, followed 
by activation of CTLs at the time of antigen clearance from the blood, was associated with 
survival (Baize et al., 1999).  In contrast, fatal outcome was associated with impaired 
humoral responses, with no detectable virus-specific IgG.  This was in addition to the early 
activation of T cells that were unable to control virus replication, followed by large 
decreases in T cells, possibly due to apoptosis.  Asymptomatic individuals developed IgM 
responses at approximately 10 to 18 days following presumed exposure, and IgG responses 
approximately one week after the appearance of IgM (Leroy et al., 2000). 
Data from EVD patients evacuated to Europe following EBOV infection during the 2013-
2016 outbreak in West Africa revealed robust EBOV-specific humoral responses during 
convalescence, with the generation of neutralising antibodies (Dahlke et al., 2017b; Kreuels 
et al., 2014; Luczkowiak et al., 2016; Wolf et al., 2015). 
Cell-mediated immune response 
IL-10 expression was upregulated early and transiently in asymptomatic EBOV patients, 
whereas in fatal EVD cases, IL-10 upregulation occurred later during infection (Baize et al., 
2002; Leroy et al., 2001).  IL-10 is an anti-inflammatory cytokine and can regulate immune 
responses by inhibiting Th1 cells and NK cells, by directly inhibiting INF production, and by 
stimulating the activity of anti-inflammatory Treg cells (Couper et al., 2008).  Therefore, 
upregulation of IL-10 early during infection could help control and downregulate the 
inflammatory response, whereas upregulation of IL-10 later in disease could contribute to 
the decrease in T cell responses observed late in lethal cases of EBOV infection (Baize et al., 
1999; Leroy et al., 2001; Prescott et al., 2017). 
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A study of four survivors from the 2013-2016 outbreak in West Africa showed robust T and 
B cell activation during the acute phase of EBOV infection in all four patients (McElroy et al., 
2015).  However, these patients were treated at a hospital in the USA, and received 
substantial supportive care as well as experimental therapeutic interventions.  Therefore it 
is unclear if any of these interventions impacted the course of disease, or modified the 
immune responses in these patients (McElroy et al., 2015).  High levels of activated CD8+ 
and CD4+ T cells were observed in two of the patients up to one month following discharge 
from hospital, suggesting persistence of viral antigen and ongoing T cell stimulation.  
Examination of lymphocyte dynamics during the convalescent phase of an EVD survivor 
who received only supportive therapy and no experimental drugs detected EBOV specific T 
cells and also demonstrated the persistence of T cell activation (Dahlke et al., 2017b). 
Another study of patients from the 2013-2016 EVD outbreak in Guinea demonstrated that 
expression of the inhibitory molecules cytotoxic T lymphocyte antigen 4 (CTLA-4) and 
programmed cell death 1 (PD1) on peripheral blood CD4+ and CD8+ T cells was significantly 
upregulated in fatal EVD cases, and correlated with elevated inflammatory markers and 
high viremia (Ruibal et al., 2016).  Survivors displayed significantly lower expression of 
CTLA-4 and PD1, as well as lower inflammation, however overall T cell activation was similar 
for both survivors and non-survivors.  CTLA-4 and PD1 are key regulators of T cell 
homeostasis, therefore it could be hypothesised that upregulation of CTLA-4 and PD1 on T 
cells in fatal EVD cases, caused by excess expression of pro-inflammatory mediators, leads 
to inhibition of T cell function and poor viral clearance.  This study suggests that 
dysregulation of the T cell response may be a key component of EVD pathophysiology. 
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Long-term immunity 
It is thought that EVD survivors are protected against subsequent infection with EBOV, and 
that both neutralising antibodies and T cell responses to the EBOV GP are involved.  In an 
animal study, cynomolgus macaques that survived a previous EBOV challenge by receiving 
ZMAb, a cocktail of three EBOV GP-specific monoclonal antibodies (mAbs), beginning one 
or two days post-infection (Qiu et al., 2012), were re-challenged 10 weeks after the initial 
challenge (Qiu et al., 2013b).  All NHPs survived re-challenge and showed no signs of 
disease, indicating that a robust immune response was generated during the initial EBOV 
challenge and treatment with ZMAb, which resulted in sustained protection against a 
second lethal exposure. 
The duration of the immune response to EBOV in human EVD survivors is unknown.  It is 
likely that virus-specific IgG response declines over time (Wauquier et al., 2009), however 
various studies of survivors from previous EBOV outbreaks have found that specific IgG 
antibodies were still detectable in some individuals up to 11 years after infection (Corti et 
al., 2016; Ksiazek et al., 1999b; Wauquier et al., 2009).  A recent study of 14 survivors from 
the 1976 Yambuku EVD outbreak found that 12 of these survivors had detectable levels of 
anti-EBOV GP IgG 40 years after infection, and four of these displayed neutralising activity 
against live EBOV (Rimoin et al., 2018). 
There is little information regarding the memory T cell response following EBOV infection in 
humans.  A recent study investigating the immune responses of EVD survivors of the 2013-
2016 West African EBOV epidemic in Sierra Leone found that CD8+ T cells against the NP 
dominated the EBOV-specific responses, while only a minority of individuals had memory 
CD8+ T cell responses to the EBOV GP (Sakabe et al., 2018). 
 
 
32 
 
1.3.3 Neutralising antibodies 
Virus neutralisation by antibodies, as discussed here, is defined as the reduction of virus 
infectivity by the binding of antibodies to the viral particles (Klasse, 2014; Klasse and 
Sattentau, 2002).  Neutralisation can be mediated by a number of different mechanisms, 
which are often classified according to which step in the viral replication cycle is blocked, 
these include; inhibition of virion attachment to target cells, inhibition of fusion of the virial 
membrane with the host membrane, inhibition of the entry of the genome of non-
enveloped viruses into the cell cytoplasm, and inhibition of a function of the virion core 
through a signal transduced by an antibody (Dimmock, 1984; Mandel, 1978).  The 
mechanism of neutralisation is determined by both the properties of the viral epitope and 
the antibody that binds to it.  Therefore, as a virus has at least several unique epitopes on 
its surface, any one virus can be neutralised in several different ways.  These are 
determined primarily by the specificity of the reacting antibody (Reading and Dimmock, 
2007), and thus mechanisms of neutralisation are often analysed using mAbs.  mAbs are 
produced by a single clone of B cells and are specific for a single epitope (Kohler and 
Milstein, 2005). 
EBOV neutralising antibodies 
Based on the entry process of EBOV into host cells, three mechanisms of neutralisation 
have been proposed (Saphire and Aman, 2016): inhibition of cathepsin-mediated cleavage, 
blockage of NPC1 binding, and interference of GP2 structural rearrangements required for 
fusion of viral and host membranes.  The different structural regions of EBOV GP1,2 and 
examples of reported mAbs that bind to them are shown in Figure 1.6. 
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Figure 1.6: Schematic representation of Ebola virus (EBOV) surface glycoprotein 
(GP1,2) trimer.  Glycan cap is shown in shades of purple, GP1 core in shades of green, 
GP2 in orange, and tip of internal fusion loop (IFL) in pink.  Red dotted line represents 
cathepsin cleavage loop.  Examples of different monoclonal antibodies (mAbs) that 
bind to each region are listed.  Figure adapted from (Saphire and Aman, 2016). 
 
The first EBOV neutralising antibody, KZ52, was isolated from B cells of a human survivor of 
the 1995 Kikwit, DRC EVD outbreak (Maruyama et al., 1999).  KZ52 binds to residues within 
both GP1 and GP2 at the base of the GP trimer (Lee et al., 2008), locking GP in its pre-fusion 
conformation and therefore preventing the conformational rearrangements required to 
drive membrane fusion (Aman, 2016).  ZMAb is a cocktail of three EBOV GP-specific mAbs, 
1H3, 2G4 and 4G7, that were previously generated from mice vaccinated with a vesicular 
stomatitis virus (VSV)-based EBOV vaccine (VSVG-EBOVGP) (Qiu et al., 2011).  Two of the 
ZMAb antibodies, 2G4 and 4G7, are neutralising and target a GP base epitope shared with 
KZ52, whereas the third antibody, 1H3, binds within the glycan cap and is non-neutralising 
in vitro (Audet et al., 2014; Murin et al., 2014).  This suggests that Fc-mediated effector 
functions may play a role in protection against EBOV by non-neutralising antibodies (Gunn 
et al., 2018). 
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mAb100 and mAb114 are two other mAbs isolated from a human survivor of the 1995 
Kikwit EVD outbreak that neutralise EBOV (Corti et al., 2016).  mAb100 binds the GP base at 
a 60 angle relative to KZ52 and contacts residues near the tip of the GP2 IFL as well as 
residues at the GP1 N terminus, locking GP in its pre-fusion conformation (Misasi et al., 
2016).  Part of the mAb100 epitope is within the cathepsin cleavage site, and therefore 
mAb100 may also neutralise EBOV by inhibiting cleavage.  mAb114 binds to both the RBD 
and the glycan cap, with the glycan cap fraction not essential for binding (Misasi et al., 
2016).  Therefore, mAb114 is able to remain attached to GP after cathepsin cleavage and 
blocks GP interaction with NPC1. 
A number of additional neutralising epitopes within EBOV GP have also been identified.  
Antibodies against the IFL (Furuyama et al., 2016; Wec et al., 2017), against epitopes 
proximal to the viral membrane (termed ‘stalk-binders’) (Bornholdt et al., 2016b; Flyak et 
al., 2016), and that react to the region between the KZ52 epitope and the tip of the IFL 
(Bornholdt et al., 2016b) have all been isolated.  Several of these antibodies show cross-
neutralising activity towards multiple ebolavirus species, suggesting that development of 
broadly neutralising immunotherapies and cross-protective vaccines might be achievable 
(Zhao et al., 2017). 
FVM02 and FVM04 are mAbs derived from cynomolgus macaques immunised repeatedly 
with a mixture of engineered GPs and VLPs for three different filovirus species (EBOV, SUDV 
and MARV) (Keck et al., 2015).  FVM02 is a pan-filovirus antibody that binds to the tip of the 
IFL with high affinity.  FVM02 does not neutralise virus (EBOV and SUDV) in vitro, but 
provides significant protection from lethal EBOV challenge in mice, and therefore may 
function through Fc-mediated effector mechanisms in vivo (Schmaljohn and Lewis, 2016).  
FVM04 is a pan-ebolavirus mAb that binds to a conformational epitope within the core of 
GP1, encompassing the tip of the RBD crest and the base of GP1, and blocks NPC1 binding.  
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FVM04 effectively neutralises EBOV and SUDV in vitro and protects mice and guinea pigs 
from both EBOV and SUDV infection (Howell et al., 2016).  CA45 is another immunisation-
elicited macaque antibody that protects rodents from EBOV and SUDV infection (Zhao et 
al., 2017).  It binds to a conserved epitope that includes residues within the IFL of GP2 as 
well as the N terminus of GP1, and neutralises EBOV, SUDV, BDBV and RESTV in vitro.  CA45 
appears to function by partially inhibiting cathepsin-mediated GP cleavage and, by blocking 
virus entry post-cleavage (Zhao et al., 2017).  It has recently been demonstrated that a 
cocktail of FVM04 and CA45 is able to protect NHPs against EBOV and SUDV infection when 
delivered four days post-infection (Brannan et al., 2019). 
Several glycan cap binders with cross-reactivity to multiple ebolavirus species and potent 
neutralising activity have also been reported (Bornholdt et al., 2016b; Flyak et al., 2016; 
Holtsberg et al., 2015; Keck et al., 2015).  These antibodies also bind to sGP and the 
mechanism by which these antibodies neutralise is not clear. 
A novel phenomenon of ‘cooperative neutralisation’ by mAb pairs has been described, 
whereby neutralisation by a weakly or moderately neutralising mAb is enhanced when they 
are paired with a specific non-neutralising mAb (Howell et al., 2017).  For example, the mAb 
FVM09 has almost no EBOV neutralising activity alone, however combination with the 
poorly neutralising antibody m8C4, was able to convert m8C4 into a potent neutraliser, and 
this cocktail fully protected EBOV infected mice.  Binding of GP by FVM09 may cause a 
conformational change that leads to better access of m8C4 to its epitope (Howell et al., 
2017). 
Measurement of neutralising antibodies 
The plaque reduction neutralisation test (PRNT), first developed in the 1950s (Dulbecco et 
al., 1956), is a traditional assay for the measurement of neutralising antibodies, and has 
been applied to a wide variety of viruses including EBOV (Maruyama et al., 1999).  Briefly, 
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samples are serially diluted and incubated with a standardised amount of virus to allow any 
antibodies in the sample to bind to the virus.  The mixture is then added to a confluent 
monolayer of permissive cells and after a further short incubation period sufficient for virus 
to infect the cells, the sample suspension is replaced with a semi-solid overlay medium to 
prevent the virus from spreading to non-adjacent cells.  Plates are then incubated, fixed, 
and stained.  Virus infection is quantified indirectly by observing plaques of virus-induced 
cytopathic effect (CPE), which is measured in plaque forming units (PFU)/ml.  The 
neutralising antibody titres are defined as the sample dilutions that result in a certain 
reduction [usually 50% (PRNT50) or 90% (PRNT90)] relative to the total number of plaques 
counted without antibody. 
Neutralising antibody titres can also be determined by performing a focus reduction 
neutralisation test (FRNT), which is a variation of the PRNT, but instead of using cell lysis to 
detect plaque formation, utilise recombinant virus expressing a labelled protein or 
immunostaining of a specific viral antigen to detect infected host cells and infectious virus 
particles before an actual plaque is formed.  Like the PRNT, host cell monolayers are 
infected with various dilutions of the sample-virus mix and overlaid with a semi-solid 
medium that restricts the spread of infectious virus, creating localised clusters (foci) of 
infected cells.  Plates are subsequently probed with labelled antibodies against the viral 
antigen if necessary, and microscopy is used to count and quantify the number of foci; 
results are expressed as focus forming units (FFU)/ml. The neutralising antibody titre of a 
sample is determined as the dilution showing a reduction [e.g. 80% (FRNT80)] in foci 
compared to control without antibody. 
PRNT remains widely regarded as the ‘gold standard’ for the detection of neutralising 
antibodies for a number of viruses due to its high sensitivity and specificity, despite having 
limitations.  The use of infectious virus often requires a high level of containment and 
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expert handling and manipulation, which require expensive facilities and highly trained 
staff.  Furthermore, the assay format and time required for plaque development, which can 
take three to 14 days depending on the virus, makes it time consuming and restricts 
throughput. 
Serological studies are fundamental to assess the neutralising ability of antibodies targeted 
to EBOV GP, however due to its severe pathogenicity, potential transmission from person-
to-person contact, and lack of approved vaccines or antiviral treatments, EBOV is classified 
as a Hazard Group (HG) 4 pathogen, and handling of EBOV for clinical, diagnostic, or 
research-based purposes is limited to containment level (CL) 4 laboratories.  High 
containment facilities are expensive and are not readily available, especially in countries 
and organisations with limited resources.  Development of novel serological assays that 
utilise genetically modified recombinant or chimeric viruses with attenuated pathogenicity 
have enabled more widespread investigation of neutralising antibodies against highly 
pathogenic viruses including EBOV, for example during serosurveillance and vaccine or 
antiviral evaluation studies (Bentley et al., 2015; Mather et al., 2013).  
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1.4 Pseudotyped viruses  
Pseudotyped viruses can be used as alternatives to live infectious virus in serological assays 
for the investigation of viral infection or vaccine seroconversion (Bentley et al., 2015; King 
and Daly, 2014; Mather et al., 2013).  A pseudotyped virus is a replication-defective 
chimeric virion that consists of the structural and enzymatic core of one virus, bearing the 
envelope protein or glycoprotein of another, and encodes a quantifiable reporter gene.  
Transduction of target cells by a pseudotyped virus is dependent on the ability of the 
envelope glycoprotein to interact with receptors on the cell surface.  If binding and 
transduction are successful, the genome is transferred from the pseudotyped virus to the 
target cell and the reporter gene expressed, resulting in a quantitative read out. 
Pseudotyped viruses have been used for a variety of applications including the study of 
virus-host cell interactions, identification of potential virus entry inhibitors, and 
measurement of neutralising antibodies (King et al., 2016; Li et al., 2018; Temperton et al., 
2015).  This avoids the use of native, pathogenic virus and the need for high bio-
containment facilities, making pseudotyped viruses safer and less expensive alternatives.  
Furthermore, the range of reporter genes available, such as -galactosidase, green 
fluorescent protein (GFP) or luciferase, provide a variety of cost and time benefits (Wright 
et al., 2009), making the application of pseudotyped virus assays accessible to laboratories 
with differing resource levels. 
Retroviruses, including lentiviruses and gammaretroviruses such as human 
immunodeficiency virus (HIV) and murine leukemia virus (MLV), respectively, have been 
used as cores for pseudotyped viruses, as well as rhabdoviruses, such as VSV.  Pseudotyped 
virus systems have also been developed based on influenza virus (Powell et al., 2012). 
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1.4.1 Retrovirus-based pseudotyped viruses 
Retroviruses are able to incorporate foreign proteins, including host-derived proteins and 
envelope proteins of other viruses, into their envelope membrane (Landau et al., 1991), 
and have been extensively used as cores for pseudotyped viruses (Temperton et al., 2015).  
Retroviruses are single-stranded, positive-sense RNA viruses that replicate with a DNA 
intermediate through the process of reverse transcription.  Their genome consists of two 
identical single-stranded RNA molecules within the virion.  Following entry into the 
cytoplasm of a host cell, the viral RNA is converted into complementary DNA (cDNA) by the 
viral reverse transcriptase enzyme, and becomes integrated into the host genome as a 
provirus.  
Pseudotyped retroviruses can be produced by co-transfection of producer cells using a 
three-plasmid system (Naldini et al., 1996; Soneoka et al., 1995) (Figure 1.7).  The core 
plasmid encodes the gag-pol genes, responsible for the production and enzymatic 
processing of the core structural proteins, with the packaging signal psi () omitted to 
prevent replication competence and remove the potential risk of pathogenic virus 
proliferation.  The second plasmid encodes the envelope glycoprotein gene from the virus 
of interest, and the third plasmid encodes the chosen reporter gene and  flanked by long 
tandem repeats (LTRs), which facilitate integration into the target cell genome.  After 
transcription and translation of the imported genes, an RNA dimer of the reporter gene is 
packaged into the core.  Pseudotyped virus capsids subsequently transit to the plasma 
membrane of the producer cell where they bud extracellularly; acquiring an envelope 
consisting of a lipid bilayer derived from the plasma membrane containing heterologous 
viral envelope proteins, and can be harvested in the culture supernatant. 
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Figure 1.7: Schematic representation of three plasmid co-transfection system of 
pseudotyped virus production.  Producer cells are transfected with plasmids 
encoding the gag-pol genes, the envelope glycoprotein gene, and the reporter gene.  
Following transfection and infection, pseudotyped viruses are harvested in the 
culture supernatant.  (Abbreviations: PRO, promoter; LTR, long tandem repeat; , 
packaging signal psi).  Figure adapted from (Bentley et al., 2015). 
 
The viral components are separated across multiple plasmids so that multiple 
recombination events would be needed to produce replication-competent virus.  Also, as 
the genetic material packaged by the pseudotyped virus does not encode a viral envelope 
protein, the pseudotyped virus is capable of transducing susceptible target cells, but is 
unable to produce new virus progeny.  The retrovirus- and lentivirus-based pseudotyped 
virus systems have undergone a number of developments to further improve safety, such 
as deletion of accessory genes and promoter sequences, and provision of required 
elements on a separate fourth plasmid (Dull et al., 1998; Zufferey et al., 1998; Zufferey et 
al., 1997). 
1.4.2 Rhabdovirus-based pseudotyped viruses 
Rhabdoviruses, such as VSV, can also be used as pseudotyped virus cores (Takada et al., 
1997).  VSV has a single-stranded, negative-sense RNA genome of approximately 11 kb in 
length that encodes five major viral proteins; nucleoprotein (N), phosphoprotein (P), matrix 
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protein (M), glycoprotein (G) and large protein (L).  The G protein mediates both host cell 
binding and fusion with the endosomal membrane following endocytosis.  The P and L 
proteins are subunits of the viral RNA-dependent RNA polymerase.  VSV is able to 
incorporate heterologous transmembrane proteins into its viral membrane and has been 
shown to readily form pseudotypes when co-infected along with other enveloped viruses 
(Huang et al., 1974).  Pseudotyped VSVs can be generated by combining a recombinant VSV 
genome, in which the VSV-G gene has been deleted (rVSV-G) and replaced with a reporter 
gene (represented here by a *), with an expression plasmid encoding the desired 
heterologous virus envelope protein (Whitt, 2010). 
In order to recover rVSV-G* from plasmids, cells are transfected with the rVSV-G* 
genome plasmid along with plasmids individually encoding the VSV-G, N, P and L, all of 
which are under control of T7 promoters.  T7 RNA polymerase is provided either by 
infection of the producer cells with a recombinant virus expressing the T7 RNA polymerase, 
or by using a cell line stably expressing the T7 RNA polymerase.  Following transfection and 
incubation, the virus recovery supernatant is harvested and filtered to remove any T7 RNA 
polymerase helper virus.  The primary recovery virus is then amplified by transfection of 
cells with a VSV-G expression plasmid followed by infection with the primary recovery virus, 
with subsequent plaque purification, to ensure homogeneity and that there is no residual 
T7 RNA polymerase helper virus that may have carried over during the initial rVSV-ΔG* 
amplification after filtering (Whitt, 2010).  G-complemented rVSV-ΔG* (rVSV-ΔG*-VSV-G) 
plaque isolates are then amplified and working stocks generated and titrated, and used to 
produce heterologous pseudotypes as detailed below. 
Producer cells are transfected with a heterologous viral envelope protein expression 
plasmid and are subsequently infected with rVSV-ΔG*-VSV-G at a high multiplicity of 
infection (MOI) to ensure every cell is infected.  During budding, the rVSV-ΔG* acquires an 
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envelope consisting of a lipid bilayer derived from the plasma membrane containing 
heterologous viral envelope proteins (Figure 1.8).  Pseudotyped VSVs are then harvested in 
the culture supernatant.  Before use, the pseudotyped virus is treated with a VSV-G 
neutralising antibody to reduce background infection mediated by residual virus possessing 
VSV-G, which can be carried over during preparation (Whitt, 2010).  As the genome of the 
resultant pseudotyped virus does not encode a viral envelope protein, the pseudotyped 
virus is capable of transducing susceptible target cells, but is unable to produce new virus 
progeny. 
 
 
 
 
 
Figure 1.8: Schematic representation of pseudotyped vesicular stomatitis virus 
(VSV) production.  Producer cells are transfected with an expression plasmid 
encoding a heterologous viral envelope gene, and are subsequently infected with a 
VSV-G-complemented pseudotyped VSV encoding a reporter gene (*G-VSVG).  The 
resulting pseudotyped virus is able to transduce target cells but is unable to produce 
infectious progeny virus.  (Abbreviations: PV, pseudotyped virus).  Figure adapted 
from (Tani et al., 2011). 
 
Additional working stocks of rVSV-G*-VSV-G virus can be generated by a similar method 
as that used to pseudotype heterologous envelope proteins onto rVSV-G*, except that the 
cells are transfected using a VSV-G expression plasmid, and the infection is performed at a 
lower multiplicity to prevent accumulation of defective-interfering particles (Whitt, 2010). 
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1.4.3 Neutralisation of pseudotyped viruses 
Pseudotyped viruses can be used in serological assays, to measure neutralising antibodies 
against the envelope glycoprotein coating the pseudotype (Figure 1.9).  If target cell 
receptor binding and transduction by the pseudotyped virus are successful, the genome of 
the pseudotyped virus is transferred to the target cell and the reporter gene expressed.  
However, if neutralising antibodies to the surface glycoprotein are present, the 
pseudotyped virus does not bind to and transduce the target cell, and the reporter gene is 
not expressed.  Neutralisation can then be quantified as a decrease in reporter gene 
expression relative to pseudotyped virus infection without antibody. 
 
 
 
 
 
 
 
Figure 1.9: Schematic representation of pseudotyped virus neutralisation assay.  
Samples are serially diluted and incubated with a standardised amount of 
pseudotyped virus.  In the absence of neutralising antibodies to the viral surface 
glycoprotein, the pseudotyped virus is able to bind to and transduce the target cell.  
The genome is transferred to the target cell and the reporter gene expressed.  
However, if neutralising antibodies are present, the pseudotyped virus does not bind 
to and transduce the target cell, and the reporter gene is not expressed.  
Neutralisation can then be quantified as a decrease in reporter gene expression 
relative to pseudotyped virus infection without antibody. Figure adapted from 
(Bentley et al., 2015). 
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Pseudotyped viruses provide ideal and safe alternatives to live infectious virus, especially 
those that require a high level of bio-containment (Mather et al., 2013).  Pseudotyped virus 
neutralisation assays have been developed for a wide variety of viruses, including severe 
acute respiratory syndrome coronavirus (SARS-CoV), influenza and rabies virus, and have 
been shown to be highly sensitive and specific (Temperton et al., 2007; Wright et al., 2008).  
Furthermore, results correlated with those from the respective authentic virus 
neutralisation assays (Temperton et al., 2005; Wright et al., 2009).  Pseudotyped virus 
neutralisation assays remove the need to handle native, pathogenic virus in high bio-
containment facilities, making these assays safer, less expensive and more widely available.  
They are usually high throughput and often use smaller sample volumes compared to 
traditional assays.  In addition, the flexibility and choice of reporter systems available for 
pseudotyped virus assays can make them quicker, cheaper, and easier to perform, such as 
automated, and less subjective assay readouts and data analysis. 
1.4.4 Reverse genetics systems 
Reverse genetics systems can be used to study the replication cycles of highly pathogenic 
RNA viruses, such as filoviruses, and to develop and assess novel antiviral therapies and 
mechanisms (Hoenen and Feldmann, 2014).  Reverse genetics, as defined here, is the 
production and subsequent replication and transcription of virus RNA genomes, or 
truncated genome analogues (minigenomes), from cDNA (Hoenen et al., 2011). 
Minigenome systems have been used to study EBOV genome replication and transcription 
(Muhlberger et al., 1999).  In a minigenome, some or all of the EBOV ORFs have been 
removed and replaced with a reporter gene, which is flanked by the terminal non-coding 
regions (leader and trailer).  The minigenome is expressed in mammalian cells (usually by 
transcription using T7 RNA polymerase) together with the viral proteins L, VP35, VP30 and 
NP.  The minigenome is encapsidated by NP, and then replicated and transcribed by the 
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other nucleocapsid proteins using cis-acting signals localised in the leader and trailer, 
leading to reporter activity that reflects replication and transcription (Hoenen and 
Feldmann, 2014). 
EBOV transcription and replication competent VLP (trVLP) systems have been established 
that allow the study of EBOV morphogenesis, budding, and entry, in addition to replication 
and transcription (Hoenen et al., 2006; Hoenen et al., 2014; Watanabe et al., 2004).  These 
systems can also be used to study antiviral agents with inhibitory effects against EBOV, as 
well as interactions between host proteins and EBOV (McCarthy et al., 2016; Nelson et al., 
2016; Wang et al., 2018; Yu et al., 2018).  EBOV trVLP systems are based on classical 
minigenome systems, but include expression of the other viral proteins VP24, VP40 and GP.  
The presence of VP40 leads to the formation of trVLPs, which bear GP on their surface, and 
contain a minigenome-containing nucleocapsid on the inside.  These trVLPs can be used to 
infect naïve target cells, or target cells that have been pre-transfected with expression 
plasmids for L, VP35, VP30 and NP, to facilitate replication and transcription of 
minigenomes brought into the target cells within trVLPs.  This results in reporter activity in 
target cells, which reflects the replication of the minigenomes in the producer cells, 
morphogenesis and budding of trVLPs, their entry into target cells, and, in the case of naive 
target cells, also primary transcription (i.e. transcription by viral proteins brought into 
target cells within trVLPs), or, in the case of pre-transfected target cells, also genome 
replication and secondary transcription (i.e. transcription by viral proteins produced in 
target cells) in target cells (Figure 1.10).  
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Figure 1.10: Schematic representation of trVLP assay with a monocistronic 
minigenome.  Producer cells are transfected expression plasmids for the 
minigenome assay components (EBOV nucleocapsid proteins NP, VP35, VP30, L, a 
monocistronic minigenome and the T7 polymerase) as well as VP40, GP and VP24. 
This leads to the formation of trVLPs that incorporate minigenome-containing 
nucleocapsids (f).  These trVLPs can then infect target cells (g), which are either pre-
transfected with expression plasmids for NP, VP35, VP30, and L (top), resulting in 
replication and secondary transcription (d) leading to reporter expression (e), or 
naive target cells (bottom), resulting in primary transcription of the minigenomes (h), 
also leading to reporter expression (e).  (Abbreviations: RV, recombinant virus).  
Figure adapted from (Hoenen et al., 2014). 
 
The monocistronic minigenome system described above can only mediate single cycle 
infection of target cells.  Therefore, a tetracistronic minigenome system has been 
developed that, in addition to a reporter gene, also contains the genes encoding for VP40, 
GP and VP24 and can establish multicycle infection (Watt et al., 2014) (Figure 1.11).  This 
system leads to the production of trVLPs that can infect target cells; however VP40, GP, and 
VP24 are produced after viral genome transcription, rather than being overexpressed from 
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plasmids.  As a result, the kinetics and expression levels of these proteins much more 
closely mimic those found during the viral lifecycle, and it is possible to continuously 
passage tetracistronic minigenome-containing trVLPs. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: Schematic representation of trVLP assay with a tetracistronic 
minigenome.  Producer cells are transfected with expression plasmids for EBOV 
nucleocapsid proteins (NP, VP35, VP30, L), a tetracistronic minigenome (mg) and the 
T7 polymerase.  Initial transcription (a), encapsidation (b), genome replication (c) and 
transcription (d) as well as translation (e) occur as in a monocistronic minigenome 
assay.  However, in addition to reporter mRNA, mRNAs for VP40, GP and VP24 are 
also transcribed from the tetracistronic minigenome, resulting in the formation of 
trVLPs (f).  These trVLPs infect target cells that have been pre-transfected with 
expression plasmids for the nucleocapsid proteins NP, VP35, VP30 and L, as well as 
the cellular EBOV attachment factor Tim-1, resulting in genome replication and 
transcription, and production of trVLPs that can be used to infect fresh target cells.  
Figure adapted from (Hoenen et al., 2014). 
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Recombinant virus systems, which encode a heterologous viral envelope gene instead of its 
own envelope gene in its genome, are also available by establishment of reverse genetics 
(Schnell et al., 1996; Tani et al., 2011) (Figure 1.12), and have been used to study EBOV 
entry into target cells, and evaluate anti-EBOV neutralising antibodies (Garbutt et al., 2004; 
Konduru et al., 2018; Lee et al., 2017; Takada et al., 2003; Wong et al., 2010). 
To generate recombinant virus, producer cells are infected with a VSV-G-complemented 
recombinant virus encoding a foreign envelope gene instead of VSV-G (rVSV-ΔG-Env-VSV-
G).  During budding, the rVSV-ΔG-Env acquires an envelope consisting of a lipid bilayer 
derived from the plasma membrane containing heterologous viral envelope proteins 
(Figure 1.12).  Recombinant virus can then be harvested in the culture supernatant.  As the 
genome of the resultant recombinant virus encodes a viral envelope protein, the 
recombinant virus is replication-competent, and is capable of infecting susceptible target 
cells and producing infectious progeny viruses. 
 
 
 
 
 
Figure 1.12: Schematic representation of recombinant vesicular stomatitis virus 
(VSV) production.  Producer cells are infected with a VSV-G-complemented 
recombinant virus encoding a foreign envelope gene instead of VSV G (*G-VSVG-
Env).  The resulting recombinant virus is able to undergo a fully productive infection 
generating infectious progeny viruses that can be passaged into naïve cells.  
(Abbreviations: RV, recombinant virus).  Figure adapted from (Tani et al., 2011). 
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1.5 EVD treatment and prevention 
Efforts to develop effective vaccines and therapeutics against EBOV began soon after its 
discovery in 1976; however, there are still no licenced treatments available for EVD.  EBOV 
infection is managed with supportive therapy to maintain effective blood volume and 
electrolyte balance.  The 2013-2016 EBOV outbreak in West Africa constituted a public 
health emergency of international concern, and highlighted the urgent need for medical 
countermeasures against EBOV.  This outbreak greatly expedited the development and 
clinical evaluation of several promising therapies for EVD (Liu et al., 2017; Mendoza et al., 
2016).  These included small molecule inhibitors and immunotherapies, the latter of which 
are discussed below. 
1.5.1 Convalescent therapy 
Convalescent therapy is the treatment of an infectious disease by transferring blood 
products, which likely contain specific antibodies against the pathogen causing the disease, 
from convalescent donors to infected patients (Garraud et al., 2016).  During the 1995 EVD 
outbreak in Kikwit, eight people received whole blood transfusions from convalescent 
patients and seven survived (Mupapa et al., 1999).  However due to the small number of 
people treated, the possibility that patients had already developed antibodies, additional 
supportive care and lack of control subjects, the ability to draw conclusions regarding the 
efficacy of convalescent blood treatment was limited (Sadek et al., 1999).  Furthermore, 
transfusion of convalescent blood from NHP survivors of EVD into naïve animals shortly 
after EBOV challenge was not efficacious, casting further doubt on the therapeutic benefit 
of convalescent blood for treatment of EVD (Jahrling et al., 2007).  In addition, another NHP 
study assessing the protective efficacy of convalescent sera from rhesus macaques 
surviving EBOV challenge, showed that treatment of naïve NHPs with convalescent sera at 
the onset of viremia did not provide protection against lethal EBOV challenge (Mire et al., 
2016).  However, treatment of three naïve NHPs at two, four and eight days post-EBOV 
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exposure with concentrated, polyclonal IgG antibody from vaccinated NHP survivors of a 
prior EBOV challenge prevented mortality in all animals (Dye et al., 2012).  Two of the three 
NHPs had no clinical signs of illness, while the third developed mild and delayed signs of 
disease prior to recovery.  This study suggested a potential protective effect of antibody 
treatments for EVD. 
During the 2013-2016 EVD outbreak in West Africa, the World Health Organisation (WHO) 
prioritised the evaluation of convalescent whole blood and plasma transfusion (World 
Health Organization, 2014b).  Blood and plasma from EVD survivors are local and readily 
available sources of anti-EBOV antibodies that are specific to circulating strain, and can be 
used under circumstances of limited medical resources during EVD outbreaks.  However 
establishment of large-scale transfusion programmes can be challenging during outbreak 
settings and within resource-poor areas.  Donors must be clinically asymptomatic and have 
twice tested negative for EBOV RNA in two independent blood samples taken at least 48 
hours apart.  Donor testing is also performed to prevent transmission of blood-borne 
pathogens such as HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) and syphilis, as well 
as blood typing to avoid ABO blood group reactions. 
A non-randomised clinical trial conducted in Guinea to evaluate the safety and efficacy of 
convalescent plasma, found no significant difference in mortality between those treated 
with convalescent plasma and historical controls, suggesting limited efficacy of antibody 
therapy (van Griensven et al., 2016b).  However the levels of EBOV-specific neutralising 
antibodies in the convalescent plasma were unknown during the trial.  Follow up data 
revealed that the dose of antibodies in the donations was low, and there was no significant 
correlation between antibody dose and mortality (van Griensven et al., 2016a).  Therefore, 
the amount of EBOV-specific antibodies transfused may have been insufficient to have an 
impact on EVD and larger antibody doses may be required to observe a clinical effect.  In 
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addition, a study assessing the effectiveness of convalescent whole blood in the treatment 
of EVD patients in Sierra Leone also did not demonstrate a significant improvement in 
survival, although there was a significant decrease in viral load following the first 24 hours 
of treatment (Sahr et al., 2017), suggesting that convalescent therapy alone may not be an 
effective treatment for EBOV infection. 
1.5.2 Monoclonal antibodies (mAbs) 
An alternative to the use of polyclonal antibody preparations for the treatment of 
infectious diseases is provided by the development of mAb therapies (Both et al., 2013; 
Salazar et al., 2017).  mAbs can be manufactured in large scale and can be engineered to 
improve stability, safety, immunogenicity and therapeutic efficacy.  However, they are 
expensive to produce and have relatively small markets, making them largely unavailable, 
especially to countries with low-income economies. 
As described in section 1.3.3, the mAb KZ52 was isolated from B cells of a human survivor of 
the 1995 Kikwit EVD outbreak (Maruyama et al., 1999).  KZ52 was able to neutralise EBOV 
in vitro and protected rodents from EBOV infection (Parren et al., 2002), however it was 
ineffective at inhibiting viral replication and preventing disease in NHPs (Oswald et al., 
2007), suggesting that neutralising activity alone may not always be sufficient for 
protection against EBOV (Gunn et al., 2018).  Reduced viral loads and partial protection of 
rhesus macaques were achieved with a cocktail of two human-mouse chimeric mAbs 
(ch133 and ch226) with strong neutralising activity against EBOV, administered 
intravenously at 24 hours before, and 24 and 72 hours after EBOV challenge (Marzi et al., 
2012).  A cocktail (MB-003) of three human-mouse chimeric (c) or humanised (h) mAbs 
(c13C6, h13F6, and c6D8), manufactured in the tobacco plant, Nicotiana benthamiana, 
provided 67% protection in rhesus macaques when treatment was initiated one or two days 
after EBOV exposure, with no clinical indications of disease observed in survivors (Olinger et 
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al., 2012).  Another cocktail (ZMAb) of three EBOV GP-specific mAbs (1H3, 2G4 and 4G7), 
previously generated from mice vaccinated with recombinant VSVG-EBOV GP, resulted in 
complete protection of cynomolgus macaques, with little viremia and no apparent side 
effects, when three doses were administered three days apart beginning one day after 
lethal infection with EBOV (Qiu et al., 2012).  These studies highlighted the importance of 
antibodies in controlling EBOV replication and supported the use of mAbs to treat EVD. 
In order to develop an improved mAb cocktail that could be used as an EVD therapeutic in 
humans, the different components of MB-003 and ZMAb were tested in lethal EBOV 
challenge experiments in guinea pigs and NHPs (Qiu et al., 2014).  The individual murine 
antibodies in ZMAb were first chimerised with human constant regions and then produced 
in Nicotiana benthamiana before efficacy testing in animals.  The optimised mAb 
combination was named ZMapp™ (Mapp Biopharmaceutical, Inc.) and consisted of c13C6 
from MB-003 and c2G4 and c4G7 from ZMAb.  ZMapp completely protected rhesus 
macaques when administered as late as five days post-EBOV infection (Qiu et al., 2014). 
During the 2013-2016 West African EBOV outbreak, the WHO declared that the use of 
experimental drugs for the humanitarian treatment of EVD patients was ethical (World 
Health Organization, 2014a).  Several drugs and vaccines for EVD had shown promising 
results in the laboratory and in animal models, but had not yet been evaluated for safety 
and efficacy in humans.  Ethical criteria guided the provision of such interventions and 
included, transparency about all aspects of care, fairness, informed consent, freedom of 
choice, confidentiality, respect for the person, preservation of dignity, involvement of the 
community and risk-benefit assessment.  When unproven interventions were used to treat 
patients, there was a moral obligation to collect and share all scientifically relevant data 
generated.  Researchers also had a moral duty to evaluate these interventions in the best 
possible clinical trials under the circumstances in order to establish the safety and efficacy 
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of the interventions, or to provide evidence to stop their use (World Health Organization, 
2014a). 
ZMAb and ZMapp were administered to human EVD patients under compassionate use 
protocols, however, as patients often also received additional treatments and supportive 
care measures, the significance of the effect of the mAb cocktail treatments could not be 
conclusively determined (Lyon et al., 2014; Petrosillo et al., 2015; Schibler et al., 2015; 
Zeitlin et al., 2016).  In March 2015, a randomised controlled trial was launched to evaluate 
the efficacy of ZMapp (Davey et al., 2016).  Patients were randomised to receive either 
optimised standard of care or optimised standard of care plus three intravenous infusions 
of ZMapp three days apart (Dodd et al., 2016).  Although the estimated effect of ZMapp 
appeared to be beneficial, there was no statistically significant mortality benefit conferred 
by ZMapp.  It is possible that efficacy was not demonstrated as the study was 
underpowered, or that the dosing schedule was not optimised. 
As discussed in Section 1.3.3, mAb114 is a mAb isolated from a human survivor of the 1995 
Kikwit EVD outbreak (Corti et al., 2016).  It binds to the glycan cap and inner chalice of GP, 
and remains associated with GP after proteolytic removal of the glycan cap, thereby 
inhibiting binding of cleaved GP to NPC1 (Misasi et al., 2016).  Rhesus macaques treated 
with three doses of mAb114 beginning one, or five days post-EBOV infection survived, 
suggesting that monotherapy with a single mAb may be a possible treatment option for 
EVD (Corti et al., 2016).  However, animals that began treatment one day post-EBOV 
infection still displayed transient viremia on days four to 15 post-challenge.  In contrast, 
animals treated with three doses of a cocktail of mAb100 and mAb114, beginning one day 
post-EBOV infection, survived and exhibited no viremia, suggesting that use of mAb 
cocktails may be more protective.  Furthermore, cocktails of more than one antibody 
reduce the possibility of treatment failure that may occur with genetic changes.  Therefore 
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combination therapy is justifiable for the treatment of EVD; however it is not clear what 
combination of epitopes is best to target (Saphire and Aman, 2016). 
1.5.3 Vaccines 
A number of different vaccine platforms have been evaluated against EBOV including 
inactivated virus, DNA, protein subunits, VLPs and viral vectors.  The majority of these 
vaccines express EBOV GP as the primary immunogen, as it is the only viral protein on the 
virion surface and mediates attachment and entry into host cells.  Therefore EBOV GP is a 
key antigenic target for the development of vaccines against EVD, and has been shown to 
induce both antigen-specific cellular and humoral immune responses (Patel et al., 2018; Qiu 
et al., 2009).  Additional EBOV proteins, such as NP, have also been shown to be 
immunogenic (Prehaud et al., 1998; Sakabe et al., 2018), and have been included in EBOV 
vaccine approaches (Bazhan et al., 2019; Bounds et al., 2017; Marzi et al., 2015a).  Several 
vaccines have been shown to protect NHPs from EBOV infection, however, prior to 2014, 
only a limited number of Phase I clinical trials had been conducted (Reynolds and Marzi, 
2017).  The 2013-2016 EBOV outbreak greatly expedited the development and clinical 
evaluation of the most promising vaccine candidates for EVD. 
DNA vaccines 
DNA vaccines are easy to produce and are considered safe; however they are poorly 
immunogenic in humans and often require multiple doses to achieve strong immune 
responses (Lu et al., 2008).  Several techniques can be applied to enhance the 
immunogenicity of DNA vaccines, such as the inclusion of adjuvants or optimisation of 
delivery method or immunisation regime, e.g. heterologous prime-boost (Ferraro et al., 
2011). 
The first vaccine strategy to be 100% protective against lethal EBOV challenge in NHPs was 
a DNA prime vaccine in conjunction with a recombinant human adenovirus serotype 5 
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(Ad5) vector expressing EBOV GP boost (Sullivan et al., 2000).  Cynomolgus macaques were 
immunised with three doses of DNA encoding EBOV GP, NP and SUDV GP at four week 
intervals, followed by an Ad5-EBOV GP boost three months later.  The NHPs were 
challenged with a lethal dose of EBOV three months after the final vaccination.  All animals 
survived infection and displayed no clinical signs of disease or detectable viremia. 
A Phase I clinical trial demonstrated that three doses of the DNA vaccine was safe and well 
tolerated in humans (Martin et al., 2006).  Antigen-specific antibody and T cell responses 
were induced, however multiple doses were required and responses declined rapidly. 
Virus like particles (VLPs) 
VLPs can be utilised as a non-replicating, protein subunit-based vaccine platform.  VLPs 
have similar morphology to that of the authentic virus and are considered safe and 
immunogenic (Martins et al., 2013; Warfield and Aman, 2011). 
EBOV VLPs can be produced by expression of VP40 and GP in either mammalian or insect 
cells, and in some cases the NP is also included (Warfield and Aman, 2011).  NHPs 
vaccinated three times at six week intervals with EBOV VLPs plus RIBI adjuvant elicited 
EBOV-specific humoral and cellular immune responses (Warfield et al., 2007).  Animals 
were completely protected from lethal EBOV challenge four weeks after the last 
vaccination, with no clinical signs or detectable viremia.  NHPs vaccinated with two doses of 
EBOV- or SUDV-like particles plus QS-21 adjuvant were completely protected against lethal 
EBOV or SUDV challenge, respectively (Warfield et al., 2015).  Furthermore, the EBOV-like 
particles also provided cross-protection against TAFV, suggesting that development of a 
cross-protective VLP-based vaccine may be possible. 
Non-replicating viral vectors 
Several promising viral vector-based vaccine candidates expressing EBOV genes have been 
shown to protect NHPs from EBOV infection (Reynolds and Marzi, 2017). 
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Replication-deficient adenoviruses are commonly employed as viral vector platforms for 
the development of vaccines.  A single immunisation of Ad5 expressing EBOV GP was able 
to protect cynomolgus macaques against lethal EBOV challenge four weeks later, and 
protection correlated with antigen-specific antibody responses (Sullivan et al., 2006; Wong 
et al., 2012).  However, passive transfer of polyclonal antibodies from Ad5-EBOV GP-
vaccinated to naïve NHPs induced only partial survival, suggesting a limited role for humoral 
immunity (Sullivan et al., 2011).  CD8+ T cell depletion resulted in abrogation of protective 
immunity, with only 20% survival following EBOV challenge, indicating that CD8+ T cells are 
important for Ad5-EBOV GP-induced immune protection against EBOV infection in NHPs.  A 
single dose of an Ad5-vectored vaccine expressing the Makona EBOV GP elicited specific 
humoral and T cell immunity in NHPs, and conferred 100% protection when animals were 
challenged with EBOV four weeks after vaccination (Wu et al., 2016). 
Clinical trials have demonstrated that the Ad5-EBOV GP vaccine is safe and immunogenic in 
humans, however the short duration of antibody responses raised the possibility that a 
prime-boost strategy may be required to induce more durable immunity  (Li et al., 2017; 
Zhu et al., 2015; Zhu et al., 2017).    Furthermore, there are concerns regarding pre-existing 
immunity to the Ad5 vector in humans, which may attenuate humoral and cellular 
immunogenicity (Ledgerwood et al., 2010; Mast et al., 2010), and therefore the protective 
efficacy of AdHu5-based vaccines (Kobinger et al., 2006).  This can be circumvented by 
using different Ad serotypes that exhibit lower seroprevalence in humans, such as Ad26 and 
Ad35, or by using chimpanzee Ad (ChAd) serotypes. 
Vaccination of NHPs with Ad26-EBOV GP and SUDV GP followed by a boost with Ad35-EBOV 
GP and SUDV GP one month later induced antigen-specific B and T responses, and resulted 
in complete protection against lethal EBOV challenge four weeks after boost vaccination 
(Geisbert et al., 2011). 
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The Ad26-EBOV GP vaccine together with a Modified Vaccinia Ankara (MVA) vector 
expressing filovirus antigens (EBOV GP, SUDV GP, MARV GP and TAFV NP) (MVA-BN-filo) 
was assessed in a Phase I clinical trial and demonstrated good safety and immunogenicity 
(Milligan et al., 2016).  Immune responses were observed following primary immunisation 
with Ad26-EBOV GP, and boosting with MVA-BN-Filo resulted in sustained elevation of 
EBOV GP-specific immunity, with humoral immune responses persisting for up to one year 
(Winslow et al., 2017). 
A single inoculation of a replication-deficient ChAd3 vector expressing EBOV GP provided 
complete protection of cynomolgus macaques from lethal EBOV infection five weeks after 
vaccination, which was associated strongly with antibody responses.  However humoral and 
cellular responses declined over time and protection waned to 50% over ten months 
(Stanley et al., 2014).  Boosting of the ChAd3-EBOV GP vaccine with MVA expressing EBOV 
and SUDV GP eight weeks later was able to provide 100% protection from lethal EBOV 
infection ten months post-prime vaccination.  This long-term protection was attributed to 
the generation of both effector and memory CD8+ T cells. 
The ChAd3-based vaccine was accelerated for human Phase I clinical trials during the 2013-
2016 EBOV epidemic in West Africa, either as a monovalent vaccine expressing EBOV GP 
only (De Santis et al., 2016), or as a bivalent vaccine expressing the GPs of both EBOV and 
SUDV (Ledgerwood et al., 2017).  Both vaccines were shown to be safe and immunogenic in 
humans.  For the bivalent strategy, antigen-specific antibody responses measured four 
weeks after vaccination were in the range reported to be associated with vaccine-induced 
protection in NHP challenge studies, and responses were sustained to week 48.  However 
for the monovalent formulation, antibody titres were lower and started to decrease by six 
months post-vaccination.  Boost of either vaccine with MVA-BN-filo was safe, and enhanced 
antigen-specific cellular and humoral immune responses compared to ChAd3 vaccination 
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alone, suggesting that a prime-boost strategy could confer long-term protection against 
EBOV infection (Ewer et al., 2016; Tapia et al., 2016). 
Replication-competent viral vectors 
Replicating viral vectors are highly immunogenic and elicit robust immune responses; 
however they carry the risk of recombination and reactogenicity (Ura et al., 2014). 
VSV naturally infects livestock and various animals, and can cause asymptomatic infection 
or mild, flu-like illness in humans.  However human infection is very rare, resulting in very 
limited pre-existing immunity in the human population.  The VSV surface glycoprotein (G) 
can be replaced with a heterologous viral surface protein, resulting in an attenuated 
replication-competent virus that can be used as a vaccine (Garbutt et al., 2004; Lawson et 
al., 1995; Roberts et al., 1999). 
A single dose of a VSV-EBOV GP vaccine was able to fully protect NHPs from lethal EBOV 
challenge four weeks post-vaccination (Jones et al., 2005).  The surviving animals were 
challenged with SUDV 234 days later, however only 25% survived, indicating a lack of cross-
protection between ebolavirus species.  A single-dose blended vaccine containing VSV-
EBOV, VSV-SUDV and VSV-MARV GP protected NHPs from lethal EBOV, SUDV, TAFV and 
MARV challenge 28 days after vaccination, demonstrating the potential for a multivalent 
vaccine (Geisbert et al., 2009).  NHPs depleted of CD8+ T cells during vaccination survived 
subsequent EBOV challenge, suggesting a minimal role for CD8+ T cells in VSV-EBOV GP-
mediated protection.  Whereas animals depleted of CD4+ T cells during vaccination 
succumbed to infection and did not have a detectable anti-EBOV GP IgG response.  In 
contrast, depletion of CD4+ T cells during challenge resulted in survival of the animals.  
These results demonstrated a minimal role for CD4+ T cells in VSV-EBOV GP-mediated 
protection against lethal EBOV infection, whereas the presence of EBOV GP-specific 
antibodies was required for survival, indicating that antibodies play a critical role in VSV-
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EBOV GP-mediated protection against EBOV infection (Marzi et al., 2013).  In addition, the 
VSV-EBOV GP vaccine was able to completely protect NHPs from lethal EBOV challenge as 
early as seven days post-vaccination, suggesting that the vaccine is fast-acting and could be 
used for ring vaccination strategies during outbreaks (Marzi et al., 2015b). 
These preclinical studies supported the acceleration of VSV-EBOV GP clinical trials during 
the 2013-2016 West African EVD outbreak.  Phase I trials demonstrated that the vaccine 
was safe and generally well tolerated in humans, although mild to moderate side effects 
and adverse reactions were observed in some participants (Agnandji et al., 2017; Agnandji 
et al., 2016; ElSherif et al., 2017; Huttner et al., 2015; Regules et al., 2017).  The vaccine was 
immunogenic and induced EBOV GP-specific antibodies, which were sustained up to two 
years after vaccination (Heppner et al., 2017; Huttner et al., 2018; Kennedy et al., 2017). 
There is little information regarding the cell-mediated immune response to VSV-EBOV GP 
vaccination in humans (Lai et al., 2015), although studies have reported the generation of 
EBOV GP-specific T cells and cytokine networks following immunisation (Dahlke et al., 
2017a; Farooq et al., 2016). 
The VSV-EBOV GP vaccine was used in a ring vaccination Phase III efficacy trial in Guinea to 
assess the efficacy of the vaccine to protect against EVD, and therefore prevent EBOV 
transmission and control the epidemic (Henao-Restrepo et al., 2017).  The results indicated 
that VSV-EBOV GP is a safe and fast-acting vaccine, and showed 100% efficacy after 10 days 
of vaccination with no new cases of EVD occurring among immediately vaccinated contacts 
and contacts of contacts.  This study demonstrated the feasibility of using the VSV-EBOV GP 
vaccine in a ring vaccination design to help control outbreaks.  However, there are still 
some concerns regarding the safety of VSV-EBOV GP, especially in vulnerable populations 
such as children and young adults, pregnant women or immunocompromised individuals 
(Agnandji et al., 2017).  In March 2016, ring vaccination with the VSV-EBOV GP vaccine was 
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introduced in Guinea in response to a reported flare up of EVD, suggesting that ring 
vaccination can be rapidly and effectively implemented as part of the response to EVD 
outbreaks (Gsell et al., 2017).  Subsequently, the VSV-EBOV GP vaccine was used in 2018 in 
the DRC to vaccinate high risk populations against EVD in affected areas, and has also been 
used to vaccinate over 60,000 individuals during the ongoing EBOV outbreak in the DRC 
(World Health Organization, 2019). 
1.5.4 Correlates of protection 
In 2002, the US Food and Drug Administration (FDA) established the ‘animal rule’ for 
regulatory approval of drugs and biological products when human efficacy studies are not 
ethical and field trials to study effectiveness are not feasible (Food and Drug 
Administration, 2015).  The animal rule allows data from animal studies to provide 
substantial evidence of effectiveness when the following criteria are met: 
1. There is a reasonably well-understood pathophysiological mechanism of the toxicity of 
the substance and its prevention or substantial reduction by the product; 
2. The effect is demonstrated in more than one animal species expected to react with a 
response predictive for humans, unless the effect is demonstrated in a single animal 
species that represents a sufficiently well-characterised animal model for predicting the 
response in humans; 
3. The animal study endpoint is clearly related to the desired benefit in humans, generally 
the enhancement of survival or prevention of major morbidity; and 
4. The data or information on the kinetics and pharmacodynamics of the product or other 
relevant data or information, in animals and humans, allows selection of an effective 
dose in humans. 
NHPs are considered the ‘gold standard’ animal model for EBOV (Bennett et al., 2017; 
Geisbert et al., 2015), as they can be lethally infected with non-adapted human isolates of 
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EBOV and the resulting disease pathogenesis closely resembles that observed in humans 
(Bente et al., 2009; Feldmann and Geisbert, 2011). 
Bridging of animal protection data to humans is a key aspect of the demonstration of 
efficacy using animal data.  An immune correlate can be used to bridge the gap between 
animal efficacy studies and human immunogenicity trials.  A correlate, as defined here, is 
an immune response that is responsible for and statistically interrelated with protection 
(Plotkin, 2010).  However the human correlates of protection for EBOV are currently 
unclear (Bradfute and Bavari, 2011).  Studies of EVD survivors have identified qualitative 
associations between immune end points and survival; however they have not identified 
predictive markers of protective immunity.  Furthermore, immunity that contributes to 
survival during natural infection may not be the same as immunity that can protect 
following active or passive immunisation. 
The protective effect of antibodies against EVD had been unclear based on early passive 
transfer studies in animals and humans (Zeitlin et al., 2016), particularly polyclonal and 
convalescent blood product preparations (discussed in Section 1.5.1).  However NHP 
studies using anti-EBOV mAbs have highlighted the importance of antibodies in controlling 
EBOV infection (discussed in Section 1.5.2).  Although it is not clear what antibody 
mechanism (i.e. neutralisation of Fc-mediated effector functions) is associated with 
protection (Gunn et al., 2018; Saphire et al., 2018). 
Several vaccines have been shown to be effective against EBOV challenge in NHP studies 
and have been evaluated for safety and immunogenicity in clinical trials (discussed in 
Section 1.5.3).  However is unknown how well correlates of protection in NHPs apply to 
humans.  Furthermore, it is likely that correlates of protection induced by vaccination are 
different depending on the vaccine platform used, and are possibly related to underlying 
immune mechanisms of virus clearance (Sullivan et al., 2009).  EBOV GP-specific antibodies 
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have been shown to be associated with protection of NHPs after vaccination with VSV-
EBOV GP vaccine (Marzi et al., 2013), whereas CD8+ T cells may be more important for Ad5-
EBOV GP-induced immune protection against EBOV in NHPs (Sullivan et al., 2011).  In 
addition, variations in methodology used for assessment of immunogenicity, and the 
absence of standard assays introduce uncertainty into comparisons of different vaccine 
platforms and clinical trials. 
1.5.5 Immune escape 
Typically, RNA viruses have high spontaneous mutation rates due to error-prone RNA-
dependent RNA polymerases (Alfson et al., 2015; Holland et al., 1982).  During virus 
infection and transmission from person-to-person, EBOV may be predicted to evolve and 
changes within the genome be selected.  During the 2013-2016 EBOV outbreak, sequencing 
studies were performed to assess mutation rates and to support molecular epidemiology 
(Carroll et al., 2015; Gire et al., 2014; Park et al., 2015; Quick et al., 2016; Simon-Loriere et 
al., 2015; Tong et al., 2015).  These results and other data revealed mutations in the genetic 
sequence encoding EBOV GP.  Preliminary studies into this topic suggest that a mutation 
encoding a valine substitution for alanine at residue 82 of the EBOV GP that appeared early 
during the 2013-2016 epidemic, is associated with increased infectivity of human cells 
(Diehl et al., 2016; Dietzel et al., 2017; Kurosaki et al., 2018; Ueda et al., 2017; Urbanowicz 
et al., 2016b), potentially by reducing the threshold for activation of GP2 (Wang et al., 
2017).  However no significant differences were found in disease progression, pathogenicity 
or virus shedding of EBOV Makona isolates derived from different stages of the epidemic in 
rhesus macaques (Marzi et al., 2018). 
As mentioned above, EBOV GP is a target for novel EBOV vaccines and immunotherapies.  
Therefore mutations in EBOV GP may have important implications for anti-GP-based 
interventions, i.e. changes in the EBOV GP may affect the ability of antibodies to bind, 
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thereby leading to the emergence of escape mutants (Kugelman et al., 2015a; Kugelman et 
al., 2015b; Miller et al., 2016).  Investigation of how changes in EBOV GP might affect 
antibody neutralisation is the subject of this study. 
 
1.6 Hypothesis 
The following hypothesis was investigated: 
 Naturally acquired mutations in EBOV GP can result in escape from neutralising 
antibodies derived from EVD convalescent volunteers, EBOV GP vaccinated individuals, 
and EBOV GP-specific mAbs. 
To test the above hypothesis, specific objectives for the study were to: 
1. Optimise an EBOV GP pseudotyped virus system and compare neutralisation by EVD 
survivor plasma with live EBOV. 
2. Identify mutations that arose in the EBOV GP during the 2013-2016 EBOV epidemic that 
may have an impact on immune escape. 
3. Generate EBOV GP mutant pseudotyped viruses and assess escape from neutralisation 
by anti-EBOV GP polyclonal and mAb samples. 
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Chapter 2 Materials and Methods 
2.1 Plasmids for generation of pseudotyped viruses 
2.1.1 Plasmids 
The HIV-1 gag-pol plasmid p8.91 (Zufferey et al., 1997), the firefly luciferase reporter 
construct pCSFLW (Wright et al., 2008), and a pCAGGS EBOV (Mayinga) GP (GenBank 
accession number NC_002549) expression construct (Figure 2.1A) were kind gifts from 
Edward Wright [University of Westminster, London, United Kingdom (UK)].  A pcDNA3.1 
expression plasmid (ThermoFisher Scientific, Paisley, UK) for codon optimised EBOV 
(Makona) GP [GenBank accession number KJ660348 (Baize et al., 2014)] (Figure 2.1B) was 
kindly provided by Georgios Pollakis (University of Liverpool, Liverpool, UK).  A VSV-G 
expression plasmid was obtained from Masayuki Shimojima (National Institute of Infectious 
Diseases, Tokyo, Japan). 
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A 
 
 
 
 
 
 
 
 
Feature Plasmid bases 
CMV enhancer 87 – 371 
Beta-actin promoter 382 – 662 
EBOV GP 1757 – 3787 
M13 reverse primer 4281 – 4297 
SV40 promoter 4465 – 4644 
SV40 origin 4500 – 4577 
pBR322 origin 5013 – 5632 
Ampicillin resistance gene 5787 – 6647 
AmpR promoter 6689 – 6717 
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B 
 
 
 
 
 
 
 
 
Feature Plasmid bases 
CMV promoter 232 – 819 
T7 promoter/priming site  863 – 882 
EBOV GP 944 – 2971 
BGH reverse priming site 3009 – 3026 
BGH polyadenylation sequence 3015 – 3239 
f1 origin 3285 – 3713 
SV40 early promoter and origin 3718 – 4061 
Neomycin resistance gene 4123 – 4917 
SV40 early polyadenylation signal 5091 – 5221 
pUC origin 5604 – 6274 
Ampicillin resistance gene 6419 – 7415 
 
Figure 2.1: A) pCAGGS EBOV (Mayinga) and B) pcDNA3.1 EBOV (Makona) GP 
expression vectors were sequenced across the ORF to obtain continuous data for one 
or both strands.  The sequenced region is indicated by a green arrow.  The positions 
of primer sites utilised in the sequencing and site-directed mutagenesis processes are 
also highlighted.  The plasmid maps were generated in SeqBuilder DNA Lasergene 11 
(Madison, WI, USA). 
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2.1.2 E. coli transformation 
One Shot® TOP10 competent cells (Invitrogen, Paisley, UK) were transformed with plasmid 
DNA according to the manufacturer’s instructions.  Briefly, 1 or 5 μl of plasmid DNA was 
added directly to the vial of competent cells, mixed by tapping gently, and incubated on ice 
for 30 minutes.  The cells were incubated for exactly 30 seconds in a 42C water bath then 
placed on ice.  250 μl of pre-warmed Super Optimal broth with Catabolite repression (SOC) 
medium (2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 20 mM glucose) was added to each vial and the cells were shaken at 37C for 
exactly 1 hour at 225 rpm in a shaking incubator.  The transformation mix was diluted in 
SOC medium and spread on Luria Bertani (LB) agar (Lennox) (15 g/l agar, 10 g/l tryptone, 5 
g/l yeast extract, 5 g/l NaCl) (Sigma-Aldrich, Gillingham, UK) containing 100 µg/ml ampicillin 
(Sigma-Aldrich).  The plates were inverted and incubated at 37C overnight.   
2.1.3 E. coli culture 
E. coli clones were amplified in liquid culture by transferring a single colony from a freshly 
streaked selective agar plate to 5 ml LB Lennox medium (10 g/l tryptone, 5 g/l yeast extract, 
5 g/l NaCl, 2.2 g/l inert binding agents) (Sigma-Aldrich) containing 100 µg/ml ampicillin.  
Cultures were incubated for approximately 8 hours at 37C with vigorous shaking 
(approximately 250 rpm).  Cultures were diluted 1/500 into 100 ml (high-copy plasmids) 
selective LB Lennox medium and grown at 37C for 12 to 16 hours with vigorous shaking 
(approximately 250 rpm).  The bacterial cells were harvested by centrifugation at 3000 x g 
for 30 minutes at 4C and the supernatant discarded. 
2.1.4 Plasmid DNA purification 
Plasmid DNA was extracted from transformed E. coli using EndoFree® Plasmid Maxi or 
QIAprep® plasmid Miniprep kits (both Qiagen, Manchester, UK) as per the manufacturer’s 
instructions.  Briefly, neutralised bacterial lysates were cleared by centrifugation and 
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loaded onto anion-exchange tips, where plasmid DNA selectively binds under appropriate 
low-salt and pH conditions.  RNA, proteins, metabolites, and other low-molecular-weight 
impurities were then removed by a medium-salt wash, and ultrapure plasmid DNA was 
eluted in high-salt buffer.  The DNA was concentrated and desalted by isopropanol 
precipitation and collected by centrifugation.  Plasmid DNA was dissolved in endotoxin-free 
Buffer Tris-EDTA (TE) or nuclease-free water and the concentration determined by 
spectrophotometry (Nanodrop 2000; ThermoFisher Scientific). 
2.1.5 Restriction enzyme digest  
Restriction enzymes (New England Biolabs (NEB), Hitchin, UK) were used according to the 
manufacturer’s instructions.  Briefly, 1 unit of enzyme (1 µl) was added to 1 µg DNA 
(plasmid).  Each reaction included the appropriate NEB buffer, with or without bovine 
serum albumin (BSA) as prescribed and was made up to the required volume with nuclease-
free water.  The reaction was incubated at 37C for at least 1 hour.  For digestion with two 
enzymes, a double-digest was performed provided enzyme conditions were compatible. 
2.1.6 Separation of DNA fragments by agarose gel electrophoresis 
Horizontal gels were prepared by dissolving agarose (1%) in Tris-acetate 
ethylenediaminetetraacetic acid (TAE) buffer.  Sybr® Safe DNA gel stain (ThermoFisher 
Scientific) was added so that DNA fragments were visible under ultra-violet light for image 
capture (UVIdoc).  Samples of DNA were loaded into each gel using gel loading dye and 
were run in parallel with 1 kb DNA ladder (ThermoFisher Scientific).  Electrophoresis was 
performed at 100 V for up to 1 hour. 
2.1.7 Site-directed mutagenesis 
Site-directed mutagenesis was carried out on plasmid pcDNA3.1 EBOV (Makona) GP using 
QuikChange Lightning Site-Directed Mutagenesis kits (Agilent Technologies, Stockport, UK) 
as per the manufacturer’s instructions.  Briefly, 125 ng forward and reverse primers were 
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added.  Primers (Table 2.1) were designed using the manufacturer’s online primer design 
tool.  They were required to be 25-45 base pairs in length with base pair changes at or near 
the centre of the sequence.  Template dsDNA was present at between 10 and 100 ng.  5 µl 
10x reaction buffer, 1 µl dNTP mix and 1.5 µl QuikSolution reagent were added.  The 
reaction volume was made up to 50 µl using nuclease-free water and 1 µl of QuikChange 
Lightning Enzyme was added. 
 
Table 2.1 Primers designed for site-directed mutagenesis.  Base pair changes were made 
to plasmid pcDNA3.1 EBOV (Makona) GP in order to introduce the desired amino acid 
substitution.  Mutations are shown in red bold letters. 
Amino acid 
change 
Primer name  Primer sequence (5’ to 3’) 
A82V C245T_C246G 
F CCCCATCTCTTGGTCACGCTGGGCACATCG 
R CGATGTGCCCAGCGTGACCAAGAGATGGGG 
G74R G220C_C222G 
F GGTGGCCACCCGATTGCCCTCGAGGTTC 
R GAACCTCGAGGGCAATCGGGTGGCCACC 
R29K C85A_G86A 
F GGGGGATGCTGAAGGTCTTCTGGAACAGGATGATGA 
R TCATCATCCTGTTCCAGAAGACCTTCAGCATCCCCC 
I371L A1111C_C1113G 
F GAGGGCTGGTGCTCAGGGTGGCCAGGGTG 
R CACCCTGGCCACCCTGAGCACCAGCCCTC 
G480S G1438A 
F GTTGGTGATCAGGCTCAGCTTGCCAGAGC 
R GCTCTGGCAAGCTGAGCCTGATCACCAAC 
G480D G1439A 
F GTGTTGGTGATCAGGTCCAGCTTGCCAGAGC 
R GCTCTGGCAAGCTGGACCTGATCACCAACAC 
P330S C988A_C989G 
F GGTGGTGTTTGTCTCGCTGTCGCTGCTGGTTCTG 
R CAGAACCAGCAGCGACAGCGAGACAAACACCACC 
N107D A319G 
F CAGGTTGTAGCAGTCCTCGGCCCACTCGC 
R GCGAGTGGGCCGAGGACTGCTACAACCTG 
H407Y C1219T 
F GCCCGTCTGTGGTACTGTCCCACTTGG 
R CCAAGTGGGACAGTACCACAGACGGGC 
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Initial denaturation was performed at 95C for 2 minutes.  Cycling conditions were 18 cycles 
of 95C for 20 seconds, 60C for 10 seconds and 68C for 30 seconds per kilobase (kb) of 
plasmid length.  A final extension step of 68C for 5 minutes was performed before cooling 
the reaction to 4C.  2 µl of Dpn I restriction enzyme was added directly to each 
amplification reaction, mixed gently and thoroughly, and incubated immediately at 37C for 
5 minutes to digest the parental supercoiled dsDNA.  Mutated DNA was then transformed 
into E. coli XL10-Gold ultracompetent cells. 
2.1.8 DNA sequencing 
Sanger sequencing of DNA samples was performed using an external sequencing service 
(GENEWIZ, Takeley, UK).  Plasmid DNA was sent at, or above, the minimum concentration 
and volume required.  Where universal primers were not available, sequences for custom 
synthesised primers (Table 2.2) were provided.  Primers were designed to bind to the 
template sequence at approximately 700 base pair intervals, were typically 20-30 
nucleotides long and had a guanine-cytosine (GC)-content of between 40 and 60%.  
Sequences with secondary structure [examined using an online tool 
(http://biotools.nubic.northwestern.edu/OligoCalc.html)] were avoided. 
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Table 2.2 Custom primers designed for DNA sequencing of Ebola virus (EBOV) 
Makona and Mayinga glycoprotein (GP).  Forward (F) and reverse (R) primers were 
designed to bind to the template sequence at approximately 700 base pair intervals. 
Primer name  Primer sequence (5’ to 3’) 
EBOV Makona GP   
1 F ATCGATTCAAGCGGACCAGCTTC 
2 F GAAAGTTAACCCCGAGATCGACAC 
3 F ATCTACACCGAGGGCCTGATGCA 
4 R GGACACCTTGTGCACGTATCTGCAT 
5 R TCTGTGGTGCTGTCCCACTTGGGT 
EBOV Mayinga GP   
6 F GGTGTCGTTGCATTTCTGATACTGCCCC 
7 F CGAGCAAGAGCACTGACTTCCTGGA 
8 R GCCACTCCATTCCCTTCGAGATTCAG 
9 R CGCCGGACTCTGACCACTGATGTTT 
10 R TGCGTAGCTCAGTTGTGGCTCTCAG 
 
2.2 Cells for pseudotyped virus assays 
2.2.1 Cell culture 
Cell line Human embryonic kidney (HEK) 293T/17 (CRL-11268 American Type Culture 
Collection (ATCC), Teddington, UK) was maintained in Dulbecco’s Modified Eagle Medium 
(DMEM), high glucose, with L-glutamine (Gibco®, Paisley, UK) supplemented with 10% fetal 
bovine serum (FBS), heat inactivated (Sigma-Aldrich).  Cells were maintained in static tissue 
culture flasks, incubated at 37C, 5% CO2 and 95% humidity.  Cells were passaged every 2-3 
days.  Briefly, the cell monolayer was washed with phosphate buffered saline (PBS) without 
calcium or magnesium (Gibco®) using a volume equivalent to half the volume of culture 
medium.  Trypsin-EDTA (0.05%) (Gibco®) was pipetted onto the washed cell monolayer 
using 1 ml per 25 cm2 of surface area.  The culture flask was rotated to cover the monolayer 
with trypsin and incubated at 37C, 5% CO2 and 95% humidity for 2 to 5 minutes.  The 
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culture flask was examined to ensure that cells were detached, and the side of the culture 
flasks was gently tapped to release any remaining attached cells if necessary.  The cells 
were resuspended in a small volume of fresh serum-containing medium to inactivate the 
trypsin.  The required volume of cells was transferred to a fresh culture flask containing 
pre-warmed medium up to the appropriate volume.  No more than a total of 50 passages 
were performed. 
Cell lines Vero C1008 [Vero 76, clone E6, Vero E6 (85020206 European Culture of 
Authenticated Cell Cultures (ECACC), Salisbury, UK) and Huh-7 (Arvind Patel, University of 
Glasgow, UK) cells were maintained as described above.  Cells were passaged every 2-4 
days. 
HeLa cells (ECACC 93021013) were cultured as described above in Minimum Essential 
Media (MEM) + GlutaMAX (Life Technologies, Paisley, UK) supplemented with 10% FBS and 
1x MEM Non-Essential Amino Acids (NEAA) solution (Life Technologies).  Cells were 
passaged every 2-3 days. 
 
2.3 Generation of pseudotyped viruses 
2.3.1 Production of EBOV GP pseudotyped lentiviruses by transfection 
The generation of lentiviral pseudotyped viruses was performed as detailed previously 
(Mather et al., 2014; Temperton et al., 2007; Wright et al., 2008).  24 hours prior to 
transfection, approximately 8 x 105 293T/17 cells were seeded into sterile, 6 well cell 
culture plates (Corning, Ewloe, UK) and incubated at 37C, 5% CO2 and 95% humidity until 
60-80% confluence.  The medium was replaced with fresh medium.  The HIV gag-pol 
plasmid, p8.91, and the firefly luciferase reporter construct, pCSFLW, were transfected 
simultaneously with the EBOV (Mayinga) GP expression vector at a ratio of 0.6:0.9:0.6 µg 
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(core:reporter:envelope) using 10 µl of 1 µg/ml polyethylenimine (PEI) (408727 Sigma-
Aldrich) per 1 µg DNA in Opti-MEM® medium (Gibco®).  Following overnight transfection, 
the cells were incubated with fresh medium and incubated at 37C, 5% CO2.  Pseudotyped 
virus supernatants were harvested at 48 and 72 hours post-transfection, passed through a 
0.45 µm pore filter (Millex®, Millipore, Watford, UK) and stored at -80C. 
2.3.2 Production of EBOV GP pseudotyped VSV-G by transfection and infection 
EBOV GP pseudotyped viruses were prepared using rVSV-G with luciferase reporter (rVSV-
G-Luc) by a method similar to that described previously (Whitt, 2010).  24 hours prior to 
transfection, approximately 2.4 x 106 293T/17 cells were seeded into sterile, 100 mm cell 
culture dishes (Corning) and incubated at 37C, 5% CO2 and 95% humidity until 60-80% 
confluence.  The medium was replaced with fresh medium (DMEM, 10% FBS).  The cells 
were transfected with the EBOV GP expression vectors using TransIT®-LT1 Transfection 
Reagent (Mirus Bio, Madison, Wisconsin (WI), USA) as per the manufacturer’s instructions.  
Briefly, the TransIT®-LT1 Reagent was warmed to room temperature, and vortexed gently 
before use.  For each 100 mm cell culture dish, 45 µl TransIT®-LT1 Reagent was added to 
600 µl Opti-MEM® medium in a sterile tube and incubated for 5 minutes at room 
temperature.  15 µg plasmid DNA was added to 600 µl Opti-MEM® medium in a separate 
sterile tube.  The diluted DNA mixture was the added to the diluted TransIT®-LT1 Reagent, 
pipetted gently to mix completely, and incubated at room temperature for 15 to 30 
minutes.  The TransIT®-LT1 Reagent:DNA complex was added drop-wise to different areas 
of the cell layer and the culture dish was gently rocked back-and-forth and from side-to-
side to evenly distribute the TransIT®-LT1 Reagent:DNA complex.  Following overnight 
transfection, the medium was removed and the cells were infected with rVSV-G-Luc-VSV-
G virus at a MOI of 5 in Opti-MEM® medium and incubated at 37C, 5% CO2.  After 2 hours, 
the inoculum was removed, cells were washed twice with Dulbecco’s phosphate buffered 
saline (DPBS) (Gibco®), and fresh medium was added.  Pseudotyped virus supernatants 
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were harvested at 18-24 hours post-infection, clarified twice by centrifugation at 200 x g for 
5 minutes at 10C and stored at -80C.  Prior to use, the pseudotyped viruses were 
incubated with anti-VSV-G hybridoma cell culture supernatant (Masayuki Shimojima, 
National Institute of Infectious Diseases, Tokyo, Japan) at a 1:125 dilution for 1 hour at 
37C. 
2.3.3 Expansion of rVSV-G-Luc-VSV-G virus stock by transfection and infection 
rVSV-G-Luc-VSV-G virus stock was amplified by a method similar to that described above 
to generate EBOV GP pseudotyped VSV (Section 2.3.2), except that the virus was 
pseudotyped with VSV-G, and the infection was performed at a lower MOI, to prevent 
accumulation of defective-interfering particles (Whitt, 2010).  293T/17 cells were seeded 
and transfected with a VSV-G expression plasmid as described in Section 2.3.2.  Following 
overnight transfection, the medium was removed and the cells were infected with rVSV-
G-Luc-VSV-G virus at an MOI of 0.1 in Opti-MEM® medium and incubated at 37C, 5% CO2.  
After 1-2 hours, the inoculum was removed, cells were washed twice with DPBS, and fresh 
medium was added.  rVSV-G-Luc-VSV-G virus supernatants were harvested and stored as 
described in Section 2.3.2. 
 
2.4 Titration of pseudotyped viruses 
2.4.1 Pseudotyped lentivirus titration by luciferase assay 
Five-fold serial dilutions of pseudotyped virus at a starting dilution of 1:5 were prepared in 
quadruplicate in Opti-MEM® medium at a final volume of 100 µl/well in 96 well solid white 
flat bottom polystyrene TC-treated microplates (Corning).  100 µl of approximately 2 x 104 
293T/17, Huh-7 or Vero E6 cells, or 1 x 104 HeLa cells were then added to each well and 
incubated at 37C, 5% CO2 for 48 hours.  The medium was removed and 50 µl of a 50:50 
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mix of Bright-Glo™ luciferase assay reagent (Promega, Southampton, UK):fresh medium 
was added to each well, and incubated for at least 2 minutes at room temperature to allow 
complete cell lysis.  Luminescence was measured within 5 minutes following lysis using a 
Glomax®-Multi+ detection system luminometer (Promega), and relative luminescence units 
per ml (RLU/ml) were determined. 
2.4.2 Pseudotyped VSV-G titration by luciferase assay 
24 hours prior to transduction, approximately 2.5 x 104 293T/17 or 1 x 104 Huh-7, HeLa cells 
or Vero E6 cells were seeded in 96 well solid white flat bottom polystyrene TC-treated 
microplates and incubated at 37C, 5% CO2 and 95% humidity.  The medium was removed 
and two-fold serial dilutions of pseudotyped virus in Opti-MEM® medium, starting with 
neat pseudotyped virus were added to each well in quadruplicate at a final volume of 100 
µl/well.  After 24 hours, a chemiluminescent readout was taken as described above (Section 
2.4.1).  The negative cut-off was set at 2.5 times the average of the cells only control wells.  
50% tissue culture infectious dose (TCID50)/ml values were determined using the Reed-
Muench method (Reed and Muench, 1938). 
2.4.3 rVSV-G-Luc-VSV-G virus titration by plaque assay 
24 hours prior to transfection, approximately 3.0 x 105 Vero E6 cells were seeded into 12 
well plates (ThermoFisher Scientific) and incubated at 37C, 5% CO2 and 95% humidity.  The 
medium was replaced with fresh medium.  The cells were transfected with a pVSV-G 
expression plasmid using TransIT®-LT1 Transfection Reagent (Mirus Bio) as per the 
manufacturer’s instructions as described above (Section 2.3.2).  At 5-6 hours post-
transfection, the medium was removed and the cells were inoculated with 200 µl/well of a 
ten-fold dilution series of rVSV-G-Luc-VSV-G virus in Opti-MEM® medium at a starting 
dilution of 1:1000 in duplicate, and incubated at 37C, 5% CO2.  After 1 hour, the inoculum 
was removed and cells were washed twice with Opti-MEM® medium.  Approximately 1 ml 
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of overly medium (1% again prepared in DMEM, 5% FBS) was added to each well and 
incubated at 37C, 5% CO2 for 48 hours.  Agar plugs were removed and cells were fixed in 
20% formaldehyde DPBS for at least 1 hour.  Cells were then stained with crystal violet.  
Plates were washed with tap water, air dried, and plaques were counted. 
The rVSV-G-Luc-VSV-G virus was also assayed for luciferase activity in 293T/17 cells at 24 
hours post-infection as described above (Section 2.4.2), using a five-fold serial dilution 
series of pseudotyped virus at a starting dilution of 1:25. 
 
2.5 Neutralisation of pseudotyped viruses 
2.5.1 Human plasma samples 
Plasma samples from EVD survivors of the 2013-2016 EBOV outbreak, recruited 3 to 14 
months post-infection from two regions of Guinea (Gueckedou and Coyah), and from 
negative control blood donors in the UK and Guinea (Table 2.3) were heat inactivated at 
56C for 30 minutes.  The samples were obtained from a pre-existing biobank, for which 
live EBOV neutralisation (Agnandji et al., 2016) data were available (Thomas Strecker, 
Philipps University of Marburg, Germany) in link-anonymised format.  The biobank was 
established by Horizon 2020 EU research initiative ‘EVIDENT’ under appropriate ethical 
approval from the Guinean National Ethics Committee. 
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Table 2.3 Ebola virus disease (EVD) survivor and negative plasma samples tested in 
EBOV GP pseudotyped virus neutralisation assays.  Plasma samples from EVD 
survivors of the 2013-2016 EBOV outbreak, recruited 3 to 14 months post-infection 
from two regions of Guinea (Gueckedou and Coyah), were obtained from a pre-
existing biobank.  Live EBOV (Mayinga) neutralisation data were available for each 
sample. 
Sample Sex 
Age 
(years) 
Date discharged 
from ETC 
Live EBOV (Mayinga) 
neutralisation (GMT) 
Gueckedou – Survivors 
G001 - - 15-Apr-14 181 
G002 - - 03-May-14 4 
G003 - - 01-Jul-14 91 
G004 M 62 10-Oct-14 76 
G005 F 48 08-Sep-14 128 
G006 M 26 01-Jul-14 4 
G007 F 38 08-Oct-14 362 
G008 F 35 08-Sep-14 609 
G009 F 45 17-Sep-14 32 
G010 M 37 29-May-14 76 
G011 F 26 08-May-14 645 
G013 F 28? 13-Sep-14 108 
G014 M 40 05-Jun-14 181 
G015 M 28 05-Jun-14 128 
G016 M - 08-Jun-14 38 
G017 M 38 27-May-14 724 
G018 F 40 30-Dec-14 54 
G019 M - 17-Dec-14 38 
G020 F 27 31-Dec-14 45 
G021 F 48 07-Jun-14 215 
G022 F 19 04-Jul-14 6 
G023 F 30 03-May-14 38 
G024 F 30 17-Jun-14 76 
G025 F 44 13-Jun-14 91 
G026 M 45 13-Nov-14 45 
G027 M 48 26-Jul-14 38 
G028 F 22 22-Nov-14 54 
G029 F 20 11-Aug-14 32 
G030 M 44 18-May-14 23 
G031 M 45 26-Apr-14 54 
G032 M 35 08-Jun-14 10 
G033 F 30 16-Nov-14 54 
G035 M 45 29-May-14 215 
G036 F 40 20-Apr-14 512 
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G037 F 17 09-Apr-14 609 
G038 F 30 04-Apr-14 45 
G039 F 27 21-Jun-14 431 
G040 F 24 12-Apr-14 45 
G041 M 22 02-Jul-14 861 
G042 M 17 - 181 
G043 F 28 27-Jun-14 76 
G044 M 49 15-Apr-14 76 
G045 M 38 03-Sep-14 108 
G046 M 48 18-Sep-14 861 
G047 F 22 08-Oct-14 76 
G048 M 18 29-Aug-14 724 
G049 F 43 10-Sep-14 152 
G051 M 36 - 724 
G052 F 30 03-Dec-14 32 
 Coyah - Survivors   
CS001 F 26 14-Dec-14 1218 
CS002 F 27 27-Nov-14 152 
CS003 M 40 25-Oct-14 54 
CS004 F 22 19-Mar-15 91 
CS005 F - 23-Oct-14 108 
CS011 M - 25-Dec-14 13 
CS012 M - 22-Oct-14 91 
CS013 F - 29-Oct-14 861 
CS014 F - 22-Oct-14 152 
CS015 F - 12-Dec-14 45 
CS021 F - 02-Dec-14 19 
CS022 F - 14-Dec-14 91 
CS025 F - 26-Oct-14 76 
CS031 M - 09-Feb-15 54 
CS032 F - 08-Oct-14 181 
CS033 F - 19-Jan-15 54 
CS034 F - 20-Oct-14 152 
CS041 F - 02-Dec-14 108 
CS042 F - 10-Dec-14 64 
CS043 F - 06-Dec-14 152 
CS044 F - 19-Jan-15 256 
CS045 M - 05-Sep-14 128 
CS048 F - 20-Nov-14 38 
CS050 F - 06-Dec-14 108 
CS051 M 19 27-Mar-15 128 
CS052 M 28 27-Mar-15 304 
CS053 M - 22-Apr-15 256 
CS054 M - 12-Dec-14 861 
CS055 M - 12-Dec-14 38 
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CS056 F - 31-Dec-14 4 
CS059 F - 22-Dec-14 362 
CS061 M - 02-Jan-15 304 
CS062 M - 25-Dec-14 181 
CS063 M - 25-Dec-14 91 
CS064 M - 19-Jan-15 4 
CS066 M - 31-Dec-14 76 
CS067 F 32 28-Feb-15 45 
CS070 F - 03-Jan-15 54 
CS071 F - 27-Feb-15 38 
CS072 M - 13-Dec-14 362 
CS073 M - 07-Dec-14 91 
CS074 M - 22-Oct-14 91 
CS075 F - 11-Dec-14 76 
CS076 F - 13-Dec-14 128 
CS077 M - 06-Dec-14 45 
CS078 M - 13-Dec-14 32 
CS079 F 35 08-Mar-15 76 
CS080 F - 16-Dec-14 91 
CS081 M - 24-Oct-14 54 
CS082 F - 08-Dec-14 32 
CS083 F 65 --/06/2015 4 
CS084 F 40 29-May-15 38 
CS085 F - - 27 
CS087 M - 08-Oct-14 64 
CS089 M - 06-Mar-15 54 
CS090 M - 19-Apr-15 362 
CS091 M - 05-Feb-15 76 
CS092 M - 27-Dec-14 362 
CS093 F - - 11 
CS094 F - 14-Dec-14 54 
CS099 - - - 76 
CS100 F 35 08-Mar-15 76 
CS101 F 40 25-Feb-15 91 
CS102 M - 21-Dec-14 45 
CS103 F - 11-Nov-14 54 
CS104 F - 08-Mar-15 45 
CS105 F - 03-Jan-15 152 
CS106 M - 17-Oct-14 609 
CS107 M - 24-Nov-14 23 
CS108 M - 31-Dec-14 45 
CS109 M - 27-Dec-14 32 
CS113 F 37 03-Apr-15 108 
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 Gueckedou – Negatives 
GC025 M 22 N/A 4 
GC026 M 36 N/A 5 
GC027 M 19 N/A 4 
GC028 M 24 N/A 5 
G050 M 
 
N/A 4 
 Coyah - Negatives    
CN001 M - N/A 4 
CN002 - - N/A 4 
CN003 - - N/A 4 
CN004 M - N/A 4 
CN005 M - N/A 4 
Abbreviations: ETC, Ebola treatment centre; GMT, Geometric mean titre; - , data 
unknown. 
 
2.5.2 Pseudotyped lentivirus neutralisation assay 
Two- or three-fold serial dilutions of plasma samples at a starting dilution of 1:5 or 1:10, 
respectively, were prepared in duplicate in Opti-MEM® medium at a final volume of 50 
µl/well in 96 well solid white flat bottom polystyrene TC-treated microplates and incubated 
with 50 µl of a standardised RLU per well of pseudotyped virus [as calculated from the 
titration assay (Section 2.4.1)] prepared in Opti-MEM® medium for 1 hour at 37C.  100 µl 
of approximately 2 x 105 293T/17 cells were then added to each well and incubated for 48 
hours at 37C, 5% CO2, prior to taking a chemiluminescent readout as described in Section 
2.4.1.  Infectivity was calculated using the formula: Percentage (%) infectivity = [(RLU with 
sample)/(RLU without sample)] x 100. 
2.5.3 Pseudotyped VSV-G neutralisation assay 
24 hours prior to neutralisation, approximately 1 x 104 Vero E6 cells were seeded in 96 well 
solid white flat bottom polystyrene TC-treated microplates and incubated at 37C, 5% CO2 
and 95% humidity.  Two-fold serial dilutions of plasma samples at a starting dilution of 1:10 
were prepared in duplicate in Opti-MEM® medium at a final volume of 120 µl/well were 
prepared in 96 well microplates and incubated with 120 µl of a standardised RLU per well of 
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pseudotyped virus [as calculated from the titration assay (Section 2.4.2)] prepared in Opti-
MEM® medium for 1 hour at 37C.  The medium was removed from the cells, 50 µl of the 
plasma-pseudotyped virus mixtures were added to each well in quadruplicate at incubated 
at 37C, 5% CO2.  After 1 hour, 50 µl of fresh medium was added to each well.  
Luminescence was measured after 24 hours (Section 2.4.1) and infectivity was calculated as 
described above (Section 2.5.2). 
2.5.4 Statistical analysis 
50% inhibitory concentration (IC50) with 95% confidence interval (95% CI) of pseudotyped 
virus neutralisation were estimated by model of nonlinear regression fit with settings for 
log (inhibitor) vs. normalised response curves using GraphPad Prism v5 (San Diego, 
California (CA), USA). 
Statistical comparison between two unpaired groups was performed using the Mann-
Whitney test (GraphPad Prism v5).  Comparison between multiple unpaired groups was 
achieved using one-way Analysis of Variance (ANOVA) (GraphPad Prism v5).  Multiple 
comparisons after ANOVA was examined by post hoc Tukey’s multiple comparison test 
(GraphPad Prism v5).  Multiple matched or paired groups were compared using the 
Friedman test (GraphPad Prism v5). 
Correlation between two variables was quantified using Spearman nonparametric 
correlation (GraphPad Prism v5). 
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Chapter 3 Assessment of an EBOV GP pseudotyped lentivirus 
neutralisation assay 
3.1 Introduction 
In order to test the study hypothesis that naturally occurring mutations in EBOV GP can 
result in escape from neutralising antibodies derived from EVD convalescent volunteers and 
EBOV GP vaccinated individuals (see Section 1.6), an EBOV GP pseudotyped virus 
neutralisation assay needed to be used.  EBOV is classified as a HG4 biological agent, and 
for research-based purposes must be handled within CL4 facilities.  These are widely limited 
and require highly trained staff, and expensive and specialised equipment.  Furthermore, 
genetic manipulation and potential ‘gain of function’ experiments involving pathogens with 
pandemic potential are complex, time-consuming and costly, and are sometimes 
considered controversial (Fears and ter Meulen, 2015; Kilianski et al., 2016).  As discussed 
in Chapter 1.4, pseudotyped viruses can be used in experiments as safer alternatives to live 
infectious viruses that require a high level of bio-containment.  Retrovirus-based EBOV GP 
pseudotyped viruses have previously been used to investigate EBOV tropism, host cell 
attachment factors and mechanisms of entry (Alvarez et al., 2002; Chan et al., 2000b; Wool-
Lewis and Bates, 1998).  They have also been utilised to undertake genetic manipulation of 
EBOV GP in order to identify residues important for binding and entry (Brindley et al., 2007; 
Kuhn et al., 2006; Manicassamy et al., 2005), and determination of epitope residues for 
therapeutic mAbs (Davidson et al., 2015).  For the current study, EBOV GP pseudotyped 
lentiviruses were initially generated using a HIV-1 gag-pol packaging and luciferase reporter 
construct pNL4.3.Luc.R-E- (Connor et al., 1995; He et al., 1995).  However, luminescence 
generated following infection of 293T/17 target cells was very low, which could have been 
due unreliability of EBOV GP incorporation and/or particle assembly (Urbanowicz et al., 
2016a).  Furthermore, the assay was non-specific, as the pseudotyped viruses were able to 
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be neutralised by EBOV negative plasma samples.  Therefore, an alternative HIV-1-based 
pseudotyped virus system was selected for the current study on the basis that the required 
plasmids and methodology were available for use (Long et al., 2015; Wright et al., 2008).  
Lentivirus-based EBOV GP pseudotyped virus neutralisation assays have been used to study 
immune responses to EBOV infection and vaccination (Ewer et al., 2016; Luczkowiak et al., 
2016; Rimoin et al., 2018; Sullivan et al., 2006), as well as for evaluation of 
immunotherapeutics (Corti et al., 2016; Zhang et al., 2016).  Before the EBOV GP 
pseudotyped virus neutralisation assay could be used to investigate the effects of EBOV GP 
mutations, its suitability needed to be assessed. 
3.1.1 Generation and quantification of pseudotyped lentiviruses 
Pseudotyped lentiviruses can be produced by co-transfection of producer cells using a 
three-plasmid system (Naldini et al., 1996) (Figure 1.7).  The first plasmid encodes the gag-
pol genes, responsible for the production and enzymatic processing of the core structural 
proteins.  The second plasmid encodes the envelope glycoprotein gene from the virus of 
interest, and the third plasmid encodes the chosen reporter gene, which becomes 
packaged into the core.  The plasmids available for the current study were a HIV-1 gag-pol 
plasmid (p8.91), a firefly luciferase reporter construct (pCSFLW) and a pCAGGS EBOV 
(Mayinga) GP expression construct (Section 2.1.1).  Following transfection of 293T cells with 
the appropriate plasmids, cells are incubated for 2-3 days and pseudotyped viruses 
harvested.  The pseudotyped virus supernatants are clarified by filtration and/or 
centrifugation and stored at -80C. 
Pseudotyped viruses can be quantified by measuring reporter gene, e.g. luciferase, 
expression in susceptible target cells.  Serial dilutions of the pseudotyped virus are 
prepared prior to the addition of permissive cells.  After 2 days incubation, the transduced 
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cells are lysed and luciferase substrate added.  Luminescence is measured and RLU/ml 
calculated according to the dilution factor. 
3.1.2 Neutralisation of pseudotyped viruses 
Pseudotyped viruses can be used to measure neutralising antibodies against the envelope 
glycoprotein coating the pseudotype (Mather et al., 2013) (Figure 1.9).  Samples are serially 
diluted and incubated with a standardised amount of pseudotyped virus for 1 hour at 37C.  
Target cells are then added and incubated for 2 days, prior to measuring reporter gene 
expression as described above.  Neutralisation can then be quantified as a decrease in 
reporter gene expression relative to pseudotyped virus infection without antibody. 
3.1.3 Use of pseudotyped viruses as alternatives for infectious virus 
As previously mentioned, pseudotyped viruses can be used as surrogates in receptor 
binding and serological assays instead of live infectious virus.  However, important 
processes in the assembly and maturation of the envelope protein in the native, wild-type 
virus may be different in the generation of a pseudotyped virus.  Furthermore, the density 
of envelope protein on the surface of a pseudotyped virus may not be the same as that 
found on the respective live virus.  It is therefore important to carefully compare results 
obtained with assays using pseudotyped viruses with those from assays using authentic, 
live virus.  Method optimisation and standardisation, to ensure accuracy and 
reproducibility, as well as establishment of reference material of known neutralising 
antibody titres, are integral to maximising the use of alternative assays for the detection of 
neutralising antibodies against highly pathogenic viruses such as EBOV (Mather et al., 
2013).  Accordingly, aims for EBOV GP pseudotyped lentivirus construction, and assessment 
for suitability for use were as described below. 
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3.2 Chapter aims 
The overall objective for this Chapter was to assess the suitability of an EBOV GP 
pseudotyped lentivirus system to measure the neutralising ability of EVD convalescent 
plasma.  Specific objectives were to: 
 Propagate and confirm identity of the required plasmids. 
 
 Generate and quantify stocks of EBOV GP pseudotyped lentivirus. 
 
 Optimise EBOV GP pseudotyped lentivirus neutralisation assay methodology. 
 
 Assess neutralisation of EBOV GP pseudotyped lentivirus by EVD survivor plasma. 
 
 Compare neutralisation results of EBOV GP pseudotyped lentivirus with live EBOV. 
 
3.3 Results 
3.3.1 Preparation of plasmids for production of EBOV GP pseudotyped lentivirus 
The HIV-1 gag-pol plasmid p8.91, the firefly luciferase reporter construct pCSFLW, and the 
pCAGGS EBOV (Mayinga) GP expression construct were propagated as described in Section 
2.1.  After purification using Endofree® Plasmid Maxi kits, plasmid identity was confirmed 
via analytical restriction enzyme digest (Section 2.1.5) and separation by agarose gel 
electrophoresis (Section 2.1.6).  Fragments of the expected sizes were observed for all 
digests (Figure 3.1).  In addition, the pCAGGS EBOV (Mayinga) GP expression construct was 
sequenced (Section 2.1.8) to confirm integrity of the entire ORF.  The plasmid map, 
annotated to show the restriction enzyme sites and sequenced region, is presented in 
Figure 2.1A.  The plasmids were then used to generate EBOV (Mayinga) GP pseudotyped 
virus as described in Section 2.3.1. 
 
86 
 
 
 
 
 
 
 
Figure 3.1: Analytical digest of p8.91 with BglII (#2), pCSFLW with BamHI and NotI 
(#4), and pCAGGS EBOV (Mayinga) GP with KpnI and XholI (#6).  Purified plasmid DNA 
was subject to restriction enzyme digest.  Fragments of the expected sizes were 
observed for all digests.  Undigested plasmids were included as controls (#1, #3 and 
#5). 
 
3.3.2 Cell tropism of EBOV GP pseudotyped lentivirus 
EBOV (Mayinga) GP pseudotyped virus was generated by transfection of 293T/17 cells using 
p8.91, pCSFLW and pCAGGS EBOV (Mayinga) GP as described in Section 2.3.1.  The 
pseudotyped virus was used to infect 293T/17, Huh-7, HeLa and Vero E6 cells as described 
in Section 2.4.1 and RLUs/ml were determined.  A pseudotyped virus bearing the VSV-G 
protein was used as a positive control, and cells only controls were used to determine 
background levels of luminescence.  All cell lines tested were permissive to infection by 
EBOV GP pseudotyped virus, demonstrating the broad tissue range conferred by EBOV GP, 
although differences in infectivity were observed (Figure 3.2).  Highest luminescence values 
were observed in 293T/17 cells (8 x 107 RLU/ml), followed by Huh-7 cells (5 x 107 RLU/ml).  
RLUs/ml generated by infection of 293T/17 cells were approximately 2, 33 and 196 times 
greater than those produced by infection of Huh-7, HeLa and Vero E6 cells, respectively.  
This variation may reflect a general defect in viral entry in these cells, or a problem in 
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integration or expression of the HIV-1 genome (Wool-Lewis and Bates, 1998).  The relatively 
low level of transduction exhibited by Vero E6 cells might reflect the poor ability of HIV to 
replicate in many non-human primate (NHP) cells (Besnier et al., 2002).  Based on this 
result, the 293T/17 target cell line was selected for use in all subsequent neutralisation 
assays. 
 
 
 
 
 
 
 
Figure 3.2: Infection of different cell lines with EBOV (Mayinga) GP and VSV-G 
pseudotyped viruses.  Pseudotyped viruses were serially diluted and incubated with 
2x104 293T/17, Huh-7 or Vero E6 cells, or 1x104 HeLa cells per well.  Luminescence 
was detected after 48 hours and relative luminescence units (RLUs)/ml were 
calculated.  Error bars are 1 standard error above and below the mean, n=4.  
Background luminescence is represented by cells only controls. 
 
3.3.3 Assessment of EBOV GP pseudotyped lentivirus input for neutralisation 
To assess the effects of differing amounts of pseudotyped virus input on the neutralisation 
assay results, plasma samples from a UK negative control individual (PN004) and from a 
Guinean EVD survivor donor (CS001) were screened against three different amounts (2.2 x 
104, 8.6 x 104  and 2.4 x 105 RLU/well) of EBOV (Mayinga) GP pseudotyped virus (Section 
2.5.2).  Percentage infectivity was determined relative to infectivity of 293T/17 cells by 
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EBOV GP pseudotyped virus alone (Figure 3.3A), and IC50 of pseudotyped virus 
neutralisation were estimated by model of nonlinear regression dose-response curves as 
described in Section 2.5.4 (Figure 3.3B).  Plasma from EVD survivor CS001 displayed 
neutralising activity against all amounts of EBOV GP pseudotyped virus tested (Figure 3.3A).  
Negative plasma (PN004) displayed no or little inhibitory effect against EBOV GP 
pseudotyped virus, however IC50 values increased gradually with decreasing amounts of 
pseudotyped virus input (Figure 3.3B).  There was better separation of the positive and 
negative responses when at least 8.6 x 104 RLU/well was used (Figure 3.3B).  Lower 
pseudotyped virus input resulted in larger variability and less curve fitting, as supported by 
decreasing R2 values (Figure 3.3C).  Therefore a pseudotyped virus input of at least 8.6 x 104 
RLU/well, with a target input of 2.0 x 105 RLU/well, was used in subsequent neutralisation 
assays. 
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Figure 3.3: Effect of EBOV (Mayinga) GP pseudotyped virus input on neutralisation by 
EVD survivor (CS001) plasma.  Different amounts of pseudotyped virus were 
incubated with dilutions of heat inactivated plasma samples at 37C for 1 hour 
before the addition of 293T/17 cells.  Luminescence was detected after 48 hours and 
A) percentage infectivity was calculated.  Dotted line represents 50% infectivity.  B) 
The IC50 of pseudotyped virus neutralisation were estimated by model of nonlinear 
regression dose-response curves, and C) the R2 values of dose-response curves were 
determined. 
 
3.3.4 Neutralisation of EBOV GP pseudotyped lentivirus by EVD survivor plasma 
Neutralisation of EBOV (Mayinga) GP pseudotyped virus by plasma samples collected from 
119 EVD survivors of the 2013-2016 EBOV outbreak 3 to 14 months post-infection, and 10 
negative control donors from Guinea (Section 2.5.1) was evaluated (Section 2.5.2) over the 
course of seven assays.  In order to control for any differences due to variability in 
pseudotyped virus production and/or titration, the same batch of pseudotyped virus was 
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used for all assays.  Assay controls and reproducibility are discussed in Section 3.3.5.  The 
IC50 of pseudotyped virus neutralisation were estimated by model of nonlinear regression 
dose-response curves as described in Section 2.5.4.  The results are presented in Figure 3.4.  
Dose-response curves were unable to be fitted for 21 (20 EVD survivor and one negative) 
out of the 129 samples tested due to lack of neutralisation, and therefore IC50 values could 
not be calculated for these samples.  Although there appeared to be little difference in 
neutralisation titres between the EVD survivor and negative plasma samples, there was a 
statistically significant difference between the two groups (Mann-Whitney, p = 0.0023). 
 
 
 
 
 
 
 
Figure 3.4: Neutralisation of EBOV (Mayinga) GP pseudotyped virus by EVD survivor 
and negative plasma samples.  Pseudotyped virus was incubated with dilutions of 
heat inactivated plasma samples at 37C for 1 hour before the addition of 293T/17 
cells.  Luminescence was detected after 48 hours and percentage infectivity was 
calculated.  The IC50 of pseudotyped virus neutralisation were estimated by model of 
nonlinear regression dose-response curves.  Data are shown for individuals, and the 
geometric mean with 95% CI.  Dotted line represents background level of 
pseudotyped virus neutralisation (6.28) and is equal to UK negative control plasma 
mean plus two standard deviations.  Statistically significant difference is highlighted 
(**p < 0.05; Mann-Whitney). 
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To further validate the EBOV GP pseudotyped virus neutralisation assay, a human anti-
EBOV GP mAb, KZ52 (IBT Bioservices, Rockville, Maryland (MD), USA), and anti-EBOV 
plasma, human WHO reference reagent (Code 15/220 National Institute of Biological 
Standards and Control (NIBSC), Potters Bar, UK) were tested (Section 2.5.2).  KZ52 is an 
antibody isolated from a human survivor of the 1995 outbreak in Kikwit that neutralises 
EBOV in vitro and recognises a conformational epitope at the base of the GP (Lee et al., 
2008; Maruyama et al., 1999; Parren et al., 2002).  Anti-EBOV plasma, human WHO 
reference reagent has been established by the WHO Expert Committee on Biological 
Standardization (ECBS) for use in serology assays (World Health Organization & WHO Expert 
Committee on Biological Standardization, 2015), and the source material is plasma 
obtained from a single donor recovered from EVD.  The anti-EBOV plasma, human WHO 
reference reagent was able to neutralise the EBOV GP pseudotyped virus (Figure 3.5A), 
however human anti-EBOV GP mAb, KZ52 was not (Figure 3.5B).  This suggests that the 
conformation or density of EBOV GP on the pseudotyped virus may differ from that on live 
virus. 
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Figure 3.5: Neutralisation of EBOV (Mayinga) GP pseudotyped virus by A) EVD 
survivor and negative control (PN004) plasma samples and B) human anti-EBOV GP 
mAb, KZ52.  Pseudotyped virus was incubated with dilutions of heat inactivated 
plasma samples at 37C for 1 hour before the addition of 293T/17 cells.  
Luminescence was detected after 48 hours and percentage infectivity was calculated.  
Dotted lines represent 50% infectivity. 
 
3.3.5 Reproducibility and correlation with live EBOV neutralisation 
Plasma from Guinean EVD survivor G037, and a UK negative control donor PN004, were 
included in each neutralisation assay to serve as a positive and negative control, 
respectively.  Neutralisation of EBOV (Mayinga) GP pseudotyped virus by plasma from EVD 
survivor G037 was fairly consistent (Figure 3.6); IC50 values ranged from 39.11 to 121.68, 
with an average of 69.17.  The average IC50 value of PN004 from all the assays plus two 
standard deviations was used to determine background neutralisation (IC50 of 6.28). 
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Figure 3.6: Reproducibility of neutralisation of EBOV (Mayinga) GP pseudotyped virus 
by positive (G037) and negative (PN004) control plasma samples.  Pseudotyped virus 
was incubated with dilutions of heat inactivated plasma samples at 37C for 1 hour 
before the addition of 293T/17 cells.  Luminescence was detected after 48 hours and 
percentage infectivity was calculated.  The IC50 of pseudotyped virus neutralisation 
were estimated by model of nonlinear regression dose-response curves.  Data are 
shown for individuals and the mean with standard deviation, n=7.  Dotted line 
represents background level of pseudotyped virus neutralisation (6.28) and is equal 
to negative control plasma mean plus two standard deviations. 
 
Out of the 119 EVD survivor samples tested, 20 were deemed below the background limit 
of the assay (Figure 3.4).  Three of the 10 Guinean negative plasma samples tested were 
above the background level of neutralisation.  The reason for this non-specific 
neutralisation is unknown; however it could be due to interference by specific antibodies to 
related viruses or pre-existing immunity (Boisen et al., 2015; O'Hearn et al., 2016; Schoepp 
et al., 2014), although this is unlikely as these samples were negative in a live EBOV 
neutralisation assay and also in an EBOV enzyme linked immunosorbent assay (ELISA) (data 
not shown). 
For each sample tested, pre-existing data from a live EBOV neutralisation assay were 
available (Section 2.5.1).  There was a positive correlation (rs = 0.52) when IC50 values of 
EBOV GP pseudotyped virus neutralisation were compared with geometric mean titre 
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(GMT) values for live EBOV neutralisation using the nonparametric Spearman correlation 
coefficient (Figure 3.7), and this was statistically significant (p < 0.0001). 
 
 
 
 
 
 
Figure 3.7: Correlation of EBOV GP pseudotyped virus (IC50) and live EBOV (GMT) 
neutralisation using the nonparametric Spearman correlation coefficient, n=108.  
Dotted lines represent background level of neutralisation.  Background level of 
pseudotyped virus neutralisation (6.28) is equal to negative control plasma mean 
plus two standard deviations.  Seropositivity in the live EBOV neutralisation assay is 
defined by a GMT > 8. 
 
3.4 Discussion 
In this Chapter, the suitability of an EBOV GP pseudotyped lentivirus system to measure the 
neutralising ability of EVD convalescent plasma was assessed.  The pseudotyped virus 
system used was selected based on the plasmids and methodology that were available at 
the onset of the study (Long et al., 2015; Wright et al., 2008).  Furthermore, this system had 
been applied during a Phase I clinical study to measure neutralising antibodies following 
EBOV vaccination (Ewer et al., 2016).  A number of lentivirus-based EBOV GP pseudotyped 
virus neutralisation assays have been used to investigate immune responses to EBOV 
infection and vaccination (Luczkowiak et al., 2016; Rimoin et al., 2018; Sullivan et al., 2006), 
r
s
 = 0.52 
p < 0.0001 
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as well as for evaluation of mAb therapies (Corti et al., 2016; Davidson et al., 2015; Zhang et 
al., 2016). 
3.4.1 Generation and quantification of EBOV GP pseudotyped lentivirus 
EBOV (Mayinga) GP pseudotyped virus was successfully generated by transfection using 
plasmid DNA encoding EBOV GP, along with HIV-1 gag-pol packaging, and luciferase 
reporter constructs.  The pseudotyped virus was titrated using a range of target cell lines 
and quantified by measuring luminescence.  Previous studies have shown that EBOV GP has 
a broad host range, infecting cells derived from a wide variety of species and tissues (Chan 
et al., 2000b; Wool-Lewis and Bates, 1998).  In this study, all cell lines tested (293T/17, Huh-
7, HeLa and Vero E6) were permissive to infection by EBOV GP pseudotyped virus, although 
differences in luminescence were observed.  This may reflect a general defect in viral entry 
in different cells, or a problem in integration or expression of the HIV-1 genome (Wool-
Lewis and Bates, 1998).  A relatively lower level of transduction was exhibited by Vero E6 
cells, which might be due to an intrinsic restriction factor, TRIM5α, which restricts retroviral 
infection by specifically recognising the HIV-1 capsid and promoting its rapid, premature 
disassembly (Stremlau et al., 2006).  Highest luminescence values were obtained following 
infection of 293T/17 cells, which have previously been reported to be permissive to EBOV 
infection, and have been used as target cells in pseudotyped virus assays (Corti et al., 2016; 
Davidson et al., 2015; Kuhn et al., 2006; Manicassamy et al., 2005; Wool-Lewis and Bates, 
1998).  Therefore this cell line was selected for use in subsequent neutralisation assays. 
3.4.2 Neutralisation of EBOV GP pseudotyped lentivirus by EVD survivor plasma 
Pseudotyped virus neutralisation assays have been developed for a variety of pathogens, 
including rabies (Nie et al., 2017; Wright et al., 2008), Middle East respiratory syndrome 
coronavirus (MERS-CoV) (Zhao et al., 2013), chikungunya virus (Kishishita et al., 2013; 
Salvador et al., 2009) and influenza (H5N1) (Garcia et al., 2010; Wang et al., 2010).  Samples 
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from vaccinated individuals and/or from patients recovered from the disease of interest are 
often used in the optimisation of these assays to assess experimental parameters that can 
affect assay performance, and to ensure accuracy and reproducibility.  The lentivirus-based 
EBOV GP pseudotyped virus generated for the current study was used to assess the 
neutralising activity of plasma from EVD survivors of the 2013-2016 EBOV outbreak and a 
UK negative control donor.  Decreasing quantities of pseudotyped virus led to more 
variable and unreliable results, and therefore a pseudotyped virus input of at least 8.6 x 104 
RLU/well was used in subsequent neutralisation assays.  Plasma from a UK negative control 
donor displayed little or no neutralising activity against EBOV GP pseudotyped virus and 
was used to determine a background level of neutralisation for the assay.  The EBOV GP 
pseudotyped lentivirus neutralisation assay was able to measure neutralising antibodies in 
plasma from EVD convalescent patients and was reproducible. 
3.4.3 Suitability of EBOV GP pseudotyped lentivirus neutralisation assay for future use 
As mentioned previously, pseudotyped viruses can be used in serological assays as 
alternatives to live infectious virus.  Pseudotyped virus assays used to profile neutralising 
antibody responses against SARS-CoV (Temperton et al., 2005), influenza (H5N1 and H7N9) 
(Alberini et al., 2009; Qiu et al., 2013a; Temperton et al., 2007; Wang et al., 2010), rabies 
(Nie et al., 2017; Wright et al., 2009; Wright et al., 2008) and chikungunya virus (Kishishita 
et al., 2013), for example, found that results correlated with, or were more sensitive than 
those from conventional replication-competent or live virus assays.  A Phase I EBOV vaccine 
study found that neutralising antibody titres in a live EBOV and an EBOV pseudotyped virus 
assay correlated positively with each other (rs = 0.57, p = 0.001) (Ewer et al., 2016).  
However, a comparison of a range of assays for antibody to EBOV (Wilkinson et al., 2017), 
raised questions of the reliability and relevance of neutralisation of the lentiviral 
pseudotypes evaluated.  This was both in relation to specificity, as a number of negative 
samples were scored positive, and poor quantitative correlation with the wild-type 
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neutralisation assays.  The EBOV GP pseudotyped lentivirus neutralisation assay assessed 
for the current study correlated positively with a live EBOV neutralisation assay.  However, 
the discriminatory power of the assay with regards to differing antibody titres appeared to 
be low.  Some of the samples tested, which showed neutralising activity against live EBOV, 
did not display neutralisation against the pseudotyped virus and vice versa, therefore 
raising questions on the sensitivity and specificity of the pseudotyped virus assay.  In the 
current study, human embryonic kidney (293T/17) cells were used for the pseudotyped 
virus neutralisation assays, whereas African green monkey kidney (Vero) cells were used in 
the live EBOV assay, and therefore this could account for some of the differences in results 
observed between the two assays.  Furthermore, a human anti-EBOV GP mAb, KZ52, did 
not display neutralisation in the pseudotyped virus neutralisation assay, suggesting that the 
EBOV GP on the pseudotyped virus may not be folded correctly.  KZ52 has been shown 
previously to neutralise live EBOV and EBOV pseudotyped viruses (Davidson et al., 2015; 
Dias et al., 2011; Luczkowiak et al., 2016; Maruyama et al., 1999; Shedlock et al., 2010).  
Therefore, the apparent poor sensitivity of the current assay may explain the lack of 
neutralisation displayed by KZ52, and neutralisation may be observed using a higher 
concentration. 
There are several differences between the EBOV GP pseudotyped virus and the live EBOV 
neutralisation assays that could affect their results (Saphire et al., 2018).  Firstly, the round, 
spherical shape of EBOV GP pseudotyped lentivirus compared to the filamentous shape of 
authentic EBOV could affect their susceptibility to neutralisation.  Also, the density of GP on 
the surface of the pseudotyped virus may not be the same as that found on live EBOV and 
may result in the loss or masking of quaternary epitopes (Mather et al., 2013; Nelson et al., 
2008).  Furthermore, processes in the assembly and maturation of GP in live EBOV, such as 
trimer formation and glycosylation, may be different in the generation of EBOV 
pseudotyped virus resulting in different targets and/or conformational epitopes when using 
98 
 
whole live EBOV as opposed to EBOV GP alone in a pseudotyped virus.  The presence of sGP 
in the live EBOV assay compared to no sGP in the EBOV GP pseudotyped virus assays could 
also have an effect on neutralisation.  In the live EBOV assay, sGP could reduce 
neutralisation of circulating virus by sGP-cross-reactive antibodies, however in the current 
study, weaker relative neutralisation was observed in the pseudotyped virus assay.  
Therefore, other components, such as cell debris or free GP generated during pseudotyprd 
virus production by transfection could interfere with neutralisation in the pseudotyped 
virus assay.  Finally, detection of infected cells via measurement of luminescence in the 
EBOV GP pseudotyped virus neutralisation assay compared to plaque formation in the live 
EBOV neutralisation assay could affect neutralisation readout. 
 
3.5 Conclusions 
The EBOV GP pseudotyped lentivirus neutralisation assay was able to detect neutralising 
antibodies in plasma from EVD survivors and correlated positively with a live EBOV 
neutralisation assay.  However, the ability of the pseudotyped virus neutralisation assay to 
differentiate between neutralising activity appeared to be limited.  In order to study the 
effects of EBOV GP mutations on neutralising antibodies, a sensitive and specific EBOV GP 
pseudotyped virus assay is needed.  Therefore, a VSV-based pseudotyped virus system was 
investigated to determine if this was a more suitable platform than HIV-1 to measure the 
neutralising ability of EVD convalescent plasma, and is described in Chapter 4. 
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Chapter 4 Assessment of an EBOV GP pseudotyped VSV neutralisation 
assay 
4.1 Introduction 
Like retroviruses, rhabdoviruses, such as VSV, can also be used as pseudotyped virus cores 
(Takada et al., 1997), and have been used to study pathogenic viruses that require high 
level bio-containment facilities, including SARS-CoV (Fukushi et al., 2005), influenza 
(Zimmer et al., 2014) and Crimean-Congo haemorrhagic fever (CCHF) (Suda et al., 2016).  
However establishment of a VSV-based pseudotyped system is slightly more complex than 
retrovirus-based, and requires stocks of VSV-G protein pseudotyped rVSV, in which the 
VSV-G gene has been deleted and replaced with a reporter gene, to be generated and 
quantified (Whitt, 2010).  VSV-based pseudotyped viruses have previously been used to 
investigate EBOV tropism, host cell attachment factors and mechanisms of virus entry 
(Chandran et al., 2005; Dube et al., 2009; Hoffmann et al., 2017; Ito et al., 1999; 
Kondratowicz et al., 2011; Kuroda et al., 2015), as well as for measurement of neutralising 
antibodies to EBOV (Ito et al., 2001; Takada et al., 2003). 
4.1.1 Generation and quantification of pseudotyped VSVs 
Pseudotyped VSVs can be produced by combining an rVSV genome, in which the VSV-G 
gene has been deleted and replaced with a reporter gene, represented here by a *, (rVSV-
G*), with an expression plasmid encoding the envelope protein from the virus of interest 
(Whitt, 2010) (Figure 1.8).  Following transfection of 293T [or baby hamster kidney (BHK-
21)] cells with the appropriate viral envelope protein expression plasmid, cells are 
incubated for 1 day and infected with rVSV-G* that has previously been pseudotyped with 
VSV-G protein (rVSV-G*-VSV-G) at an MOI of approximately 3-5, to ensure every cell is 
infected, for 1-2 hours.  Pseudotyped viruses are then harvested at 18-24 hours post-
infection.  The pseudotyped virus supernatants are clarified by centrifugation and stored at 
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-80oC.  Before use, the pseudotyped virus is treated with a VSV-G neutralising antibody to 
reduce background infection mediated by residual virus possessing VSV-G, which can be 
carried over during the preparation of the pseudotyped virus.  Additional working stocks of 
rVSV-G*-VSV-G virus can be generated by a similar method as that used to pseudotype 
heterologous envelope proteins onto rVSV-G*, except that the cells are transfected using 
a VSV-G expression plasmid, and the infection is performed at a lower multiplicity to 
prevent accumulation of defective-interfering particles (Whitt, 2010).  rVSV-G*-VSV-G 
virus can be titrated by plaque assay on Vero E6 cells by pre-transfection with pVSV-G 
expression plasmid, followed by infection with serial dilutions of rVSV-G*-VSV-G virus for 
1 hour.  After 2 days incubation under a semi-solid overlay medium, cells are fixed and 
stained, plaques are counted, and PFUs/ml calculated according to the dilution factor.  
rVSV-G*-VSV-G virus can also be titrated and quantified by measuring reporter gene 
expression in susceptible target cells as detailed below. 
Like pseudotyped lentiviruses, pseudotyped VSVs can be quantified by measuring reporter 
gene, e.g. luciferase, expression in target cells.  Serial dilutions of the pseudotyped virus are 
prepared and added to permissive cell monolayers.  After 1 day incubation, the transduced 
cells are lysed and luciferase substrate added.  Luminescence is measured and RLU/ml 
calculated according to the dilution factor.  An alternative method for quantifying 
pseudotyped viral particles is to titrate for determination of TCID50.  This is the 
concentration of virus required to produce a CPE in 50% of tissue cultured cells inoculated, 
and can be determined using the Reed-Muench method (Reed and Muench, 1938). 
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4.1.2 Use of pseudotyped VSVs as alternatives for infectious virus 
Pseudotyped VSV neutralisation assays have been developed for a variety of pathogens, 
and comparative serology studies have shown that results from conventional assays using 
live, native virus correlate well with those obtained by pseudotyped virus neutralisation 
assays (Fukushi et al., 2006; Logan et al., 2016).  VSV-based pseudotyped viruses have 
previously been used in neutralisation assays to assess EBOV vaccines (Agnandji et al., 
2017; Agnandji et al., 2016; Huttner et al., 2018; Huttner et al., 2015; Regules et al., 2017) 
and antibody-based therapies (Bornholdt et al., 2016a; Holtsberg et al., 2015; Howell et al., 
2017; Howell et al., 2016; Keck et al., 2015; Takada et al., 2007; Zhao et al., 2017).  Before 
the EBOV GP pseudotyped VSV neutralisation could be used to study the effects of EBOV 
GP mutations, its suitability to study the properties of neutralising antibodies derived from 
EVD convalescent volunteers, needed to be assessed.  Accordingly, aims for this Chapter 
were as follows. 
 
4.2 Chapter aims 
The overall objective for this Chapter was to assess the suitability of an EBOV GP 
pseudotyped VSV system to measure the neutralising ability of EVD convalescent plasma.  
Specific objectives were to: 
 Amplify and titrate working stock of rVSV-G-Luc-VSV-G virus. 
 
 Generate and quantify stocks of EBOV GP pseudotyped VSV. 
 
 Optimise EBOV GP pseudotyped VSV neutralisation assay methodology. 
 
 Assess neutralisation of EBOV GP pseudotyped VSV by EVD survivor plasma. 
 
 Compare neutralisation results of EBOV GP pseudotyped VSV with EBOV GP 
pseudotyped HIV-1 and live EBOV. 
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4.3 Results  
4.3.1 rVSV-G-Luc-VSV-G virus expansion and titration 
A working stock of rVSV-G-Luc-VSV-G virus was prepared by transfection of 293T/17 cells 
using pVSV-G followed by infection with rVSV-G-Luc-VSV-G virus, as described in Section 
2.3.3.  The rVSV-G-Luc-VSV-G virus was titrated by plaque assay on Vero E6 cells by pre-
transfection with pVSV-G expression plasmid, followed by infection with rVSV-G-Luc-VSV-
G virus for 1 hour (Section 2.4.3).  Plaque assays were fixed and stained 48 hours post-
infection.  The titre of the rVSV-G-Luc-VSV-G virus stock was determined as 1.75x108 
pfu/ml (Figure 4.1A).  The rVSV-G-Luc-VSV-G virus was also assayed for luciferase activity 
in 293T/17 cells at 24 hours post-infection, as described in Section 2.4.2.  The titration of 
luciferase activity showed that the dilution corresponding to 95% of the maximum value 
was equal to the dilution needed for MOI 5 (Figure 4.1B).  The rVSV-G-Luc-VSV-G virus was 
then used to generate EBOV (Mayinga) GP pseudotyped virus as described in Section 2.3.2. 
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Figure 4.1: rVSV-G-Luc-VSV-G titration.  A) Vero E6 cells, pre-transfected with pVSV-
G expression plasmid for 5-6 hours, were infected with serial dilutions of 
pseudotyped virus for 1 hour.  After 2 days incubation under a semi-solid overlay 
medium, cells were fixed and stained.  B) 293T/17 cells were infected with serial 
dilutions of pseudotyped virus for 24 hours and luminescence (RLU/well) was 
detected.  Error bars are 1 standard error above and below the mean, n=4. 
 
4.3.2 Cell tropism of EBOV GP pseudotyped VSV 
EBOV (Mayinga) GP pseudotyped VSV was generated by transfection of 293T/17 cells using 
pCAGGS EBOV (Mayinga) GP, and subsequent infection with rVSV-G-Luc-VSV-G virus as 
described in Section 2.3.2.  The pseudotyped virus was titrated on 293T/17, Huh-7, HeLa 
and Vero E6 cell monolayers, luminescence was measured, and TCID50/ml values were 
calculated as described in Section 2.4.2.  These cell lines were permissive to infection, 
although differences in luminescence were observed, with highest pseudotyped virus titres 
being obtained in Vero E6 cells (Figure 4.2).  The TCID50/ml values generated by infection of 
Vero E6 cells were approximately 1.5, 22 and 30 times greater than those produced by 
infection of 293T/17, Huh-7 and HeLa cells, respectively (Figure 4.2B).  Based on these 
 -4  -5  -6 
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results, the Vero E6 target cell line was selected for use in all subsequent neutralisation 
assays. 
 
A 
 
 
 
 
B 
 
 
 
 
Figure 4.2: Infection of different cell lines with EBOV (Mayinga) GP pseudotyped 
virus.  2x104 293T/17, Huh-7 or Vero E6 cells, or 1x104 HeLa cells per well were 
infected for 24 hours with serial dilutions of pseudotyped virus.  A) Luminescence 
(RLU/well) was detected (error bars are 1 standard error above and below the mean, 
n=4), and B) Pseudotyped virus titres (TCID50/ml) were calculated. 
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4.3.3 Assessment of EBOV GP pseudotyped VSV input on neutralisation 
To assess the effects of differing amounts of pseudotyped virus input on the neutralisation 
assay results, human anti-EBOV GP mAb KZ52 was screened against four different dilutions 
of EBOV GP (Mayinga) pseudotyped virus (Section 2.5.3).  KZ52 was selected for the current 
study as it was commercially available, and there was accompanying information regarding 
its neutralisation activity against EBOV GP pseudotyped VSV expressing luciferase.  
Percentage infectivity was determined relative to infectivity of Vero E6 cells by EBOV GP 
pseudotyped virus alone, and IC50 of pseudotyped virus neutralisation were estimated by 
model of nonlinear regression dose-response curves (Section 2.5.4).  KZ52 neutralised all 
dilutions of EBOV GP pseudotyped virus tested (Figure 4.3) and IC50 values decreased with 
decreasing amounts of pseudotyped virus input (Figure 4.3B).  When using neat, or a 1:2 
dilution of pseudotyped virus, IC50 of virus neutralisation were similar to that expected 
according to the manufacturer’s product data sheet (0.06 µg/ml).  Therefore a dilution of 
EBOV GP (Mayinga) pseudotyped VSV that corresponded to approximately 3.0 x 104 
RLU/well was used in subsequent neutralisation assays. 
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Figure 4.3: Neutralisation of different amounts of EBOV (Mayinga) GP pseudotyped VSV 
by anti-EBOV GP mAb, KZ52.  A) Different dilutions of pseudotyped virus were incubated 
with dilutions of KZ52 at 37C for one hour before being added to Vero E6 cell 
monolayers.  Luminescence was detected after 24 hours and percentage infectivity was 
calculated.  Error bars are 1 standard error above and below the mean, n=4.  B) IC50 of 
pseudotyped virus neutralisation were estimated by model of nonlinear regression 
dose-response curves. 
 
4.3.4 Neutralisation of EBOV GP pseudotyped VSV by control samples 
To further validate the EBOV GP pseudotyped virus neutralisation assay, KZ52, and plasma 
from a Guinean EVD survivor (G037) and from a UK negative control donor (PN004) were 
tested in a number of independent assays, and IC50 of pseudotyped virus neutralisation 
were estimated by model of nonlinear regression dose-response curves (Section 2.5.4).  
KZ52 and EVD survivor G037 plasma were able to neutralise the EBOV GP pseudotyped 
virus (Figure 4.4).  Neutralisation of EBOV GP pseudotyped virus by KZ52 was very 
reproducible; IC50 values ranged from 0.06 to 0.11 µg/ml, with an average of 0.07 µg/ml.  
Neutralisation of EBOV GP pseudotyped virus by EVD survivor G037 plasma was less 
reproducible; IC50 values ranged from 202 to 2117, with an average of 887. The negative 
plasma displayed no neutralisation against EBOV GP pseudotyped virus and dose-response 
curves were unable to be fitted.  Therefore an IC50 value of 20, which was the lowest 
dilution of sample tested in the assay, was assigned as the background level of 
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neutralisation for the assay.  Anti-EBOV plasma, human WHO reference reagent was also 
tested in the assay, and was able to neutralise the EBOV GP pseudotyped virus, with an IC50 
of 923 (Figure 4.4). 
 
 
 
 
 
 
Figure 4.4: Reproducibility of neutralisation of EBOV (Mayinga) GP pseudotyped virus 
by positive (G037 and WHO) and negative (PN004) control plasma samples and 
human anti-EBOV GP mAb, KZ52.  Pseudotyped virus was incubated with dilutions of 
samples at 37C for 1 hour before being added to Vero E6 cell monolayers.  
Luminescence was detected after 24 hours and percentage infectivity was calculated.  
The IC50 of pseudotyped virus neutralisation were estimated by model of nonlinear 
regression dose-response curves.  Data are shown for individuals and the geometric 
mean with 95% CI.  Dotted line represents background level of pseudotyped virus 
neutralisation and is equal to the lowest dilution of sample tested in the assay (1/20). 
 
4.3.5 Neutralisation of EBOV GP pseudotyped VSV by EVD survivor plasma 
Neutralisation of EBOV (Mayinga) GP pseudotyped virus by plasma samples collected from 
30 EVD survivors of the 2013-2016 EBOV outbreak 3 to 14 months post-infection (Table 
4.1), and 10 negative control donors from Guinea (Section 2.5.1) was evaluated as 
described in Section 2.5.3.  Due to time constraints and limited amount of EBOV (Mayinga) 
GP pseudotyped virus available, a smaller number of EVD survivor plasma samples was 
tested in the EBOV GP pseudotyped VSV neutralisation assay than was tested in the HIV-1 
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based assay (Section 3.3.4).  Samples covering a range of EBOV neutralising ability were 
selected based on their performance in a live EBOV neutralisation assay (Table 4.1). 
 
Table 4.1 Ebola virus disease (EVD) survivor samples tested in the EBOV GP 
pseudotyped virus neutralisation assay.  Plasma samples from EVD survivors of the 
2013-2016 EBOV outbreak were obtained from a pre-existing biobank.  Live EBOV 
(Mayinga) neutralisation data were available for each sample. 
Sample 
Live EBOV (Mayinga) 
neutralisation (GMT) 
G041 861 
G048 724 
G011 645 
G037 609 
G036 512 
CS090 362 
CS053 256 
G021 215 
G035 215 
G001 181 
G014 181 
G005 128 
G045 108 
G013 108 
G025 91 
G024 76 
G044 76 
G033 54 
G028 54 
G031 54 
G018 54 
G026 45 
G038 45 
G040 45 
G020 45 
G027 38 
G019 38 
CS084 38 
G030 23 
G022 6 
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The IC50 of pseudotyped virus neutralisation were estimated by model of nonlinear 
regression dose-response curves as described in Section 2.5.4 and results are presented in 
Figure 4.5.  All but one of the EVD survivor plasma samples displayed neutralising activity 
against the EBOV GP pseudotyped virus.  A dose-response curve was unable to be fitted for 
this sample, and therefore an IC50 value of 20 was assigned to it.  Dose-response curves 
were unable to be fitted for seven out of the 10 negative samples tested due to lack of 
neutralisation, and therefore IC50 values of 20 were assigned to these samples.  There was a 
statistically significant difference between the two groups (Mann-Whitney, p < 0.0001). 
  
 
 
 
 
 
Figure 4.5: Neutralisation of EBOV (Mayinga) GP pseudotyped VSV by EVD survivor 
and negative plasma samples.  Pseudotyped virus was incubated with dilutions of 
heat inactivated plasma samples at 37C for one hour before being added to Vero E6 
cell monolayers.  Luminescence was detected after 24 hours and percentage 
infectivity was calculated.  The IC50 of pseudotyped virus neutralisation were 
estimated by model of nonlinear regression dose-response curves.  Data are shown 
for individuals and the geometric mean with 95% CI.  Dotted line represents 
background level of pseudotyped virus neutralisation and is equal to the lowest 
dilution of sample tested in the assay (1/20).  Statistically significant difference is 
highlighted (****p < 0.0001; Mann-Whitney). 
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4.3.6 Correlation with live EBOV neutralisation 
For each sample tested, pre-existing data from a live EBOV neutralisation assay were 
available (Section 2.5.1).  There was a positive correlation (rs = 0.86) when IC50 values of 
EBOV GP pseudotyped virus neutralisation were compared with GMT values for the live 
EBOV neutralisation assay, using the nonparametric Spearman correlation coefficient 
(Figure 4.6), and this was statistically significant (p < 0.0001). 
 
 
 
 
 
 
Figure 4.6: Correlation of EBOV GP pseudotyped VSV (IC50) and live EBOV (GMT) 
neutralisation using the nonparametric Spearman correlation coefficient, n=40.  
Dotted lines represent background level of neutralisation.  Background level of 
pseudotyped VSV neutralisation is equal to the lowest dilution of sample tested in 
the assay (1/20).  Seropositivity in the live EBOV neutralisation assay is defined by a 
GMT > 8. 
 
4.3.7 Comparison with EBOV GP pseudotyped lentivirus neutralisation 
In order to directly compare the lentivirus- (assessed in Chapter 3) and VSV-based 
pseudotyped virus systems, EBOV GP pseudotyped HIV-1 neutralisation results from the 
same 30 EVD survivor and 10 negative plasma samples that were tested in the EBOV GP 
pseudotyped VSV neutralisation assay were assessed.  In the HIV-1 based assay, dose-
response curves were unable to be fitted for three of the 30 EVD survivor samples, and six 
r
s
 = 0.86 
p < 0.0001 
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of the samples were deemed below the background level of neutralisation.  In contrast, a 
dose-response curve was unable to be fitted for only one of the EVD survivor samples 
tested in the VSV-based neutralisation assay, and this sample was also negative in the live 
EBOV neutralisation assay.  In the HIV-1 based assay, three of the 10 negative plasma 
samples tested were above the background level of neutralisation, whereas only one of the 
negative samples tested was above the background level of neutralisation in the VSV-based 
assay. 
When IC50 values of EBOV GP pseudotyped HIV-1 neutralisation of the 30 EVD survivor and 
10 negative plasma samples were compared with GMT values for the live EBOV 
neutralisation assay, there was a positive correlation (rs = 0.57) (Figure 4.7), and this was 
statistically significant (p = 0.0002). 
 
 
 
 
 
 
Figure 4.7: Correlation of EBOV GP pseudotyped HIV-1 (IC50) and live EBOV (GMT) 
neutralisation using the nonparametric Spearman correlation coefficient, n=36.  
Dotted lines represent background level of neutralisation.  Background level of 
pseudotyped HIV-1 neutralisation (6.28) is equal to negative control plasma mean 
plus two standard deviations.  Seropositivity in the live EBOV neutralisation assay is 
defined by a GMT > 8. 
 
 
r
s
 = 0.57 
p = 0.0002 
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4.4 Discussion 
As discussed in Section 1.4, pseudotyped viruses can be used as alternatives to infectious 
virus to measure neutralising antibodies to the envelope glycoprotein.  Lentiviruses and 
rhabdoviruses can provide cores for pseudotyped viruses (Page et al., 1990; Takada et al., 
1997), and have been used to study neutralising antibodies against EBOV (Sullivan et al., 
2006; Takada et al., 2003).  A previous comparison of a range of assays for antibody to 
EBOV found that the assays evaluated based on VSV gave better correlation with live EBOV 
neutralisation than those based on lentiviruses (Wilkinson et al., 2017).  The suitability of an 
EBOV GP pseudotyped lentivirus assay to measure neutralising antibodies derived from EVD 
convalescent volunteers was assessed in Chapter 3.  However the ability of the assay to 
differentiate between neutralising activity appeared to be limited, and concerns were 
raised regarding the specificity and sensitivity of the assay, especially as some of the 
negative samples displayed neutralising activity, and a human anti-EBOV GP mAb was 
unable to neutralise the EBOV GP pseudotyped HIV-1.  Therefore in this Chapter, a VSV-
based pseudotyped virus system was investigated, to determine if this was a more suitable 
platform than HIV-1 to study the effects of EBOV GP mutations on antibody neutralisation. 
4.4.1 Production and titration of rVSV-G-Luc-VSV-G virus  
Establishment of VSV-based pseudotyped virus systems is slightly more complex than 
lentivirus-based pseudotyped virus systems, and requires stocks of VSV-G protein 
pseudotyped rVSV, in which the VSV-G gene has been deleted and replaced with a reporter 
gene, represented here by a *, (rVSV-G*-VSV-G), to be generated and quantified (Whitt, 
2010).  rVSV-G-Luc-VSV-G virus was successfully prepared by transfection of 293T/17 cells 
using pVSV-G and subsequent infection with rVSV-G-Luc-VSV-G virus.  The rVSV-G-Luc-
VSV-G virus was titrated by plaque assay on Vero E6 cells, and was also assayed for 
luciferase activity in 293T/17 cells.  Titration of luciferase activity showed that the dilution 
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corresponding to 95% of the maximum value was equal to the dilution needed for MOI 5, 
which was subsequently used to produce EBOV (Mayinga) GP pseudotyped virus. 
4.4.2 Generation and quantification of EBOV GP pseudotyped VSV 
EBOV (Mayinga) GP pseudotyped VSV was successfully produced by transfection of 293T/17 
cells with plasmid DNA encoding EBOV GP, followed by infection with rVSV-G-Luc-VSV-G 
virus.  The EBOV GP pseudotyped virus was quantified by measuring luminescence in a 
range of target cell lines and TCID50 values were calculated.  All cell lines tested (293T/17, 
Huh-7, HeLa and Vero E6) were permissive to infection by EBOV GP pseudotyped virus, 
demonstrating the broad tissue range conferred by EBOV GP (Ito et al., 2001).  Highest 
titres were obtained in Vero E6 cells, which have previously been reported to be highly 
permissive to EBOV infection, and are commonly used as target cells in live EBOV, as well as 
EBOV pseudotyped VSV assays (Bornholdt et al., 2016a; Chandran et al., 2005; Holtsberg et 
al., 2015; Howell et al., 2016; Kondratowicz et al., 2011; Maruyama et al., 1999; Takada et 
al., 2007).  Therefore this cell line was selected for use in subsequent neutralisation assays. 
4.4.3 Optimisation of EBOV GP pseudotyped VSV neutralisation assay 
In order to ensure accuracy and reproducibility of neutralisation results, samples from 
vaccinated individuals and/or from patients recovered from the disease of interest are 
often used in optimisation experiments to evaluate assay parameters that could affect 
assay performance.  To assess the effects of differing amounts of pseudotyped virus input 
on neutralisation, human anti-EBOV GP mAb KZ52 was screened against different amounts 
of the EBOV GP (Mayinga) pseudotyped VSV.  KZ52 neutralised all dilutions of EBOV GP 
pseudotyped virus tested, providing evidence for correct folding of the EBOV GP on the 
pseudotyped virus.  This was in contrast to EBOV GP pseudotyped HIV-1, which was not 
neutralised by KZ52 (Figure 3.5B).  The IC50 of pseudotyped virus neutralisation values 
decreased with decreasing amounts of pseudotyped virus input, therefore a pseudotyped 
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virus input of approximately 3.0 x 104 RLU/well was used in subsequent neutralisation 
assays.  The variability in neutralisation observed between different amounts of 
pseudotyped virus input highlights the importance of including standards or reference 
material with a known activity or potency when comparing neutralising activity, allowing 
calibration of results (Temperton and Page, 2015).   
KZ52 was tested in the EBOV GP pseudotyped VSV neutralisation assay on a number of 
independent occasions and results were highly reproducible.  Anti-EBOV plasma, human 
WHO reference reagent was also able to neutralise the EBOV GP pseudotyped virus, and 
could be used to calibrate secondary reference material, which would improve 
comparability and reliability of results (Wilkinson et al., 2017).  Plasma from a UK negative 
control donor displayed no neutralising activity against EBOV GP pseudotyped VSV, and 
therefore the lowest dilution of sample tested in the assay was assigned as the background 
level of neutralisation for the assay.  This was in contrast to the HIV-1-based neutralisation 
assay, in which a low level of neutralisation was observed by the UK negative control 
plasma (Section 3.3.5), therefore the background level of neutralisation appears to be 
lower in the EBOV GP pseudotyped VSV assay. 
4.4.4 Neutralisation of EBOV GP pseudotyped VSV by EVD survivor and negative plasma 
The EBOV GP pseudotyped VSV was used to assess the neutralising activity of plasma from 
30 EVD survivors of the 2013-2016 EBOV outbreak and 10 negative control donors.  The 
EBOV GP pseudotyped VSV neutralisation assay was able to measure neutralising 
antibodies in plasma from EVD convalescent patients and results correlated positively with 
a live EBOV neutralisation assay.  Plasma from the negative control donors displayed little 
or no neutralising activity against EBOV GP pseudotyped VSV.  Therefore, the VSV-based 
neutralisation assay performed better than the lentivirus-based assay, both in relation to 
specificity and correlation with the live EBOV neutralisation assay (Section 3.3.5).  In the 
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current study, human embryonic kidney (293T/17) cells were used for the lentivirus-based 
neutralisation assay, whereas African green monkey kidney (Vero) cells were used in the 
VSV-based assay, which are also used in the live EBOV assay, and therefore this could 
account for the better performance of the VSV-based assay in relation to live EBOV 
neutralisation.  Also, the lentivirus- and VSV-based pseudotyped virus systems assed in the 
current study utilise different transfection methods, which could have implications on 
pseudotyped virus production and neutralisation results.  Processes in the assembly and 
maturation of GP, such as trimer formation and glycosylation, may differ between the 
transfection procedures, resulting in different targets and/or conformational epitopes and 
therefore neutralisation.  Other components, such as cell debris or free GP generated 
during transfection could also interfere with neutralisation. 
4.4.5 Selection of EBOV GP pseudotyped virus assay for future use 
A head-to-head comparison of neutralisation results from the EBOV GP pseudotyped 
lentivirus (HIV-1) and VSV assays of the same 30 EVD survivor and 10 negative plasma 
samples was undertaken.  For the HIV-1-based assay, dose-response curves were unable to 
be fitted for three of the EVD survivor samples, and six of the samples were deemed below 
the background level of neutralisation.  In contrast, a dose-response curve was unable to be 
fitted for only one of the samples in the VSV-based assay, and this sample was also negative 
in the live EBOV neutralisation assay, suggesting that the sensitivity and discriminatory 
power of the VSV-based assay are greater.  In the HIV-1 based assay, three of the negative 
plasma samples tested were above the background level of neutralisation, whereas only 
one of the negative samples was above the background level of neutralisation in the VSV-
based assay.  This suggests that the level of non-specific background neutralisation is 
greater in the HIV-1-based assay. 
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There was a statistically significant positive correlation when GMT values for a live EBOV 
neutralisation assay were compared with IC50 values of EBOV GP pseudotyped VSV 
neutralisation, but not with EBOV GP pseudotyped HIV-1 neutralisation.  This outcome was 
in agreement with a previous comparison of a range of assays for antibody to EBOV, which  
found that the assays evaluated based on VSV gave better correlation with live EBOV 
neutralisation than those based on lentiviruses (Wilkinson et al., 2017).   
As mentioned in Section 3.4.3, there are several differences between EBOV GP 
pseudotyped virus and live EBOV neutralisation assays that could affect their results, 
including the shape of the virions and density of GP on the viral surfaces, the presence or 
absence of sGP, and the method used to detect infected cells (Saphire et al., 2018).  
Furthermore, EBOV neutralisation assays have previously been shown to yield variable 
results (Saphire et al., 2018; Wilkinson et al., 2017), and therefore a single assay alone may 
not be enough to determine neutralisation.  However, a pseudotyped virus could be used 
as an initial qualitative, rather than quantitative, screen for escape mutants before live virus 
is used to investigate the effects of EBOV GP mutations on antibody neutralisation. 
 
4.5 Conclusions 
The EBOV GP pseudotyped VSV neutralisation assay was reproducible and correlated 
positively with a live EBOV neutralisation assay.  The sensitivity, specificity and ability of the 
VSV-based pseudotyped virus neutralisation assay to differentiate between neutralising 
activity appeared to be greater than the lentivirus-based system.  Correlation between live 
EBOV and EBOV GP pseudotyped virus neutralisation was best for the VSV-based assay 
when a head-to-head comparison with the lentivirus-based assay was carried out.  
Therefore, the VSV-based neutralisation assay was subsequently selected to test the 
hypothesis of the study (described in Section 1.6) that naturally occurring mutations in 
117 
 
EBOV GP can result in escape from neutralising antibodies derived from EVD convalescent 
volunteers and EBOV GP vaccinated individuals, and is discussed in Chapter 5.  
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Chapter 5 Production and neutralisation of mutant EBOV GP 
pseudotyped viruses 
5.1 Introduction 
Neutralising antibodies are important components of a protective immune response 
against many viral pathogens (Plotkin, 2010).  Some viruses, such as HIV and HCV for 
example, are able to escape neutralising antibody responses that arise during infection of 
individual hosts, by mutation of the viral neutralising determinants (Corti and Lanzavecchia, 
2013; Fofana et al., 2012; Hangartner et al., 2006; Richman et al., 2003; von Hahn et al., 
2007; Wei et al., 2003). 
The 2013-2016 EVD epidemic in West Africa, which gave rise to the EBOV Makona variant, 
was characterised by extensive human-to-human transmission, which resulted in an 
accumulation of mutations within the EBOV genome (Gire et al., 2014).  During the 
outbreak, sequencing studies were performed to assess mutation rates and to support 
molecular epidemiology studies, revealing mutations in the genetic sequence encoding 
EBOV GP (Carroll et al., 2015; Gire et al., 2014; Park et al., 2015; Quick et al., 2016; Simon-
Loriere et al., 2015; Tong et al., 2015).  Studies into this topic suggest that a single mutation 
encoding a valine substitution for alanine at residue 82 of the EBOV GP that arose early 
during the 2013-2016 epidemic, is associated with increased infectivity of human cells 
(Diehl et al., 2016; Dietzel et al., 2017; Kurosaki et al., 2018; Ueda et al., 2017; Urbanowicz 
et al., 2016b; Wang et al., 2017).  Mutations in the EBOV GP gene may also have important 
implications for anti-EBOV GP-based therapeutics and vaccines, i.e. changes in the EBOV GP 
may affect the ability of antibodies to bind, thereby leading to the emergence of escape 
mutants (Carroll et al., 2015; Kugelman et al., 2015a; Kugelman et al., 2015b; Miller et al., 
2016).  A useful application for pseudotyped viruses, therefore, is to investigate how 
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changes in EBOV GP might affect host cell receptor interaction and antibody binding and 
neutralisation. 
5.1.1 Generation of mutant EBOV GP pseudotyped viruses 
In order to test the study hypothesis, that naturally occurring mutations in EBOV GP can 
result in escape from neutralising antibodies, mutant EBOV GP pseudotyped viruses needed 
to be designed and produced.  The VSV-based pseudotyped virus system used for the 
current study was optimised in Chapter 4.  Site-directed mutagenesis can be used to 
introduce specific mutations into the EBOV GP gene and generate a panel of mutant EBOV 
GP expression plasmids, which can subsequently be used to generate mutant EBOV GP 
pseudotyped VSVs, as described in Section 4.1.1.  It is only following satisfactory 
preparation and characterisation of pseudotyped viruses that their relative properties can 
be effectively evaluated and compared.  The aims for this Chapter, described below, were 
implemented accordingly. 
 
5.2 Chapter aims 
The overall objective for this Chapter was to select and produce a panel of mutant EBOV GP 
pseudotyped viruses, based on mutations that occurred during the 2013-2016 EVD 
outbreak, and to investigate the potential for immune escape as per the study hypothesis 
outlined in Section 1.6.  Specific objectives for this Chapter were to: 
 
 Identify a set of mutations within the EBOV (Makona) GP that arose during the 2013-
2016 EBOV outbreak in West Africa. 
 Introduce selected mutations into an expression plasmid using site-directed 
mutagenesis. 
 Generate and quantify stocks of mutant EBOV GP pseudotyped viruses. 
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 Test a panel of mutant EBOV GP pseudotyped viruses in neutralisation assays with 
plasma from EVD survivors, EBOV GP vaccinated individuals and neutralising anti-EBOV 
GP mAbs to assess the effect on immune escape. 
 
5.3 Results 
5.3.1 Selection of EBOV GP mutations 
The initial EBOV GP sequence used in the current study was based on EBOV (Makona) 
isolate GenBank accession number KJ660348 (Baize et al., 2014), collected in Guinea in 
March 2014, and is referred to here as the ‘ancestral’ EBOV GP variant.  Using 
bioinformatics analysis of 1457 published EBOV genome sequences from the 2013-2016 
EVD outbreak, a number of non-synonymous mutations within the EBOV GP were identified 
(Section 2.1.7, Table 2.1).  Three variants of particular interest, as they contain multiple 
amino acid changes, are shown in Figure 5.1.  EBOV GP sequences containing multiple 
amino acid changes were selected for investigation, as it was thought that this would 
increase the possibility of observing any differences in neutralisation, especially by 
polyclonal antibody samples. 
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EBOV GP variant 29 74 82 107 330 371 407 480 
Ancestral (KJ660348) R G A N P I H G 
N107D, P330S, G480D R G A D S I H D 
R29K, A82V, I371L, G480S K G V N P L H S 
G74R, P330S, H407Y R R A N S I Y G 
 
Figure 5.1: Schematic representation of amino acid combinations in EBOV GP.  
Amino acid changes identified in the EBOV (Makona) GP during the 2013-2016 EBOV 
outbreak in West Africa are shown in red and bold.  A, Alanine; D, Aspartic acid; G, 
Glycine; H, Histidine;, I, Isoleucine; K, Lysine; L, Leucine; N, Asparagine; P, Proline; R, 
Arginine; S, Serine; V, Valine; Y, Tyrosine.  SP, signal peptide; RBD, receptor binding 
domain; MLD, mucin-like domain; IFL, internal fusion loop; HR, heptad repeat; TM, 
transmembrane.  Figure adapted from (Urbanowicz et al., 2016b). 
 
Further analysis of the genome sequences of EBOV from the 2013-2016 EVD outbreak was 
carried out to determine approximately when each of the EBOV GP variants was first 
observed.  An EBOV isolate containing the N107D, P330S and G480D GP mutations 
(GenBank accession number KR534528) was sampled in Guinea in September 2014 (Simon-
Loriere et al., 2015), and a variant containing the R29K, A82V, I317L and G480S GP 
mutations (GenBank accession number KU296622) was identified in Sierra Leone in January 
2015 (Arias et al., 2016).  An EBOV isolate containing a G47R GP mutation (GenBank 
accession number KR817241) was sampled in Liberia in July 2014 (Carroll et al., 2015), 
although this sequence also contained an A82V GP mutation.  An EBOV variant containing 
P330S and H407Y GP mutations (GenBank accession number LT630494) was detected in 
Guinea in March 2015 (Quick et al., 2016), however this sequence was incomplete and the 
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amino acid at position 74 of the GP was undetermined, therefore it is unknown if a G74R, 
P330S and H407Y triple GP mutation variant naturally occurred. 
5.3.2 Mutation of EBOV GP expression vector 
The starting expression vector used in the current study was a pcDNA3.1 expression 
plasmid for codon optimised EBOV (Makona) GP [GenBank accession number KJ660348 
(Baize et al., 2014)].  Site mutagenesis primers were designed accordingly and the desired 
mutations introduced sequentially into the EBOV GP sequence (Section 2.1.7, Table 2.1).  
Plasmid DNA isolated from putative clones using QIAprep® plasmid Miniprep kits was 
subjected to sequencing (Section 2.1.8) across the manipulated area to confirm that the 
desired mutation(s) had been successfully introduced.  A plasmid map, annotated to show 
the sequenced region, is presented in Figure 2.1B.  Once the expression constructs were 
confirmed to be correct, they were propagated as described in Section 2.1.  After 
purification using Endofree® Plasmid Maxi kits, plasmid identity was confirmed again via 
sequencing (Section 2.1.8).  The plasmids were then used to generate mutant EBOV GP 
pseudotyped viruses as described in Section 2.3.2. 
5.3.3 Production and titration of EBOV GP mutant pseudotyped viruses 
Mutant EBOV GP pseudotyped VSVs were generated by transfection of 293T/17 cells using 
the appropriate pcDNA3.1 mutant EBOV GP expression plasmid and subsequent infection 
with rVSV-G-Luc-VSV-G virus as described in Section 2.3.2.  The pseudotyped viruses were 
titrated on Vero E6 cell monolayers, luminescence was measured, and TCID50/ml values 
were calculated as described in Section 2.4.2.  A pseudotyped virus bearing the VSV-G 
protein was used as a positive control, and a pseudotyped virus with no envelope protein 
was used to determine background level of luminescence.  Differences in luminescence 
generated by the mutant EBOV GP pseudotyped VSVs were observed (Figure 5.2), with 
highest pseudotyped virus titres being obtained by mutant GP N107D, P330S, G480D, 
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closely followed by ancestral GP and then mutant GP R29K, A82V, I317L, G480S (Figure 
5.2B).  The TCID50/ml of mutant GP N107D, P330S, G480D pseudotyped virus was 
approximately 1.5, 2.5 and 10 times greater than that of ancestral GP, GP R29K, A82V, 
I317L, G480S and GP G74R, P330S, H407Y pseudotyped viruses, respectively.  Based on the 
titration results, a target pseudotyped virus input of approximately 2 x 104 RLU/well was 
selected for use in all subsequent neutralisation assays. 
 
A 
 
 
 
 
B 
 
 
 
 
 
Figure 5.2: Quantification of mutant EBOV GP and VSV-G pseudotyped viruses.  Vero 
E6 cell monolayers were infected for 24 hours with serial dilutions of pseudotyped 
viruses.  A) Luminescence (RLU/ml) was detected (error bars are 1 standard error 
above and below the mean, n=4), and B) TCID50/ml were calculated. 
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5.3.4 Neutralisation of mutant EBOV GP pseudotyped viruses by control samples 
Neutralisation of mutant EBOV GP pseudotyped viruses by plasma samples 
The mutant EBOV GP pseudotyped viruses were used in neutralisation assays with anti-
EBOV plasma, human WHO reference reagent, and plasma from a Guinean negative control 
donor (GC027) as described in Section 2.5.3.  Plasma from an individual who had previously 
been vaccinated with two candidate EBOV vaccines (ChAd3 and VSV-EBOV GP) was also 
tested.  Results are presented in Figure 5.3.  Plasma from the negative control donor 
displayed no neutralising activity against any of the mutant EBOV GP pseudotyped viruses, 
whereas anti-EBOV plasma, human WHO reference reagent, and plasma from the EBOV 
vaccinated individual were able to neutralise all of the mutant EBOV GP pseudotyped 
viruses tested. 
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Figure 5.3: Neutralisation of mutant EBOV GP pseudotyped viruses by positive (WHO 
reference and vaccinee) and negative (GC027) control plasma samples.  Pseudotyped 
viruses were incubated with dilutions of heat inactivated plasma samples at 37C for 
one hour before being added to Vero E6 cell monolayers.  Luminescence was 
detected after 24 hours.  Error bars are 1 standard error above and below the mean, 
n=4. 
 
For each sample and mutant EBOV GP pseudotyped virus tested, the 90% inhibitory 
concentration (IC90) of pseudotyped virus neutralisation was determined using an alteration 
of the Reed-Muench method (Reed and Muench, 1938).  Results are presented in Figure 
5.4.  For samples that did not display neutralising activity, an IC90 value of 20, which was the 
lowest dilution of sample tested in the assay, was assigned. 
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Figure 5.4: Neutralisation of mutant EBOV GP pseudotyped viruses by positive (WHO 
reference and vaccinee) and negative (GC027) control plasma samples.  Pseudotyped 
viruses were incubated with dilutions of heat inactivated plasma samples at 37C for 
one hour before being added to Vero E6 cell monolayers.  Luminescence was 
detected after 24 hours and IC90 of pseudotyped virus neutralisation were 
determined.  Horizontal line represents background level of pseudotyped virus 
neutralisation and is equal to the lowest dilution of sample tested in the assay (1/20). 
 
Neutralisation of mutant EBOV GP pseudotyped viruses by anti-EBOV GP mAb 
To further evaluate the effects of these mutations, the mutant EBOV GP pseudotyped 
viruses were used in neutralisation assays with human anti-EBOV GP mAb KZ52 as 
described in Section 2.5.3.  KZ52 was able to neutralise the ancestral GP, mutant GP N107D, 
P330S, G480D and GP R29K, A82V, I317L, G480S pseudotyped viruses, however mutant GP 
G74R, P330S, H407Y pseudotyped virus was able to escape neutralisation by mAb KZ52 
(Figure 5.5A).  For each mutant EBOV GP pseudotyped virus tested, the IC90 of pseudotyped 
virus neutralisation by KZ52 was determined as described above, and results are presented 
in Figure 5.5B.  KZ52 was unable to neutralise mutant GP G74R, P330S, H407Y pseudotyped 
virus, and therefore an IC90 of 1.25 µg/ml, which was the highest concentration of KZ52 
tested in the assay, was assigned. 
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Figure 5.5: Neutralisation of mutant EBOV GP pseudotyped viruses by human anti-
EBOV GP mAb, KZ52.  Pseudotyped viruses were incubated with dilutions of KZ52 at 
37C for one hour before being added to Vero E6 cell monolayers.  A) Luminescence 
was detected after 24 hours (error bars are 1 standard error above and below the 
mean, n=4), and B) IC90 of pseudotyped virus neutralisation were determined.    
Horizontal line represents background level of pseudotyped virus neutralisation and 
is equal to the highest concentration of KZ52 tested in the assay (1.25 µg/ml).   
 
5.3.5 Neutralisation of mutant EBOV GP pseudotyped viruses by EVD survivor plasma 
Neutralisation of the mutant EBOV GP pseudotyped viruses by plasma samples collected 
from 12 EVD survivors of the 2013-2016 EBOV outbreak 3 to 14 months post-infection 
(Section 2.5.1) was evaluated as described in Section 2.5.3.  Results for each sample and 
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pseudotyped virus tested are represented graphically as luminescence against sample 
dilution in Figure 5.6.   
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B Late 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: Neutralisation of mutant EBOV GP pseudotyped viruses by plasma 
samples from EVD survivors infected A) early or B) later on during the 2013-2016 
EBOV outbreak.  Pseudotyped viruses were incubated with dilutions of heat 
inactivated plasma samples at 37C for one hour before being added to Vero E6 cell 
monolayers.  Luminescence was detected after 24 hours.  Error bars are 1 standard 
error above and below the mean, n=4.  Live EBOV (Mayinga) neutralisation results 
(geometric mean titre) are shown in brackets. 
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The samples were divided into two groups, depending on if the donor was infected early or 
later on during the outbreak, which was determined based on the date the donor was 
discharged from the Ebola treatment centre (ETC) (Table 5.1).  Live EBOV neutralisation 
results for each sample are also shown in Table 5.1, although it should be noted that the 
EBOV strain used in the live neutralisation assay is Mayinga, not Makona. 
 
Table 5.1 Ebola virus disease (EVD) survivor plasma samples tested in the EBOV GP 
pseudotyped virus neutralisation assay.  Plasma samples from EVD survivors infected 
early or later on during the 2013-2016 EBOV outbreak were obtained from a pre-existing 
biobank.  Live EBOV (Mayinga) neutralisation data were available for each sample. 
Sample 
 Date discharged 
from ETC 
 Live EBOV (Mayinga) 
neutralisation (GMT) 
G038 
Early 
04-Apr-14 45 
G037 09-Apr-14 609 
G040 12-Apr-14 45 
G044 15-Apr-14 76 
G036 20-Apr-14 512 
G031 26-Apr-14 54 
G019 
Late 
17-Dec-14 38 
G018 30-Dec-14 54 
G020 31-Dec-14 45 
CS090 19-Apr-15 362 
CS053 22-Apr-15 256 
CS084 29-May-15 38 
Abbreviations: ETC, Ebola treatment centre; GMT, Geometric 
mean titre. 
 
The IC90 of pseudotyped virus neutralisation by each sample was determined as previously 
described (Section 5.3.4), and results are presented in Figure 5.7.  Although differences in 
IC90 values were observed, the EVD survivor plasma samples tested were still generally able 
to neutralise the mutant EBOV GP pseudotyped viruses.  Samples that did not display 
sufficient neutralising activity for an IC90 value to be able to be calculated were, G038 
against mutant GP R29K, A82V, I317L, G480S pseudotyped virus, G040 against mutant GP 
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N107D, P330S, G480D pseudotyped virus and G019 against ancestral GP pseudotyped virus, 
and therefore IC90 values of 20 were assigned to these. 
As mentioned above, although the EVD survivor plasma samples were still able to neutralise 
the mutant EBOV GP pseudotyped viruses, differences in IC90 values were observed (Figure 
5.7).  For example, plasma from EVD survivors G038, G044, G036 and G019, which were 
infected earlier on during the 2013-2016 EVD outbreak, displayed lower neutralising activity 
against pseudotyped virus bearing the R29K, A82V, I317L and G480S mutations in GP, which 
were identified later on in the outbreak, compared to pseudotyped viruses bearing GPs that 
were identified earlier during the outbreak.  Whereas plasma from EVD survivors G019, 
G020, CS090 and CS053, which were infected later on during the outbreak, displayed lower 
neutralising activity against pseudotyped virus bearing the ancestral (early) GP compared to 
pseudotyped viruses bearing GPs that were identified later on in the outbreak.  However no 
statistically significant differences in neutralisation between the mutant EBOV GP 
pseudotyped viruses were detected for either the early or late EVD survivor plasma samples 
(Friedman test, p = 0.9396 and p = 0.0882, respectively).  The mean results are presented in 
Figure 5.8. 
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Figure 5.7: Neutralisation of mutant EBOV GP pseudotyped viruses by plasma 
samples from EVD survivors infected early or later on during the 2013-2016 EBOV 
outbreak.  Pseudotyped viruses were incubated with dilutions of heat inactivated 
plasma samples at 37C for one hour before being added to Vero E6 cell monolayers.  
Luminescence was detected after 24 hours and IC90 of pseudotyped virus 
neutralisation were determined.  Horizontal line represents background level of 
pseudotyped virus neutralisation and is equal to the lowest dilution of sample tested 
in the assay (1/20). 
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Figure 5.8: Neutralisation of mutant EBOV GP pseudotyped viruses by plasma 
samples from EVD survivors infected early or later on during the 2013-2016 EBOV 
outbreak.  Pseudotyped viruses were incubated with dilutions of heat inactivated 
plasma samples at 37C for one hour before being added to Vero E6 cell monolayers.  
Luminescence was detected after 24 hours and IC90 of pseudotyped virus 
neutralisation were determined.  Geometric means with 95% CIs are shown, n=6.  
Horizontal line represents background level of pseudotyped virus neutralisation and 
is equal to the lowest dilution of sample tested in the assay (1/20). 
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5.3.6 Neutralisation of mutant EBOV GP pseudotyped viruses by anti-EBOV GP mAb 
Anti-EBOV GP mAb KZ52, at a single concentration of 1.25 µg/ml, was included in each 
neutralisation assay to serve as a positive control.  KZ52 consistently neutralised ancestral 
GP, mutant GP N107D, P330S, G480D and GP R29K, A82V, I317L, G480S pseudotyped 
viruses, however mutant GP G74R, P330S, H407Y pseudotyped virus was only partially 
neutralised by KZ52 (Figure 5.9).  This confirmed that the escape of mutant GP G74R, 
P330S, H407Y pseudotyped virus from neutralisation by KZ52 previously observed (Figure 
5.5) was reproducible.  Analysis of the data by one-way ANOVA revealed statistically 
significant differences between the groups (p = 0.0021).  The difference between individual 
groups was further examined by post hoc Tukey’s multiple comparison test using GraphPad 
Prism v5.  Statistically significant differences are highlighted in Figure 5.9. 
 
 
 
 
 
 
 
Figure 5.9: Neutralisation of mutant EBOV GP pseudotyped viruses by human anti-
EBOV GP mAb, KZ52.  Pseudotyped viruses were incubated with KZ52 (1.25 µg/ml) at 
37C for one hour before being added to Vero E6 cell monolayers.  Luminescence 
was detected after 24 hours and percentage neutralisation was calculated.  Error 
bars are 1 standard error above and below the mean, n=6.  The difference between 
groups was examined by one-way ANOVA and by post hoc Tukey’s multiple 
comparison test.  Statistically significant differences are highlighted (*p < 0.05). 
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In order to elucidate the possible mechanism of escape of mutant GP G74R, P330S, H407Y 
pseudotyped virus from neutralisation by KZ52, the amino acid positions were mapped 
onto a published structure of EBOV GP in complex with KZ52 [Protein Data Bank (PDB) 
identifier 3CSY (Lee et al., 2008)] using the molecular-graphics programme CCP4MG 
(McNicholas et al., 2011).  Amino acid position 74 is located in the RBD of EBOV GP, 
whereas positions 330 and 407 are located in the MLD (Figure 5.1).  The MLD had been 
deleted from the GP, as it is refractory to crystallisation (Lee et al., 2008), and therefore 
amino acid positions 330 and 407 could not be mapped.  By observing the EBOV GP/KZ52 
structure, it can be seen that amino acid position 74 of EBOV GP is located near the 
interface of EBOV GP and KZ52 (Figure 5.10).  Amino acid positions 82 and 107 of EBOV GP 
were also mapped onto the EBOV GP/KZ52 structure and are displayed in Figure 5.10. 
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Figure 5.10: Structure of Ebola virus (EBOV) surface glycoprotein (GP1,2) trimer in 
complex with neutralising antibody KZ52 [PDB identifier 3CSY (Lee et al., 2008)].  
GP1,2 are shown in blue, and heavy and light chains of KZ52 are shown in orange.  
Green, red and purple spheres indicate amino acid residues 74, 82 and 107 of EBOV 
GP, respectively.  Figure created by Dr Gillian Slack using CCP4MG. 
 
 
 
 
 
 
90 
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5.4 Discussion 
The primary objective for this Chapter was to compare neutralisation of mutant EBOV GP 
pseudotyped viruses by EVD survivor plasma, with a view to investigating the potential for 
immune escape of naturally occurring EBOV GP mutants.  The impact of amino acid changes 
in EBOV GP that arose during the 2013-2016 EVD epidemic on neutralisation of EBOV GP 
pseudotyped viruses by EVD survivor and EBOV GP vaccinee plasma, as well as a 
neutralising anti-EBOV GP mAb was investigated. 
5.4.1 Selection and production of EBOV GP mutant pseudotyped viruses 
Published EBOV genome sequences were compared with an early EBOV (Makona) isolate 
[GenBank accession number KJ660348 (Baize et al., 2014)], referred to here as the 
‘ancestral’ EBOV GP variant, to identify a series of mutations that occurred within the EBOV 
GP during the 2013-2016 EVD outbreak.  Three EBOV variants of particular interest, as they 
contained multiple amino acid changes in the GP, were selected for further investigation 
(Figure 5.1).  Site-directed mutagenesis was then applied to introduce the desired 
mutations into the EBOV GP sequence to generate a panel of mutant EBOV GP expression 
vectors.  The plasmids were sequenced to confirm that the modification(s) had been made 
successfully.  This was considered an essential prerequisite to the use of the plasmids in the 
generation of mutant EBOV GP pseudotyped viruses.  Long term stocks of transformed E. 
coli were deposited for each plasmid.  The extent of the sequenced regions for the mutant 
EBOV GP panel of plasmids is shown in Figure 2.1B. 
Mutant EBOV GP pseudotyped VSVs were generated by transfection of 293T/17 cells with 
plasmid DNA encoding mutated EBOV GP, followed by infection with rVSV-G-Luc-VSV-G 
virus.  After each transfection and infection, the EBOV GP pseudotyped viruses were 
harvested and quantified by measuring luminescence in Vero E6 cells.  Differences in 
luminescence were observed depending on the pseudotyped virus used for infection; 
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however these differences may be due technical variability in the production and titration 
of the pseudotyped viruses, rather than due to the mutations, and therefore repeat 
experiments are required to confirm the validity of these results.  Similar studies utilising 
EBOV GP pseudotyped viruses have found that an A82V mutation in EBOV GP is associated 
with increased infectivity of Vero cells (Diehl et al., 2016; Kurosaki et al., 2018).  Although, 
no significant differences were found in disease progression, pathogenicity or virus 
shedding of EBOV Makona isolates derived from different stages of the epidemic in rhesus 
macaques (Marzi et al., 2018).  In the current study, pseudotyped VSV bearing EBOV GP 
containing an A82V mutation did not displayed increased infectivity of Vero E6 cells 
compared to pseudotyped VSV bearing ancestral (A82) EBOV GP. 
The panel of mutant EBOV GP pseudotyped viruses were subsequently analysed in 
neutralisation assays with plasma from EVD survivors, to assess the effect on immune 
escape.  Based on the titration results, a target pseudotyped virus input of approximately 2 
x 104 RLU/well was selected for use. 
5.4.2 Neutralisation of mutant EBOV GP pseudotyped viruses by EVD survivor plasma 
It is thought that EVD survivors are protected against subsequent infection with EBOV, and 
that neutralising antibodies to the EBOV surface GP are involved.  However, mutations in 
EBOV GP may affect the ability of antibodies from convalescent patients to protect against 
new variants of the virus.  It could therefore be hypothesised that plasma from individuals 
infected early on during on outbreak may be less effective at neutralising viral variants that 
arise later in an outbreak.  Plasma from EVD survivors of the 2013-2016 EBOV epidemic that 
had been infected early (during April 2014), or later on (between December 2014 and June 
2015) during the outbreak, was evaluated for neutralisation capacity of ancestral and 
mutant EBOV GP pseudotyped viruses.  Generally, the EVD survivor plasma was still able to 
neutralise the ancestral and mutant EBOV GP pseudotyped viruses, however differences in 
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neutralisation were observed.  Three samples did not display sufficient neutralising activity 
for IC90 values to be able to be calculated.  These samples displayed relatively low levels of 
neutralisation against live EBOV (Table 5.1), therefore the lower sensitivity and high 
variability of the pseudotyped virus neutralisation assay may explain the lack of 
neutralisation observed by these samples, and neutralisation may be achieved if a lower 
dilution of sample is used. 
In the current study, plasma from four out of nine EVD survivors that were infected earlier 
on during the 2013-2016 outbreak displayed lower neutralising activity against 
pseudotyped VSV bearing EBOV GP containing R29K, A82V, I317L and G480S mutations, 
which were identified later on in the outbreak, compared to pseudotyped VSVs bearing 
EBOV GPs that were identified earlier during the outbreak.  Whereas plasma from four out 
of eight EVD survivors that were infected later on during the outbreak, displayed lower 
neutralising activity against pseudotyped VSV bearing the ancestral (early) GP compared to 
pseudotyped VSVs bearing EBOV GPs that were identified later on in the outbreak.  
Although no statistically significant differences in neutralisation between the mutant EBOV 
GP pseudotyped viruses were observed.  These results suggest that mutations in EBOV GP 
could affect the level of neutralisation of antibodies derived from EVD convalescent 
volunteers; however the mutations evaluated did not result in complete loss of 
neutralisation.  Although this is not surprising considering the polyclonal nature of 
antibodies in plasma from EVD survivors, and number of neutralising epitopes within EBOV 
GP.  These differences could also partially be due to general variability and low sensitivity of 
the neutralisation assay, rather than effects of the mutations, and therefore repeat 
experiments should be performed as the current observations have been made on the basis 
of one study.  Another limitation of this study is that it is not known which variant of EBOV 
each individual was infected with, and also the small number of samples tested. 
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5.4.3 Neutralisation of mutant EBOV GP pseudotyped viruses by EBOV GP vaccine plasma 
As discussed in Section 1.5.3, EBOV GP is a key antigenic target for the development of 
vaccines against EVD.  Neutralisation of ancestral and mutant EBOV GP pseudotyped 
viruses by plasma from an individual who had previously been vaccinated with two 
candidate EBOV vaccines (ChAd3 and VSV-EBOV GP) was assessed, to determine potential 
immune escape resulting from multiple GP amino acid changes from the vaccine GP 
antigen.  The VSV-EBOV vaccine candidate is a live attenuated recombinant virus consisting 
of the VSV strain Indiana, with the GP of the EBOV Kikwit 1995 strain replacing the gene for 
the VSV-G, whereas the ChAd3-EBOV GP vaccine consists of a recombinant replication 
deficient ChAd3 vector expressing GP from the EBOV Mayinga strain.  Amino acid 
differences in the GP of EBOV Mayinga, Kikwit and Makona strains are shown in Table 5.2.  
The GP sequences of EBOV Mayinga and Kikwit differ by 10 amino acids.  The GP sequences 
of EBOV Mayinga and Kikwit differ by 19 and 18 amino acids, respectively, compared to 
EBOV Makona.  The vaccinee plasma was able to neutralise the ancestral and mutant EBOV 
(Makona) GP pseudotyped viruses, suggesting that vaccines containing GP from previous 
EBOV strains are able to induce neutralising antibodies against variants of the EBOV 
Makona strain that arose during the 2013-2016 EVD epidemic in West Africa.  Although 
additional samples from EBOV GP vaccinated individuals should be tested as this 
observation was made on the basis of one vaccinee sample only. 
In summary, mutation of EBOV GP did not lead to escape of neutralisation of EBOV GP 
pseudotyped viruses by EVD survivor or EBOV GP vaccinee plasma.  This is likely due to the 
presence of multiple neutralising epitopes within the GP of EBOV, which are targeted by 
multiple antibodies generated as part of the hosts’ polyclonal humoral immune response to 
infection or vaccination. 
 
141 
 
Table 5.2 Amino acid differences in the GP of different EBOV strains.   
Subunit Domain Position 
Mayinga 
(NC_002549) 
Kikwit 
(AY354458) 
Makona 
(KJ660348) 
GP1 
Base 47 
Aspartic acid 
(D) 
Glutamic acid 
(E) 
Aspartic acid 
(D) 
Glycan cap 
262 Threonine (T) Threonine (T) Alanine (A) 
310 Valine (V) Alanine (A) Alanine (A) 
MLD 
314 Glycine (G) Arginine (R) Glycine (G) 
315 Alanine (A) Alanine (A) Proline (P) 
331 Glycine (G) Glycine (G) 
Glutamic acid 
(E) 
336 Threonine (T) Threonine (T) Asparagine (N) 
359 
Glutamic acid 
(E) 
Glutamic acid 
(E) 
Lysine (K) 
377 Serine (S) Proline (P) Proline (P) 
378 Leucine (L) Proline (P) Proline (P) 
382 Proline (P) Proline (P) Threonine (T) 
405 
Glutamic acid 
(E) 
Glutamic acid 
(E) 
Glycine (G) 
411 Threonine (T) Threonine (T) Alanine (A) 
422 Serine (S) Proline (P) Proline (P) 
430 Proline (P) Proline (P) Leucine (L) 
440 Serine (S) Glycine (G) Serine (S) 
441 Threonine (T) Threonine (T) Alanine (A) 
443 
Phenylalanine 
(F) 
Leucine (L) Serine (S) 
446 Proline (P) Proline (P) Leucine (L) 
455 Histidine (H) Histidine (H) Tyrosine (Y) 
GP2 
Furin 
cleavage site 
499 Threonine (T) Alanine (A) Threonine (T) 
Pre-IFL 503 Alanine (A) Alanine (A) Valine (V) 
IFL 544 Isoleucine (I) Threonine (T) Threonine (T) 
Abbreviations: MLD, Mucin-like domain; IFL, Internal fusion loop. 
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5.4.4 Neutralisation of mutant EBOV GP pseudotyped viruses by anti-EBOV GP mAb 
Various preclinical studies have demonstrated that mAbs can be effective EVD treatments, 
however a potential limitation is that epitope mutations might reduce efficacy (Moekotte 
et al., 2016).  Furthermore, EBOV escape variants have previously been discovered in 
infected NHPs after treatment with the mAb cocktail MB-003, suggesting that EBOV could 
evolve to become resistant to sequence-based candidate therapeutics (Kugelman et al., 
2015a; Kugelman et al., 2015b). 
Ancestral and mutant EBOV GP pseudotyped viruses were evaluated for their neutralisation 
by human anti-EBOV GP mAb, KZ52.  KZ52 is an antibody isolated from a human survivor of 
the 1995 outbreak in Kikwit.  KZ52 binds to residues within both GP1 and GP2 at the base of 
the GP trimer, locking GP in its pre-fusion conformation and thereby preventing the 
conformational rearrangements required to drive membrane fusion.  KZ52 recognises 
residues 42-43 at the N terminus of GP1, and 505-514 and 549-556 at the N terminus of GP2 
(Lee et al., 2008).  Alanine-scanning mutagenesis (shotgun mutagenesis) has been used to 
determine the specific epitope residues for KZ52, and results were validated by 
neutralisation escape (Davidson et al., 2015).  In the current study, mutant EBOV GP G74R, 
P330S, H407Y pseudotyped virus was able to partially escape neutralisation by mAb KZ52.  
Amino acid positions 330 and 407 are located in the MLD, which is removed during priming 
of GP in late endosomes (see Section 1.2.4), whereas amino acid position 74 is located in 
the RBD, suggesting that the G74R mutation may be responsible for reduced neutralisation 
by KZ52.  Amino acid position 74 was mapped onto a published structure of EBOV GP in 
complex with KZ52 and was shown to be located near the interface of EBOV GP and KZ52.  
Although the G74R substitution is located outside of the KZ52-specific epitope, this 
mutation may affect the KZ52 epitope conformation by changing electric charge around the 
epitope (Kajihara et al., 2013).  Interestingly, in the current study, mutant EBOV GP G74R, 
P330S, H407Y pseudotyped virus displayed lower luminescence following infection of Vero 
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E6 cells compared to the other EBOV GP pseudotyped viruses tested (Figure 5.2), and 
therefore the G74R mutation may impose a fitness cost on the virus (Zhao et al., 2006).  
However, this mutation did not affect neutralisation by EVD survivor plasma in this study, 
and therefore further investigation should be performed to determine the impact of this 
mutation on viral infectivity and fitness. 
A recent study evaluating binding of anti-EBOV GP mAbs to V82 and A82 variants of EBOV 
(Makona) GP expressed in 293T cells by flow cytometry, found that KZ52 exhibited more 
that 50% reduction in binding to V82 compared to A82 EBOV GP variants (Brannan et al., 
2019).  In the current study, KZ52 did not display decreased neutralisation of pseudotyped 
VSV bearing EBOV GP containing an A82V mutation, therefore the A82V mutation could 
reduce KZ52 binding, but without affecting neutralisation.  The mutations evaluated in the 
current study could be applied in various binding assays, to assess their effects on antibody 
binding, as well as host cell receptor binding. 
 
5.5 Conclusions 
A set of mutations that occurred within the EBOV GP during the 2013-2016 EVD outbreak 
was identified, and site-directed mutagenesis was successfully applied to generate the 
expression plasmids required.  Subsequently, they were used to generate mutant EBOV GP 
pseudotyped viruses, which were then used to test the hypothesis of the study (described 
in Section 1.6).  Thus, the impact of mutations in EBOV GP on the neutralising ability of 
antibodies derived from EVD convalescent volunteers was investigated. 
The results presented here have examined the effect of mutations in EBOV GP on antibody 
immune escape.  They support the view that multiple naturally occurring mutations in 
EBOV GP do not result in escape from neutralising polyclonal antibodies derived from EVD 
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convalescent volunteers or EBOV GP vaccinated individuals.  This suggests the presence of 
multiple neutralising epitopes within EBOV GP that enable the GP sequence of EBOV strains 
from over 20 years ago to induce antibodies that are able to neutralise newly emerging 
EBOV strains with up to 20 amino acid changes in their GP.  However, some of these 
mutations can result in reduced neutralisation by certain EBOV GP-specific mAbs.  This 
reiterates the importance of using antibody cocktail treatments targeting multiple distinct 
neutralising epitopes, rather than monotherapy with a single neutralising mAb, to reduce 
the possibility of escape from neutralisation due to mutations in EBOV GP.  These results 
also highlight the importance of rapidly sequencing viral isolates from patients to be 
treated, to ensure that the selected mAb therapy is likely to be effective (Vaughan et al., 
2018). 
The current study has developed tools with which to expedite future work.  Mutant EBOV 
GP expression plasmids have been generated and are available for pdeudotyped virus 
production and further assessment of effects of EBOV GP mutations on antibody binding 
and neutralisation.  This has the potential to provide a better understanding of the 
correlates of protection against EBOV. 
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Chapter 6 General Discussion 
It is thought that EVD survivors are protected against subsequent infection with EBOV, and 
that neutralising antibodies to the EBOV surface GP are potential correlates of protection 
(Saphire et al., 2018; Warfield et al., 2018).  Due to its severe pathogenicity, potential 
transmission from person-to-person contact, and lack of approved vaccines or antiviral 
treatments, handling of EBOV for research-based purposes is limited to CL4 laboratories.  
Pseudotyped viruses can be used in serological assays as alternatives to live infectious 
viruses that require high levels of bio-containment, to investigate host cell receptor 
interaction and antibody binding and neutralisation. 
Immune responses by an infected host exert strong selection pressures on pathogens.  The 
prolonged transmission of EBOV in humans during the 2013-2016 EVD outbreak in West 
Africa resulted in an accumulation of mutations within the EBOV genome, which may 
impact on the efficacy of vaccines and immunotherapeutics.  A useful application for 
pseudotyped viruses, therefore, is to investigate how amino acid changes in EBOV GP might 
affect neutralisation by antibodies.  The current study investigated the potential for 
naturally acquired mutations in EBOV GP to result in escape from neutralising antibodies 
derived from EVD convalescent volunteers and EBOV GP vaccinated individuals, as well as 
EBOV GP-specific neutralising mAbs. 
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6.1 Generation and neutralisation of mutant EBOV GP pseudotyped viruses 
6.1.1. EBOV GP pseudotyped virus neutralisation assays 
Pseudotyped viruses are replication-defective chimeric virions that consist of the structural 
and enzymatic core of one virus, bearing the envelope protein or glycoprotein of another, 
and encode a quantifiable reporter gene.  As discussed in Section 1.4, retroviruses and 
rhabdoviruses are commonly used as cores for pseudotyped viruses.  In the current study, 
EBOV GP pseudotyped lentivirus and VSV systems were assessed for their suitability to 
measure the neutralising activity of EVD convalescent plasma (Chapters 3 and 4, 
respectively).  The VSV-based pseudotyped virus neutralisation assay was applied in the 
current study, as its sensitivity, specificity and ability to differentiate between neutralising 
activity appeared to be greater than the lentivirus-based system (see section 4.3.7).  
Importantly, correlation between live EBOV and EBOV GP pseudotyped virus neutralisation 
was significantly greater for the VSV-based assay. 
6.1.2 Generation of mutant EBOV GP pseudotyped viruses 
As demonstrated in Chapter 5 (see Section 5.3), the envelope protein of a pseudotyped 
virus can be modified by mutating the expression plasmid used to generate the 
pseudotyped virus.  Pseudotyped viruses have previously been used to study the effects of 
mutations within the EBOV genome on host cell tropism and infectivity.  In the current 
study, bioinformatics analysis of publically available EBOV genome sequences was used to 
identify non-synonymous mutations that occurred within the EBOV GP during the 2013-
2016 EVD outbreak.  Three variants that contained multiple amino acid changes were 
selected to test the hypothesis of the study described in Section 1.6. 
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6.2 The study hypothesis 
The current study sought to address whether naturally acquired mutations in EBOV GP 
could result in escape from neutralisation by anti-EBOV GP polyclonal and mAbs. 
6.2.1 Anti-EBOV GP polyclonal antibodies 
Mutations in EBOV GP may affect the ability of antibodies from convalescent patients or 
vaccinated individuals to protect against new variants of the virus.  It was shown that 
mutations in EBOV GP did not result in significant escape in neutralisation of EBOV GP 
pseudotyped viruses by EVD survivor or EBOV GP vaccinee plasma.  This is likely due to the 
presence of multiple neutralising epitopes within the EBOV GP, which are targeted by 
multiple antibodies generated as part of the hosts’ polyclonal humoral immune response to 
infection or vaccination.  This also suggests that the presence of multiple neutralising 
epitopes in EBOV GP enable the GP sequence of EBOV strains from over 20 years ago to 
induce antibodies that are able to neutralise newly emerging EBOV strains with up to 20 
amino acid changes in their GP. 
6.2.2 Anti-EBOV GP neutralising mAbs 
Results of the current study, suggest that a G74R mutation in EBOV GP is able to result in 
escape from neutralising mAb, KZ52.  KZ52 was isolated from B cells of a human survivor of 
the 1995 Kikwit EVD outbreak (Maruyama et al., 1999) and protected rodents from EBOV 
infection (Parren et al., 2002), however it was ineffective at inhibiting viral replication and 
preventing disease in NHPs (Oswald et al., 2007), suggesting that monotherapy with this 
single neutralising mAb may not be a suitable treatment for EVD.  Furthermore, epitope 
mutations may result in reduced efficacy of mAb therapies.  EBOV escape variants have 
previously been discovered in infected NHPs after treatment with the mAb cocktail MB-
003, suggesting that EBOV could evolve to become resistant to sequence-based candidate 
therapeutics (Kugelman et al., 2015a; Kugelman et al., 2015b).  These findings reiterate the 
148 
 
importance of using antibody cocktail treatments targeting multiple distinct neutralising 
epitopes rather than monotherapy with a single neutralising mAb, to reduce the possibility 
of treatment failure due to genetic changes.  The current study further highlights the 
potential of EBOV GP evolutionary mutations to evade mAb therapeutics, and supports the 
role of real-time sequencing during outbreaks to predict the efficacy of antibody-based 
treatments. 
 
6.3 Future work 
6.3.1 Alternative pseudotyped virus platforms 
During the course of assessing the suitability of an EBOV GP pseudotyped virus assay to 
measure the neutralising ability of EVD convalescent plasma, it was apparent that 
pseudotyped virus neutralisation results are often variable and correlate poorly with live 
EBOV neutralisation (Wilkinson et al., 2017).  In addition, live EBOV neutralisation results 
could vary also.  Therefore, alternative pseudotyped virus systems could be investigated to 
determine a more suitable platform.  An EBOV pseudotyped virus (E-S-FLU) based on a non-
replicating influenza virus (S-FLU) has been described (Xiao et al., 2018) and replication-
competent VSVs pseudotyped with EBOV GP have also been used to measure anti-EBOV 
neutralising antibodies (Wec et al., 2016).  However, it also became apparent that 
neutralisation capacity can differ among assays (Saphire et al., 2018).  Therefore, 
assessment of the impact of GP mutations on neutralisation using a single assay may not be 
optimal.  Nevertheless, the EBOV GP pseudotyped VSV assay could be used as an initial 
qualitative screening assay, or as part of a panel of pseudotyped virus neutralisation assays, 
for identification of escape mutants before further investigation is carried out using 
infectious viral variants. 
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6.3.2 Additional EBOV GP mutations 
Future studies could continue to utilise the EBOV GP pseudotyped virus system to 
characterise the effect of each of the mutations assessed during the current study 
individually, as well as the effects of additional mutations.  Especially G74R, to ascertain 
whether this single mutation alone is responsible for mutant GP G74R, P330S, H407Y 
pseudotyped virus escape from neutralisation by KZ52.  An extended panel of tools has 
been made available for this purpose by the current project, as relevant primers for each 
individual mutation are available (Table 2.1), and a selection of mutant EBOV GP expression 
plasmids have already been synthesised.  Primer design and site-directed mutagenesis 
could be applied to generate additional mutant EBOV GP expression plasmids as required.  
Alternatively, custom synthesis of plasmids containing multiple mutations could also be 
utilised as far as is economically possible.  Protein structural analysis could then be further 
investigated to predict the impact of amino acid changes on EBOV GP structure and 
antibody binding. 
6.3.3 Additional antibody samples 
The mutant EBOV GP pseudotyped viruses evaluated in the current study should be used in 
further studies to characterise the effect of these amino acid changes in EBOV GP on 
neutralisation by other EBOV GP-specific mAbs.   In particular, it would be interesting to 
test mAbs that recognise a similar epitope to KZ52, such as 4G7 and 2G4 (Murin et al., 
2014), for their neutralising ability of mutant GP G74R, P330S, H407Y pseudotyped virus, 
which, in the current study, was able to escape from neutralisation by KZ52.  4G7 and 2G4 
are components of the ZMAb and ZMapp antibody cocktails, which were administered to 
EVD patients under compassionate use protocols during the 2013-2016 EBOV outbreak.  
Therefore, it would also be interesting to test these anti-EBOV therapeutics against the 
mutant EBOV GP pseudotyped viruses generated in the current study. 
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Additional plasma or serum samples from EBOV GP vaccinated individuals should also be 
tested in neutralising assays using these mutant EBOV GP pseudotyped viruses, to confirm 
that vaccines containing GP from previous EBOV strains are able to induce neutralising 
antibodies against new variants of EBOV. 
 
6.4 Conclusions 
Since its discovery in 1976, EBOV has caused sporadic outbreaks across Central Africa and 
was responsible for the 2013-2016 EVD epidemic in West Africa, which was the largest 
EBOV outbreak on record and resulted in more than 28,600 cases and over 11,300 deaths.  
This outbreak constituted a public health emergency of international concern, and 
highlighted the urgent need for vaccines and therapeutics against EBOV.  It is thought that 
EVD survivors are protected against subsequent infection with EBOV, and that neutralising 
antibodies, as well as T cell responses, to the EBOV surface GP are involved.  The vast 
number of EVD survivors from the 2013-2016 EBOV outbreak has provided an opportunity 
to study the human immune response to EBOV infection. 
The extensive human-to-human transmission of EBOV that occurred during the 2013-2016 
EVD epidemic resulted in an accumulation of mutations within the EBOV genome.  This 
raised concerns that EBOV could adapt to better infect and transmit between humans, and 
could also evolve to become resistant to sequence-based candidate therapeutics.  Results 
of the current study suggest that multiple naturally occurring amino acid changes in EBOV 
GP do not have a significant impact on polyclonal neutralising antibodies derived from EVD 
convalescent volunteers or EBOV GP vaccinated individuals, however these changes can 
result in reduced neutralisation by certain EBOV GP-specific mAbs. 
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The current study demonstrated the potential value of real-time sequencing analyses and 
pseudotyped viruses to evaluate the potential impact of EBOV GP mutations on neutralising 
antibody immune escape.  EBOV still poses a major public health threat, as evidenced by 
the current ongoing EVD outbreak in the DRC.  Therefore these types of studies are more 
pertinent than ever, and have the potential to provide a better understanding of EVD 
vaccine and therapeutic efficacy, and correlates of protection against EBOV. 
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